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ABSTRACT 
Background. The burden of drugs prescribed to older persons at the end of life has 
recently drawn increasing scrutiny. Growing evidence suggests that patients with life-
limiting diseases and poor prognosis are prescribed drugs that may do more harm than 
good or treatments that have little chance of achieving their benefit during the patients’ 
short remaining lifespan. The overall aim of this thesis was to evaluate the quality of drug 
prescribing in older adults near the end of life. Except for Study III, all studies are based 
on routinely collected administrative and healthcare data with national coverage in 
Sweden. 
Study I. We found that, throughout their last year of life, older adults (n=511 843) used 
an increasing number of prescription drugs. The proportion of older adults exposed to 
≥10 drugs increased from 30.3% one year before death to 47.2% during the last month 
of life. Polypharmacy was fuelled not only by the initiation of symptomatic drugs to 
ensure comfort but also by the frequent continuation of long-term preventive treatments 
and medicines prescribed for the management of chronic diseases that may otherwise 
lead to short-term complications. 
Study II. Older adults who died with solid cancer (n=151 201) often continued to receive 
preventive drugs until the very end of life. Over the course of the last 12 months of life, 
there was little change in the receipt of antihypertensive agents (absolute change -0.3%, 
95% CI -0.6 to 0.0), vitamin K antagonists (+1.5%, 95% CI 1.1 to 1.9), antiplatelet agents (-
1.5%, 95% CI -1.8 to -1.2), statins (-4.7%, 95% CI -5.0 to -4.4), bisphosphonates (-0.3%, 95% 
CI -0.4 to -0.2), or vitamins (+1.0, 95% CI 0.8 to 1.2). During the last year before 
death, median drug costs amounted to $1482 (interquartile range [IQR], $700-$2896]) per 
person, including $213 (IQR, $77-$490) for preventive therapies. We found important 
differences between cancer types with regard to the use and costs of preventive drugs, 
which can be explained only in part by age and chronic multimorbidity. 
Study III. Forty European experts in geriatrics, clinical pharmacology, and palliative 
medicine from 10 different countries participated in a Delphi consensus panel to identify 
drugs deemed “often adequate”, “questionable”, or “often inadequate” for use in older 
patients aged ≥75 years with an estimated life expectancy of 3 months or less. Drug 
classes rated as “often adequate” are predominantly indicated for symptom 
management and comfort care. Among the drugs and drug classes considered 
“questionable” for use near the end of life, a vast majority are prescribed for the long-
term management of non-life-threatening chronic conditions or for the secondary 
prevention of chronic diseases that may otherwise quickly lead to serious clinical 
complications. Finally, drugs defined as “often inadequate” encompasses mostly drugs 
and supplements prescribed for primary prevention or as part of a long-term strategy of 
secondary or tertiary prevention. 
4 
Study IV. By applying the list mentioned above to a cohort of 58 415 older persons who 
died from conditions potentially amenable to palliative care in 2015, we found that 32% 
continued and 14% initiated at least one drug considered “often inadequate” during their 
last three months of life. Excluding older adults who died from acute and potentially 
unpredictable fatal events had little if any influence on the results. 
Conclusion. Older people are prescribed an increasing number of drugs as they 
approach the end of life. A sizeable fraction of these drugs is not directed towards the 
relief of distressing symptoms but instead aims at prolonging survival and managing 
chronic comorbidities. We have developed a consensus-based set of explicit criteria for 
delineating drugs that are “often adequate” from those deemed “questionable” or “often 
inadequate” for use in older persons at the end of life. In the absence of high-quality data 
from randomised clinical trials and sufficiently robust observational studies, these criteria 
can be used not only to provide guidance at the bedside but also to generate comparable 
epidemiological evidence across patient groups, care settings, regions, and countries. 
Keywords. Aging; Deprescribing; Drug Prescribing; End-of-Life Care; Geriatrics; 
Inappropriate Prescribing; Older People; Polypharmacy; Quality of Care; Palliative care 
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SAMMANFATTNING 
Bakgrund. Läkemedelsbehandlingen hos äldre personer i livets slutskede har tilldragit 
sig ett ökande intresse under senare tid. Allt fler forskningsresultat tyder på att äldre 
patienter med dålig prognos förskrivs läkemedel som kan vara till mer skada än nytta, 
eller som med stor sannolikhet inte hinner vara till nytta under den korta tid patienten 
har kvar att leva. Det övergripande syftet med denna avhandling var därför att utvärdera 
kvaliteten på förskrivningen av läkemedel till äldre nära livets slut. Med undantag för 
Studie III är alla studierna baserade på rutinmässigt insamlade administrativa och 
hälsodata med nationell täckning i Sverige. 
Studie I. Vi fann att äldre personer (n = 511 843) använde ett ökande antal receptbelagda 
läkemedel under sitt sista levnadsår. Andelen äldre exponerade för ≥10 läkemedel ökade 
från 30,3% ett år före döden till 47,2% under den sista månaden i livet. Polyfarmaci drivs 
inte bara av nyförskrivning av symtomlindrande läkemedel vid livets slut, utan också av 
en fortsatt läkemedelsbehandling—med långsiktigt förebyggande läkemedel och för 
kroniska sjukdomar som annars kortsiktigt kan leda till komplikationer. 
Studie II. Äldre personer som dog av cancer (n = 151 201) fick ofta fortsatt behandling 
med förebyggande läkemedel ända fram till livets slut. Under de sista 12 månaderna av 
livet förekom endast små förändringar i medicineringen av antihypertensiva medel 
(absolut förändring -0,3%, 95% Cl -0,6 till 0,0), vitamin K-antagonister (+ 1,5%, 95% Cl 1,1 
till 1,9), trombocytaggregationshämmare (-1,5%, 95% Cl -1,8 till -1,2), statiner (-4,7%, 95% 
Cl -5,0 till -4,4), bisfosfonater (-0,3%, 95% Cl -0,4 till -0,2) eller vitaminer (+1,0, 95% Cl 0,8 
till 1,2). Under det sista levnadsåret uppgick mediankostnaden för läkemedel till $ 1482 
(interkvartilt intervall [IQR], $ 700-$ 2896]) per person, inklusive $ 213 (IQR, $ 77- $ 490) 
för förebyggande läkemedelsbehandlingar. Vi fann viktiga skillnader mellan olika 
cancertyper med avseende på användning och kostnad för förebyggande läkemedel, 
som endast delvis kan förklaras av ålder och kronisk multisjuklighet. 
Studie III. Fyrtio europeiska experter inom geriatrik, klinisk farmakologi och palliativ 
medicin från tio olika länder deltog i en Delphi-konsensuspanel för att identifiera 
läkemedel som bedömdes som ”ofta adekvata”, ”tveksamma” eller ”ofta inadekvata” för 
behandling av äldre patienter ≥75 år med en beräknad livslängd om högst tre månader. 
Läkemedelsklasser som bedömdes som ”ofta adekvata” är till övervägande del 
indicerade för symtombehandling och för att minska lidande nära livets slut. Bland de 
läkemedel och läkemedelsklasser som ansågs vara ”tveksamma” för användning i livets 
slutskede ingick huvudsakligen läkemedel för långtidsbehandling av icke livshotande 
kroniska tillstånd eller för sekundärprevention av kroniska sjukdomar som annars snabbt 
kan leda till allvarliga kliniska komplikationer. Slutligen omfattade kategorin ”ofta 
inadekvata” främst läkemedel och tillskott som förskrivs för primärprevention eller som 
del i en långsiktig strategi för sekundär- eller tertiärpreventiv behandling. 
6 
Studie IV. Den ovannämnda listan från Studie III tillämpades på en kohort av 58 415 äldre 
personer som under 2015 avled av tillstånd som ofta innebär palliativ vård. Vi fann att 
32% fortsatte med, och 14% fick en ny förskrivning av, minst ett läkemedel som 
betraktades som "ofta inadekvat", under de sista 3 månaderna i livet. Exkludering av äldre 
som dog av akuta och potentiellt oförutsägbara dödliga tillstånd hade liten eller ingen 
inverkan på studieresultaten. 
Slutsatser. Äldre personer förskrivs ett ökande antal läkemedel när de närmar sig slutet 
av livet. En stor del av dessa läkemedel är inte inriktade mot lindring av lidande och besvär 
i livets slutskede, utan syftar snarare till att förlänga överlevnaden och hantera kroniska 
sjukdomar. Vi har utvecklat en konsensusbaserad uppsättning av kriterier för att åtskilja 
läkemedel som är "ofta adekvata" från dem som kan anses vara "tveksamma" eller "ofta 
inadekvata" för behandling av äldre personer i livets slutskede. I avsaknad av 
högkvalitativa randomiserade kliniska prövningar och tillräckligt robusta 
observationsstudier, kan dessa kriterier användas, inte bara för att ge vägledning i det 
kliniska arbetet, utan också för att jämföra epidemiologiska data mellan patientgrupper, 
vårdinrättningar, regioner och länder. 
Nyckelord. Äldre människor; Deprescribing; Geriatrik; Läkemedelsförskrivning; 
Olämplig förskrivning; Palliativ vård; Polyfarmaci; Vård i livets slutskede; Vårdkvalitet; 
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1. INTRODUCTION
1.1 DYING IN OLD AGE 
Population ageing and increased age at time of death 
High-income countries have witnessed substantial gains in life expectancy in old age.1 
While women aged 65 years were expected to live for another 9 years in 1800, their life 
expectancy was 13 years in 1900 and they can now expect to live for 21 years (Figure 1). 
Recent projections suggest that this trend will continue2 and that most of the future gains 
in life expectancy will be due to enhanced longevity in old age.3,4 After the dramatic 
compression of mortality among children and young adults during the first half of the 
20th century, the last seventy years have been marked by a steep reduction of death rates 
among older adults (Figure 2). As a result, the share of older people in the total 
population has grown substantially. In Sweden, persons aged ≥75 years accounted for 
3% of the population in 1950 (n≈ 242 000), 9% in 2015 (n≈ 850 000), and should represent 
14% of the population in 2050 (n≈ 1.6 million).5 Population ageing is also a challenge for 
middle- and low-income countries, where the older population is expected to increase by 
60% between 2015 and 2030.6,7 
One of the visible features of population ageing is the concentration of deaths in the 
upper tail of the age distribution, that is among the oldest old. As illustrated in Figure 3, 
the median age at death increased from 49 to 81 years in the course of a century. In 1900, 
only 5% of the Swedish population died at age 83 or older. This proportion reached 50% 
in 2015 and should rise to 75% in 2050. These findings have led scientists to speculate 
about the biological limits of longevity, fuelling a heated debate between scholars 
claiming that human lifespan may have reached its natural ceiling8,9 and those arguing 
that there is no solid evidence to support this hypothesis10–13 and that delaying the ageing 
process is a plausible therapeutic target.14 
Figure 1. Changes in life expectancy at birth, at age 65 and 85 years in Sweden between 1800 and 
2018, and projections for 2019–2050 
Source: Human Mortality Database, University of California Berkeley and Max Planck Institute for Demographic 
Research (available at: https://www.mortality.org/). Projections from 2019 to 2050 are indicated with dotted lines 
and a derived from official population forecast data provided by Statistics Sweden. Data accessed in July 2019. 
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Figure 2. Surface plots of observed mortality rates (logarithmic scale) for females and males in 
Sweden, for ages 0 to 100 years between 1800 and 2017. 
Source: Human Mortality Database, University of California Berkeley and Max Planck Institute for Demographic 
Research. Data accessed and analysed in June 2019. Log(Mx): natural logarithm of the year-specific mortality rate. 
Figure 3. Changes in the age at time of death and in the relative distribution of deaths by age in 
Sweden between 1900 and 2018, and projections for 2019–2050 
Source: Human Mortality Database, University of California Berkeley and Max Planck Institute for Demographic 
Research; and official population projections, Statistics Sweden. Panel A represents a series of Tukey outlier box 
plots, where the lower whisker is equal to the 1st quartile – 1.5x interquartile range, and the upper whisker is equal 
to the 3rd quartile + 1.5 x interquartile range. Values provided in the centre of the box correspond to median age 
at time of death. Shaded areas correspond to violin plots depicting the distribution of deaths by single age groups. 
Data about age at time of death are truncated at 105 years to ensure the anonymity of decedents (count <10 
persons). Information about the years 2025 and 2050 are provided by Statistics Sweden as part of a larger series 
of population-level projections.15 Panel B represents the distribution of deaths according to the attained age at time 
of death. The denominator is the total number of registered deaths annually. The vertical dashed line indicates the 
break between observed deaths (1900–2018) and the projected number of deaths (2019–2050). These projections 
are based on various assumptions about mortality rates, which are detailed elsewhere.15 
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Be this as it may, even if current trends continue the marginal health gains carried by 
each additional year of life expectancy will—at least in the foreseeable future—most likely 
diminish.16 The increasing age at death has not only led to a larger number of people 
living to very old age but also to a larger number of people living and dying with a high 
burden of morbidity and disability.17–19 By comparing two waves of the Cognitive Function 
and Ageing Study in the United Kingdom, Kingston et al. showed that although older 
adults aged 65 years in 2011 could expect to live on average about 2 additional years with 
low dependency (i.e. care less than daily), they were also living 1 more year with high-
dependency (24h-care needs) than the generation 20 years before.20 This new paradigm 
of mortality is often acknowledged by demographers and epidemiologists.16,21,22 
However, its consequences in terms of care needs are seldom discussed beyond general 
considerations about the economic sustainability of healthcare systems and the 
necessity to better address the multifaceted health needs of older adults.23 
Change in the leading causes of death in older adults 
The observed changes in the leading causes of death are a key marker of the 
epidemiological transition that has occurred during the last century, which is 
characterised by a shift from infectious and acute diseases to non-communicable and 
chronic conditions. In 1900, the top three leading causes of death among older Americans 
(≥65 years) were influenza and pneumonia, tuberculosis, and diarrhoea. One hundred 
years later, heart diseases, cancer, and stroke had become the leading causes of death, 
accounting for more than 60% of all deaths in 2000.24 The World Health Organization 
(WHO) estimates that cardiovascular diseases account for a little over 50% of deaths 
among people aged 75 years and older in Europe.25 Despite some disparities in the 
proportion of deaths attributable to different causes of death, overall trends appear to 
be similar in Sweden and in other European countries (Table 1). Cancer and dementia 
are now the second and third most common causes of death, respectively. These changes 
have important consequences for policymakers and healthcare providers, as mortality 
patterns have a direct influence on care needs near the end of life.26 
Sweden, % Europe, % United States, % 
2000 2016 2000 2016 2000 2016 
Cardiovascular diseases 51.8 39.2 59.2 51.0 46.1 34.5 
Ischemic heart disease 31.1 20.1 33.9 29.9 30.3 20.3 
Stroke 13.2 8.1 18.2 12.9 9.2 6.8 
Cancer 17.2 19.7 15.2 16.9 18.0 17.5 
Neurological conditions 7.1 15.6 4.7 9.8 7.5 18.2 
Alzheimer disease and other dementias 6.3 13.8 3.7 8.2 5.9 15.7 
Chronic respiratory diseases 5.2 6.0 6.0 5.8 8.8 10.0 
Pneumonia and other respiratory infections 5.3 3.5 3.8 3.0 4.2 2.7 
Table 1. Five leading causes of death among people aged ≥75 years (2000–2016) 
Source: WHO, Global Health Estimates 2016. Available at http://terrance.who.int/mediacentre/data/ghe 
(data updated on May 22, 2018). ‘Europe’ includes all countries in the WHO European region. 
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Trajectories of functional decline and need for palliative care at the end of life 
Depending on their underlying health problems and causes of death, people who near 
the end of life experience different patterns of decline in physical function. This idea was 
first introduced in the late 60s’ by American sociologists Barney Glaser and Anselm 
Strauss who suggested the existence of three typical dying trajectories, each 
characterised by a specific duration and shape: abrupt and unexpected deaths, expected 
lingering, and entry-reentry deaths.27 These trajectories, almost exclusively based on 
qualitative research and observations, were progressively enriched to incorporate the 
emotional, psychological, and social aspects of dying28 and had much influence on 
policymakers and stakeholders who sought to improve access to end-of-life care at the 
turn of the century.29 However, robust empirical evidence remained scarce to confirm 
their validity in daily clinical practice.30,31 This prompted epidemiologists to make use of 
population-based cohorts and routinely collected data to classify deceased older persons 
in order to examine differences in healthcare utilisation and costs at the end of life.32,33 In 
the Established Populations for Epidemiologic Studies of the Elderly (EPESE) study, a 
community-based, prospective cohort in the United States, Lunney et al. analysed 
longitudinal changes in self- and proxy-reported ADL dependency among 4190 
decedents who had been interviewed during the year before death.34 They confirmed 
that a 4-group categorisation was able to differentiate people who died suddenly, with 
no or little warning sign and limited contact with healthcare services before death; from 
those who died (1) after a short period of evident decline marked by the terminal phase 
of a severe illness (typically cancer); or (2) after a trajectory of intermittent decline, with 
long-term limitations and frequent acute episodes that characterise, for instance, severe 
congestive heart failure and COPD; or (3) as the result of a slow and gradual decline in 
physical and/or cognitive functioning, such as frail older adults with dementia or 
neurodegenerative diseases (Figure 4). 
Figure 4. Illness trajectories of older adults with serious illness at the end of life 
Adapted from Lynn et al.35, and reprinted with permission from RAND corporation (Santa Monica, CA). The 
trajectory of functional decline of older people with cancer often spans 3-5 years, with a clear deterioration during 
the last 3-6 months of life. Among patients with organ failure, serious acute decompensations and clinical 
complications can result in repeated non-elective hospitalisations during the last 2-3 years of life. The trajectory 
of decline of frail older people with dementia and neurodegenerative diseases is typically longer, and punctuated 
with the gradual worsening of mobility impairments, IADL disability, cognition, communication, and dysphagia. 
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These three typical illness trajectories were subsequently popularised by Murray et al.,36 
who compared the course of physical decline with trajectories of social, psychological and 
existential distress.37,38 Table 2 shows the distribution of illness trajectories among older 
decedents in Sweden. More recent investigations have called into question the relevance 
of these four illness trajectories, driven by the observation that, at the patient level, the 
condition leading to death is seldom sufficient to predict the pattern of physical decline 
and disability near the end of life.39,40 However, other parameters remain strongly 
correlated with the underlying cause of death (e.g. prognosis, likelihood of clinical 
complications, burden of symptoms, patterns of co-morbidities, and healthcare 
utilisation). Illness trajectories thus remain a useful tool to differentiate groups of 
decedents that share a set of common features and care needs as death approaches.41 
Hence, older people who die as the result of either cancer, progressive organ failure, or 
dementia and neurodegenerative disease require access to different health services to 
address different needs at different time points over the course of their disease.42 
Understanding this high variability in dying trajectories is crucial to avoid a one-size-fits-
all approach to caring for vulnerable older adults with life-limiting illnesses. 
What these people have in common, however, is the need for adequate palliative care, 
including the management of distressing symptoms (both physical and psychological) 
and the appropriate support of family caregivers. The WHO defines palliative care as “an 
approach that improves the quality of life of patients and their families facing the 
problem associated with a life-threatening illness, through the prevention and relief of 
suffering by means of early identification and impeccable assessment and treatment of 
pain and other problems, physical, psychosocial and spiritual.”45 While the core 
components of palliative care can be provided by healthcare professionals from any 
discipline in any care setting (‘generalist palliative care’), patients with complex needs are 
usually referred to specialised multidisciplinary teams with extensive training in this field 
(‘specialist palliative care’).46–48 Palliative care was initially developed to address the needs 
of patients with terminal cancer at the end of life and was, for the most part, delivered in 
hospitals and hospice facilities.49 However, the past two decades have seen a substantial 
shift towards the broadening of the target population, the development of community-
based services, and the earlier integration of a palliative approach in standard care.50,51 
Palliative care is thus no longer focused solely on people with advanced cancer; it is also 
65-74 years 75-84 years ≥85 years Total 
Sudden death 8.1% 7.0% 7.8% 7.6% 
Short and evident decline (e.g. cancer) 47.3% 34.4% 18.6% 28.6% 
Intermittent decline (e.g. organ failure) 35.4% 38.9% 39.6% 38.7% 
Slow and gradual decline (e.g. dementia) 9.3% 19.7% 34.0% 25.1% 
Table 2. Illness trajectories among older adults who died in Sweden (2007-2015) 
Source: National Cause of Death Register, Swedish Board of Health and Welfare. Illness trajectories were 
constructed using all the diagnoses mentioned on the death certificates. Detailed methods about the 
operationalisation of these trajectories are described elsewhere.43 We applied a previously described hierarchy 
to obtain a single trajectory for each decedent (i.e. cancer > dementia > organ failure > sudden death).39,44 
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beneficial for patients with serious and life-limiting chronic conditions such as congestive 
heart failure, chronic obstructive pulmonary disease, kidney disease, diabetes, and 
dementia.52–54 Palliative, contrary to popular belief, is not limited to patients whose death 
is imminent and is not synonymous with hospice care, which is primarily directed towards 
patients with a terminal illness and a short prognosis.55,56 On the contrary, recent 
initiatives have underscored the notion that palliative care should be available from the 
time of diagnosis until death, bolstered by the mounting body of evidence showing the 
benefits of integrating a palliative approach earlier in the course of the disease, alongside 
disease-oriented treatments.57–59  
Oncologists have been particularly receptive to this new model of palliative care, 
especially since Temel et al. demonstrated in a landmark randomised controlled trial that, 
among patients with metastatic non-small-cell lung cancer, early palliative care could 
improve both well-being and survival.60 A myriad of trials have since consistently reported 
positive effects on quality of life, comfort, satisfaction with care, physician-patient 
communication, decreased aggressiveness of care at the end of life, and healthcare 
expenditures.61–64 These studies served as a springboard to promote broader and earlier 
access to palliative care integrated with standard oncologic care.65–69 In the United States, 
the 2019 clinical practice guidelines developed by the National Coalition for Hospice and 
Palliative Care insists on the fact that palliative care is “appropriate at any stage in a 
serious illness, and it is beneficial when provided along with treatments of curative or life-
prolonging intent.”70 The integration of palliative care in other medical specialities 
remains largely suboptimal, despite recent efforts to implement and evaluate tailored 
interventions targeting patients with heart failure, COPD, end-stage renal disease, 
multiple sclerosis, or dementia.71–76 The situation is especially disquieting in nursing 
homes, where access to palliative care lacks for 30% of the residents without cancer, and 
seldom occurs before the last two weeks of life when it is available.77 
In a cross-sectional study using death certificate data from 12 high-income countries, we 
found that about 64% of all deaths were directly attributable to advanced diseases that 
indicate a need for palliative care;43 a proportion similar to previously reported 
estimates.78–81 The number of older people dying from conditions amenable to palliative 
care is expected to grow markedly in the future.26 Sleeman et al. anticipate that the need 
for palliative care will increase by 87% worldwide between 2016 and 2060 (from 26 to 48 
million people annually), with a remarkably steep increase among older adults and 
people with dementia and respiratory diseases.82 This epidemiological reality is both the 
consequence and the cause of the escalating medicalisation of the final stage of life. 
“Medicine found ways to cut the mortality of heart attacks, respiratory illnesses, stroke, 
and numerous other conditions that threaten adult life”, Atul Gawande writes.83 
“Eventually, of course, we all die of something. But even then, medicine has pushed the 
fatal moment of many diseases further outward. […] Instead of just delaying the moment 
of the downward drop, treatments can stretch the descent out until it ends up looking 
less like a cliff and more like a hilly road down the mountain.”  
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1.2 THE MEDICALISATION OF DEATH AND DYING: A BRIEF HISTORY 
Over the past 70 years, medical progress has brought about dramatic changes in the 
circumstances surrounding the end of life and the moment of death. The following 
sections provide a brief overview of the main events and scientific advances that have 
contributed to the intense medicalisation of the dying process. Understanding these 
contextual factors is important to make sense of current interrogations about the 
appropriateness of drug treatments for older people near the end of life, which are at the 
core of the present thesis. 
Bringing the dead back to life 
After decades of experimental research on rats, monkeys, chickens, and dogs, the 
successful use of an electric defibrillator on a quivering open human heart by Claude 
Beck in 1947 paved the way to modern resuscitation.84 This technique was soon 
surpassed by the advent of external defibrillators, after a team of Harvard cardiologists 
led by Paul Zoll showed that ventricular fibrillation could effectively (and safely) be 
reverted with electrodes placed on the surface of the patients’ closed chest.85 
Concurrently, a group of electrical engineers and thoracic surgeons at Johns Hopkins 
University developed the prototype of a portable defibrillator mounted on a wheeled cart, 
which they unveiled in 1957.86 Three years later, building upon recent discoveries by 
anaesthesiologists James Elam and Peter Safar at Baltimore City Hospitals on mouth-to-
mouth ventilation87–89 and intrigued by earlier experiments suggesting that adequate 
blood circulation could be maintained by applying regular compression on the sternum, 
William Kouwenhoven, James Jude, and Guy Knickerbocker developed one of the most 
iconic procedures of modern medicine: cardiopulmonary resuscitation (CPR).90,91 The 
importance of CPR was quickly realised, and medical societies around the World began 
organising training programmes for clinicians and laypersons. Moreover, this 
breakthrough came at the same time as major advances in respiratory care. 
From artificial ventilation to intensive care 
In the wake of the first large-scale poliomyelitis epidemics in the United States (in 1916 
alone, nearly 30 000 people were diagnosed and 6000 died92), physicians were 
desperately trying to find a way to treat the many children and young adults who had 
been left paralyzed and often incapable of breathing on their own.93,94 Harvard 
researcher Philip Drinker devised a vacuum pump-powered machine that could provide 
artificial respiratory support over an extended time.95,96 This so-called ‘iron lung’, together 
with the improved version designed by John Emerson and the cuirass shell patented by 
Rudolf Eisenmenger, were widely used in the United States until the mid-1950s’ and saved 
or prolonged the life of tens of thousands of young patients.97–99 In England, the 1938 
epidemic prompted the mass-production of a simpler and cheaper version of Drinker’s 
iron lung, which was manufactured and subsidised by Lord Nuffield—a bicycle and car 
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tycoon turned philanthropist who also donated £2 million to help establish the Oxford 
Medical School and the Nuffield Department of Anaesthetics, the first of its kind in 
Europe. A total of 1750 ventilators were donated to hospitals across Britain and the 
Commonwealth. However, iron lungs had notable drawbacks, including the fact that 
patients had to synchronise swallowing with the machine and had to be able to maintain 
their airway open. They also remained too large, cumbersome, and expensive to 
accommodate the needs of a growing number of polio patients. In the United States, the 
epidemic took tidal-wave proportions in the early 1950s, with 65 000 new paralytic cases 
between 1951 and 1954.100 Other countries were also affected, not least in Scandinavia. 
A large international polio conference was held at the University of Copenhagen in 
September 1951. The next summer the metropolitan area of Copenhagen was hit by a 
sudden and catastrophic outbreak, most likely initiated by silent carriers among the 
experts who had attended the conference. About 2800 patients (including 860 with 
paralysis) were admitted to the Blegdam Hospital in less than five months. “During the 
week August 28 to September 3, our hospital admitted 335 patients with polio, or nearly 
50 cases daily. About one-tenth of these patients were suffocating or drowning in their 
own secretions”, Henry Lassen, the hospital’s chief physician, reported. “I do not want to 
dramatize the state of affairs existing in the middle of August 1952, but it certainly was 
desperate. Nearly all our patients with bulbar poliomyelitis had died!”101 Indeed, an 
unusually large fraction of these patients presented with both bulbar and spinal paralysis, 
a group in which intermittent negative pressure ventilation was mostly ineffective and 
mortality reached 95%. Only one iron lung and six cuirass shell respirators were available. 
“The great number of severely ill patients pouring in made therapeutic improvisations 
necessary. During these months, we have in fact been in a state of war, and we were not 
nearly adequately equipped to meet an emergency of such vast proportions.”102 
Bjørn Ibsen, a Danish anaesthesiologist who had returned to Copenhagen after spending 
a year at the Massachusetts General Hospital in Boston, was called in for a consultation 
in late August. This proved to be a watershed moment. Recognising the signs of severe 
respiratory acidosis, Ibsen quickly realised that polio patients were dying not from a 
devastating viral infection in the brain but from respiratory failure.103 He suggested that 
patients receive manual intermittent positive pressure ventilation, administered through 
a cuffed tracheostomy tube connected to a rubber bag filled with oxygen. In just a few 
days, mortality among paralytic polio patients plummeted, from about 87% down to 40%. 
However, the manual ventilation of up to 70 patients simultaneously required a 
considerable workforce (during the peak of the epidemic, 250 medical and dental 
students were enlisted to work in 6-hour shifts alongside 40 experienced physicians). It 
also became evident that a better understanding of acid-base physiology in critically ill 
patients was crucial, and that new laboratory techniques of blood gas analysis—such as 
the ones ushered by chemist Poul Astrup—were needed.104 Convinced that trained staff 
and specialised medical equipment should be concentrated in a single multidisciplinary 
unit, Ibsen established the World’s first intensive care unit (ICU) in December 1953 at the 
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Municipal Hospital of Copenhagen.105–107 In Sweden, a similar unit was created a few 
months later in Borås108 and Carl-Gunnar Engström, a physician and epidemiologist 
trained as Karolinska Institutet, introduced one of the first modern mechanical ventilators 
for long-term use.109 In the United States, Walter Dandy opened a three-bed post-
operative nursing unit for neurosurgical patients at Johns Hopkins in 1923, and a 
dedicated burn unit was created at Massachusetts General Hospital in the aftermath of 
the disastrous Cocoanut Grove nightclub fire in 1942.110,111 However, the first hospital ward 
with round-the-clock staff entirely devoted to critically ill patients was inaugurated at 
Dartmouth Medical College in 1955, at the instigation of William Mosenthal.112,113 Before 
long, leading institutions in the countries were following suit; both the ‘Shock Ward’ of the 
University of Southern California and the ‘Intensive Care Unit’ at Johns Hopkins opened 
in 1958.114,115 With the development of resuscitation, medical imaging, and respiratory 
monitoring,  and hemodynamic support, “the modern ICU was ready for prime time.”116 
When the brain dies but the heart keeps beating 
Few anticipated that the brazen successes of medicine would, in just a few years, entirely 
redefine death and dying. The rapid development of intensive care in Northern America 
and Europe resulted in a growing number of patients who could be kept alive with 
artificial ventilation despite irremediable neurological impairments. In 1959, Pierre 
Mollaret and Maurice Goulon provided a detailed account of a series of 23 unconscious 
patients who had previously been admitted in a critical care unit in Paris, France. All of 
these patients presented a complete and persistent abolition of consciousness, no 
reaction to elicitable reflexes, no spontaneous respiration, and flat electro-
encephalography (EEG) denoting the absence of electrical activity in the brain.117 The 
authors coined this state ‘coma dépassé’, i.e. beyond coma. They reflected that “such a 
coma is both a revelation and a ransom of the progress made in cardiorespiratory 
resuscitation. A revelation, because the survival of these patients was only made possible 
by the technical advances [in artificial ventilation and critical care]. A ransom, because 
survival in the context of irreversible coma requires increasingly demanding efforts from 
the ICU staff and prolongs a spectacle that is more and more painful for the families.”118 
Earlier that year, a group of neurosurgeons from Lyon, France, had proposed a set of 
diagnostic criteria for what they described as the ‘death of the nervous system’ in the 
presence of cardiac activity, and recommended that, in the future, artificial ventilation 
should be discontinued if the absence of EEG activity was confirmed.119 This approach 
was similar to that of American neurologist Robert Schwab, who suggested in 1963 that 
EEG investigation should be one of the core components of the legal determination of 
death.120 At the Massachusetts General Hospital in Boston, he had already taken 
responsibility for pronouncing the death of 15 unconscious patients based on EEG 
findings.121 This was not an isolated practice. The proliferation of patients in irreversible 
coma raised thorny ethical questions regarding the termination of life-sustaining 
treatments, igniting a heated debate in the medical community and beyond. Even 
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religious authorities were involved. Asked by an anaesthesiologist from Innsbruck, 
Austria, whether it was morally acceptable to withdraw mechanical ventilation before 
cardiac arrest, Pope Pius XII answered in the affirmative. His position was that “when the 
soul may already have left the body […], one is held to use only ordinary means, that is to 
say means that do not involve any grave burden for oneself or another.”122,123 In France, 
Pierre Wertheimer published several accounts of unconscious patients who died as the 
result of life-support termination.124,125 In Sweden, a neurosurgeon named Kjell Frykholm 
proposed that—unless they were suitable donors for organ transplants—patients with 
no brain activity should be declared dead and disconnected from the ventilator.126 
Drawing the line between life and death 
The ability to artificially maintain cardiorespiratory functions (thereby preserving organ 
perfusion and oxygenation) among patients with no measurable brain activity created a 
unique opportunity for the nascent field of organ transplantation. “By artificial means, 
different organ systems can be kept in a fairly good functioning state for a considerable 
time. It is such dead individuals with partly living organs who form one of the largest 
groups which are the best to select as organ donors”, Clarence Crafoord, a surgeon at 
Karolinska University Hospital, argued.127 Between 1960 and 1962, after a handful of 
successful kidney transplants between homozygotic and dizygotic twins, Boston 
surgeons Joseph Murray and John Merrill transplanted thirteen patients, including five 
with organs from ‘cadaveric donors’ who had been declared dead after cardiac arrest 
following the elective withdrawal of artificial ventilation.128 They later reported that, by 
March 1965, at least 241 kidney transplants from deceased donors had been performed 
internationally.129 In 1963, Thomas Starzl and James Hardy demonstrated the feasibility 
of, respectively, transplanting livers and lungs from deceased donors.130,131 French 
surgeon Jean Hamburger carried out the first renal transplant from a patient in coma 
dépassé. Yet, in all these cases organs were harvested after the donors’ death had been 
established by cardiopulmonary standards, that is after the ventilator was turned off.132 
However, it became apparent that some transplant surgeons were removing kidneys 
from coma patients who were still on life support. In Belgium, Guy Alexandre, a surgeon 
at the Catholic University of Louvain who had previously completed a research fellowship 
under Joseph Murray’s supervision, developed a set of criteria to ascertain death among 
potential donors with severe cerebral injuries whose heart had not stopped. These 
criteria overlapped substantially with those proposed by French physicians Mollaret and 
Goulon in 1959.118 Between June 1963 and March 1966, Alexandre performed nine kidney 
transplants from “heart-beating, brain-dead donors.”133,134 The case of a kidney donor 
with brain injury who died only after the respirator was disconnected following the 
nephrectomy was also reported in Newcastle, England, in 1963.135 In Sweden, the chief of 
the urology clinic at Karolinska Hospital, Gustav Giertz, recounted the 1964 case of a 40-
year-old dying women whose kidney had been removed and who remained artificially 
ventilated for 48 hours afterwards.136,137  
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Invited to participate in a close-door symposium in London to discuss the ethical and legal 
implications of medical progress (Box 1), the key figures of modern organ transplantation 
underlined the dilemmas posed by the lack of a clear and consensual characterisation of 
death for patients with irreversible brain damage.138,139 “Since we find that 
transplantation of a kidney from a living person without his permission is not acceptable, 
but that the law […] permits the use of organs from the dead”, Giertz argued, “it is then a 
question of drawing the line between life and death.”136 Legal scholars had, for the most 
part, already made up their minds. Carl Wasmuth—who would later serve both as the 
president of the American College of Legal Medicine and as the president of the American 
Society of Anesthesiologists—reiterated his contention that legislative changes were 
warranted to facilitate the decision-making process prior to organ procurement from 
dying patients.140 At the annual meeting of the American College of Legal Medicine in June 
1965, he had already affirmed in no unambiguous terms that the progress of medical 
science and transplantation had rendered the definition of death obsolete, and that it 
was thus bound to evolve: “It becomes evident that death is no longer determined by the 
lack of respiration or the lack of a heartbeat or the lack of circulation [since these two 
functions may be carried on by artificial means].”137 The first successful heart transplant 
by South African surgeon Christiaan Barnard in December 1967141,142 prompted 
questions about the vital status of the donors at the time of the organ procurement and 
made the cardiorespiratory definition of death all the more untenable.143,144  
On March 9-11, 1966, the Ciba Foundation (a non-profit organisation created in 1949 and funded by the 
Swiss pharmaceutical company CIBA, now Novartis) organised a multidisciplinary symposium on the 
ethical and legal issues raised by recent progress in organ transplantation.139 The symposium was 
instigated by Sir Michael Woodruff, an English surgeon at the University of Edinburgh who had performed 
the first kidney transplant in the UK145, because of “the growing realization that progress in medicine 
brings in its train ethical problems which are the concern not only of practising doctors but of the whole 
community.” Attendees included the World leaders in transplantation: Roy Calne (who initiated the 
transplantation programme at Cambridge University and later performed the first liver transplant in 
Europe), Jean Hamburger, Joseph Murray, John Merrill, Thomas Starzl, and Keith Reemtsma (who had 
performed the first xenotransplantation in 1964 and assembled the team that would, 12 years later, 
implant the first total artificial heart). It also included Guy Alexandre, Gustav Giertz, George Pickering, 
Robert Platt, Carl Wasmuth, and George Schreiner. Reactions to Alexandre’s proposed criteria for defining 
death were mixed. While Murray and Hamburger were positive (“this new approach […] has a serious 
pathological basis”), others were sceptical (Roy Calne: “I feel that if a patient has a heartbeat he cannot 
be regarded as a cadaver“;  Pickering: “The public […] would require a lot of evidence to persuade them 
that it was justified to take a kidney from a person who still had a heart beat and a circulation, and who, 
according to the ordinary standards, was still alive“; Reemtsma: “at present it would not be acceptable in 
many countries to remove vital organs from living persons prior to what we now accept as death”). 
However, Alexandre made his premise clear: “there has never been […] any question of taking organs 
from a dying person. The question is of taking organs from a dead person, and the point is that I do not 
accept the cessation of heart beats as the indication of death. […] I think irreversible damage to the central 
nervous system is an indication of physiological death that permits us to take an organ from a body that 
is already a cadaver.” Concluding the exchange, Michael Woodruff noted: “We really need a conference 
of a slightly different composition to consider this business of what is death.” This would occur just two 
years later, in 1968, with the installation of the Harvard Committee. 
Box 1. Questioning the ethical implications of medical progress at the Ciba symposium (1966) 
A detailed account of this symposium can be found in Ross et al., 2016 and Machado et al., 2005 133,138 
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Redefining death 
Christopher Pallis, a prominent British neurologist, commented that “modern technology, 
in its desperate attempts to save human life, has produced an entity known as brain 
death. It has also generated a conceptual crisis: that of knowing—at the simplest, bedside 
level—whether a patient is alive or dead.”146 This ethical problem was not lost on Henri 
Beecher, an anaesthesiologist at Massachusetts General Hospital who had recently made 
his mark as a sharp critic of unethical clinical research with a landmark article published 
in 1966 in the New England Journal of Medicine.147 In October 1967, concerned with the 
ethical difficulties generated by the growing number of ‘hopelessly unconscious 
patients’,148,149 he convinced the dean of Harvard Medical School to assemble an ad hoc 
committee to “come to some subtle conclusion as to a new definition of death.”150 Their 
first meeting was held in March 1968, two years to the day after the Ciba symposium. 
This committee was composed of thirteen members, including Boston surgeons Joseph 
Murray and John Merrill and neurologists Raymond Adams and Robert Schwab. The latter 
played a central role in drafting the report.150 A pioneer of electroencephalography, 
Schwab had founded the Brain Wave Laboratory (now Laboratory for NeuroImaging of 
Coma and Consciousness) at the Massachusetts General Hospital, the first hospital-based 
clinical EEG laboratory in the United States.151 Confronted to an increasing number of 
comatose patients in his critical care unit, he had developed a set of basic criteria to 
identify patients for whom “the prolongation of cardiac circulation serves no purpose.”120 
In a series of 90 cases examined between 1962 and 1968, he had established that 
unconscious patients with no elicitable reflexes, no spontaneous respiration, and a flat 
(‘isoelectric’) EEG had a very short survival and presented markedly necrosed brain tissues 
at autopsy. He came to the conclusion that the absence of EEG activity was not the mere 
indication of a dysfunction of the central nervous system; it was the sign that the brain 
was irremediably and permanently damaged and that despite a beating heart the 
patients were, in fact, dead.152 The other members of the Harvard Committee largely 
approved of Schwab’s approach.150 Technical precisions were added to operationalise the 
triad criteria, including considerations about the clinical ascertainment of un-
responsiveness (no response to external stimuli), the lack of spontaneous breathing for 
at least 3 minutes, the abolition of reflexes (e.g. fixed pupils, no ocular movement or 
blinking, absence of postural activity), and the duration of isoelectric EEG (at least 10 
minutes of recording, repeated 24 hours later). The first draft was ready by the end of 
June, and the final report was published in the Journal of the American Medical Associations 
on 5 August 1968.153 This new definition based on neurological criteria was met with 
mostly positive reactions and proved to be a turning point in the conceptualisation of 
death. It was, for instance, instrumental in the evolution of the legal definition of death in 
France (1968)154,155 and in the development of the Swedish guidelines for the diagnosis of 
irreversible loss of brain functions (1973).156–158 Nevertheless, three reasons prevented 
these criteria from prevailing entirely during the next decades.  
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First, the lack of clear equivalence between brain death and death became the subject of 
a long-lasting debate among scholars. Many were puzzled by the fact that ‘irreversible 
coma’ was presented as a criterion for pronouncing death but not as death itself, and by 
the vagueness of the proposed definition: “an organ, brain or other, that no longer 
functions […] is for all practical purposes dead.” This ambiguity reflected the hesitations 
of Beecher and Schwab (in a letter to Beecher, the latter suggested to avoid redefining 
death and, instead, to “concentrate on […] what constitutes irreversible coma”159). Wary 
of the confusion that this could cause, Joseph Murray protested in an earlier draft that 
“the term ‘brain death’ should be eliminated. Death is what we are talking about, and 
adding the adjective ‘brain’ implies […] an incomplete type of death.”150 In contrast with 
the cautionary approach of the Harvard Ad Hoc Committee, the British Conference of 
Medical Royal Colleges was unequivocal when, in 1976, it stated that “brain death 
represents the stage at which a patient becomes truly dead, because by then all functions 
of the brain have permanently and irreversibly ceased. […] The identification of brain 
death means that the patient is dead, whether or not the function of some organs, such 
as a heartbeat, is still maintained by artificial means.”160 
A second limitation was the inclusion of non-brainstem (i.e. cortical) reflexes and the 
mention of the “great confirmatory value” of an isoelectric EEG. Although subsequent 
studies corroborated the importance and reliability of EEG measurements in brain dead 
patients,161,162 it opened Pandora’s box. Before long, questions arose regarding the 
adequate time between sequential EEGs, the interpretation of cortical brain activity in 
otherwise unresponsive patients, the accuracy of brain death diagnosis based on clinical 
examination of brainstem reflexes alone, and the necessity to perform a confirmatory 
angiogram to determine the absence of cerebral blood flow.163–167 “The determination of 
brain death is still seen by many as a problem”, Peter Black laconically summarised in a 
review for The New England Journal of Medicine in 1978.168,169 This was especially 
problematic given the lack of standardisation in the criteria being used to determine 
death across U.S. jurisdictions.170 Moreover, in 1976 the United Kingdom adopted 
diagnostic criteria for brain death centred around the absence of brainstem reflexes, 
stating that “it is now widely accepted that electroencephalography is not necessary for 
diagnosing brain death.”171 This meant that unconscious patients with abolished 
brainstem function but preserved cortical activity (which EEG measures) would be 
considered alive in the United States but dead in the United Kingdom. Incidentally, this 
transatlantic divide in the definition of brain death led to the broadcasting of an episode 
of the BBC television programme Panorama entitled ‘Transplants: Are the Donors Really 
Dead?’, which sparked outrage in the British medical community.172–174 To clarify the 
situation, the President’s Commission for the Study of Ethical Problems in Medicine and 
Biomedical and Behavioural Research was established in the fall of 1978. Its main goal 
was to propose a uniform, well-defined, conceptually coherent, and socially acceptable 
notion of death in order to propose “the same basic rule about who is dead, and who is 
not, everywhere in the United States.”175 Their report, published in 1981, was largely 
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influenced by the contribution of Alexander Capron and Leon Kass176,177 and by the 
landmark paper from James Bernat.178 The whole-brain definition of death eventually 
prevailed: “An individual who has sustained either (1) irreversible cessation of circulatory 
and respiratory functions, or (2) irreversible cessation of all functions of the entire brain, 
including the brain stem, is dead.”179 This definition became the Uniform Determination 
of Death Act (UDDA), a statute which was progressively adopted by most U.S. states. The 
American Academy of Neurology guidelines were published in 1995, which largely 
contributed to standardising the neurological criteria used for the determination of brain 
death.180 Of note, the use of confirmatory EEG or cerebral blood flow test is now generally 
deemed superfluous, although it remains legally mandatory in some countries.181 
The third limitation is of contextual and historical nature. Because preoccupations about 
the determination of brain death and concerns regarding the availability of organs for 
transplantation arose in parallel, the criteria proposed by the Harvard Committee have 
cast doubt about the ulterior motives of its members.144,182 The framing and writing of the 
final report left the impression that the redefinition of death was mainly designed to 
facilitate organ procurement, and external factors largely reinforced this impression. 
During the Summer of 1968, in the aftermath of the two successful heart transplants 
performed by Christiaan Barnard a few months earlier, three international events 
addressed the issue of brain death with a clear focus on the ethical problems of organ 
procurement from deceased donors.183 The main event was Declaration of Sydney on 
Human Death issued by the 22nd World Medical Assembly, which made an explicit 
reference to “the use of cadaver organs such as heart or kidneys for 
transplantation.”184,185 Fortuitously, the Declaration of Sydney was published on 5 August, 
the same day as the article from the Harvard Committee. An even stronger connection 
between brain death and transplantation was made by the JAMA itself, who published the 
‘Ethical guidelines for organ transplantation’ of the Judicial Council of the American 
Medical Association back-to-back with Beecher’s report.186 Moreover, the report was 
released less than one week after the adoption of the Uniform Anatomical Gift Act by the 
U.S. Senate, on 30 July 1968.187 In France, the decision to codify the new definition of death 
just three days before Christian Cabrol performed the first heart transplantation in 
Europe also bolstered the suspicion that transplant surgeons influenced the legislator to 
bolster their agenda.188,189 However, historians have demonstrated with sound 
evidence150,190,191 that “although [organ transplantation] clearly benefited from a new 
definition of death, it was not a principal driving force in its creation.”166 
The tortuous and lingering process that led to the redefinition of death on neurological 
and neurophysiological grounds illustrates the ambivalence—and, for many, the 
uneasiness—of physicians regarding the most appropriate care for unconscious patients 
with no hope of recovery. This process was not primarily motivated by ontological 
concerns (what is death?) or by opportunistic motivations (when can organs be harvested?); 
it stemmed from the burgeoning ethical malaise towards the reckless use of invasive 
treatments in an attempt to salvage patients whose condition was precisely the by-
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product of medical progress. “Do not attempt to redefine death. Concentrate on the 
agreement as to what constitutes ‘irreversible coma’”, Schwab suggested in a memo to 
Beecher during the Harvard Committee. He explained: “If we establish the concept of 
irreversible coma with the cessation of function at all levels of the [central nervous 
system], it will not be difficult for those in charge […] to withhold or discontinue 
mechanical, electrical, or pharmacological aids.”159  
In a context where the ever-changing limits of what is medically possible blurred the 
boundaries between life and death, the ability to pronounce death despite the presence 
of a heartbeat was less a legal necessity than a mean to act on the  ethical obligation to 
discontinue sophisticated yet futile machinery and to withhold senseless ‘heroic 
measures’. Concerns about the futility of pursuing invasive treatments in dying patients 
had already been overtly brought up during the 1966 Ciba symposium in London.139 For 
George Schreiner (a nephrologist who would later be instrumental in obtaining federal 
funding for the End-Stage Renal Disease Medicare Program), the necessity of redefining 
death was first and foremost dictated by the gruesome reality of modern clinical practice: 
“We have seen people with a virtual transection of the brain kept alive for days and days 
simply because there was an intact cardiovascular system and a respirator. The clinician 
has to decide, from a set of criteria, at which point he will stop employing extraordinary 
means for the prolongation of life. Some research on the criteria is essential […] to decide 
how many ribs to break with cardiac massage, or how many old people should 
unnecessarily be subjected to thousands of dollars’ worth of resuscitation, or whether it 
is ever possible to die without a series of cardiac arrests.” Paradoxically, the 
unprecedented advanced of medicine had created a situation where the physicians’ 
ability to cure, save, replace and repair became more worrisome than their failure to do 
so. Karolinska Hospital urologist Gustav Giertz commented that  “the thought that we 
should be obliged to keep a patient alive with a respirator when there is no possibility of 
recovery, solely to try to prolong his life by perhaps 24 hours, is a terrifying one.”136 
Care for the dying: questioning futile treatments 
Throughout the 1950s, the number of unconscious patients supported with artificial 
ventilators increased rapidly. Among them, a small but growing fraction survived without 
regaining consciousness, sometime with no other sign of life but a beating pulse. 
Physicians tending to these patients found themselves facing unprecedented dilemmas. 
Should life-sustaining treatments be continued in patients who might essentially be 
dead? Should ‘extraordinary measures’ be attempted to resuscitate a patient with a trivial 
chance of recovery? Is it ethically acceptable to withdraw or withhold treatments 
designed to save lives? Robert Schwab, at Massachusetts General Hospital, reported what 
is probably the first documented case where artificial ventilation was purposefully 
discontinued in 1954 (for a detailed account, see Belkin, 2003191). A few years later, in 
1959, French neurologists Michel Jouvet and Pierre Wertheimer published a series of four 
clinical cases of comatose patients whose central nervous system functions are 
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irreversibly abolished, including a 53-year-old female patient for whom the respirator was 
turned off. “We believe that the prolongation of artificial ventilation is only conceivable if 
there is still a chance of central nervous system activity recovery”, they argued.125,192 Their 
contribution generated animated discussions. Mollaret and Goulon, who coined the 
expression ‘coma dépassé’, were for instance explicitly opposed to the withdrawal of 
artificial ventilation. During a lecture in Paris, the former explained: “In the face of these 
unfortunate people, when the heart continues to beat day after day without the slightest 
awakening of a function, despair vies with pity and the temptation of the liberating click 
becomes throbbing. May I be forgiven, but I have not yet been able nor willing to consent 
to the pollice verso.”118  
In the United States, these issues were first brought to light in January 1957 with the 
publication of an editorial in The Atlantic Monthly entitled “A Way of Dying”, in which a 
widow recounted the medicalised agony of her husband in a large metropolitan 
hospital.193 The editors from The New England Journal of Medicine praised the article, 
describing it as “required reading for physicians”, and harshly criticised the “immaculate, 
modern aseptic skills that can keep a diseased, half-dead, cancerous body alive, by 
intravenous nourishment and with the magic of penicillin and round-the-clock special 
nursing [with little regard for dignity]”.194 Before long, similar opinions appeared in the 
Journal of the American Medical Association. “When death is imminent and inevitable, it is 
neither scientific nor humane to use artificial life-sustainers to protract the life of a 
patient”, Franck Ayd advocated in 1962, adding that “physicians must recognize man's 
right to live and die peacefully. Otherwise life-preserving treatments may become a 
scientific weapon for the prolongation of agony.”195 Hamlin held essentially the same 
position in his article on the role of EEG in the determination of brain death two years 
later, by concluding that “withholding fruitless efforts at resuscitation […] would grant 
solace to relatives who under current hospital practices often have to await the grim and 
foregone verdict until the final beat of the dying heart has been recorded.”121 In Sweden, 
the decision of a physician to withdraw artificial hydration in an older patient who had 
experienced a massive haemorrhagic stroke came before the Royal Medical Board in 
1961. The physician was later prosecuted but finally acquitted on the grounds that 
“[although] treatment undertaken to maintain life shall not be withdrawn, it is 
conceivable that it may be justified by certain circumstances […], in which it would be 
pointless to continue the treatment.”136,196 
Concerns about the potential futility of treatments at the end of life were not limited to 
intensive care. Oncologists were also starting to question the aggressiveness of 
anticancer treatments in the terminal stage of the disease.197,198 In 1959, Edward 
Rynearson caused a fierce controversy with an essay published in the American Cancer 
Society’s journal CA, where he observed that “by means of tubes inserted into their 
stomachs, or into their veins, or into their bladders, or into their rectums, […] we can keep 
people suffering for an indeterminate number of months.”199 Six months later, the journal 
released a total of 39 letters to the editor responding to Rynearson’s article—mostly 
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concurring with his views.200 Nevertheless, in spite of a growing awareness among 
oncologists that ‘radical surgeries’ and evermore aggressive chemotherapy could be of 
limited benefit for some patients, the vast majority believed that, ultimately, medical 
decisions had to be made by medical professionals. This paternalistic approach was also 
evident in the lack of patient-physician communication regarding the disclosure of cancer 
diagnosis. In 1953, it was reported that 70% of physicians in Philadelphia never or seldom 
told their patients that they had cancer.201In a much-discussed article published in 1961, 
Donal Oken revealed that 90% of physicians preferred not to disclose the diagnosis to 
their patients, most of the time based on emotion-laden personal judgments.202 
Decisions regarding the continuation or discontinuations of life-prolonging treatments 
were often made unilaterally, with no or little discussion with patients and their 
caregivers. Some terminally ill patients were being resuscitated and put on life support 
notwithstanding their explicit wish to forgo treatments.203–205 On the other hand, for fear 
of setting off legal disputes and conflicts with family members, decisions to withdraw or 
withhold therapy were often made without their assent. These decisions were motivated 
not only by of the perceived futility of treatments for individual patients but also out of 
growing concern for the scarcity of available medical resources. Hence, in September 
1967, the British audience discovered in the popular BBC television programme 
Tomorrow’s World that, nearly 18 months before, the medical director of Neasden 
Hospital had issued a memo to all the staff regarding the criteria to select patients for 
resuscitation in the event of cardiac arrest (“the following patients are not to be 
resuscitated: very elderly, over 65 years; malignant disease; chronic chest disease; 
chronic renal disease”), causing a public outcry.206–208  
Twenty years later, a special grand jury investigation discovered that La Guardia Hospital 
in Queens, New York, had instituted a process of designating patients who should not be 
resuscitated by sticking small purple dot decals on their nursing records, which were then 
discarded when the patients were discharged or died. This so-called ‘no-code status’ was 
never mentioned to patients and family members and, in order to avoid legal exposure, 
was kept separate from the medical charts so that the decision could not be traced back 
to a specific physician.209–212 The investigation also revealed that hospital staffs commonly 
used delaying tactics to make sure that resuscitation efforts would fail while still being 
able to tell the bereaved family member that everything possible had been done.  As the 
limited efficacy of cardiopulmonary resuscitation became increasingly clear—Bedell 
reported in 1984 that only 14% of patients who underwent CPR survived until 
discharge,213 a finding well within the range of contemporaneous studies214–217—
physicians and nurses began to perform less-than-full resuscitation efforts when they 
believed that the patient’s prognosis was too poor. This practice (nicknamed ‘slow code’, 
‘Hollywood code’, ‘light-blue code’, or ‘coffee code’) was mostly used for patients with 
terminal cancer, advanced dementia, or in a vegetative state. It was seldom discussed 
openly, and most often “performed without the consent and without the knowledge of 
the patient or the patient’s family.”218  
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Towards the primacy of patient autonomy 
Between the late 1970s and the mid 1990s, the notion of patient autonomy—the right for 
a competent person to decide which medical interventions he or she wants to accept or 
refuse—gained considerable influence in Western countries, Northern America and 
Europe alike. Considerations for autonomy first arose from the Nuremberg Code and the 
Declaration of Helsinki, focused on the issue of informed consent of participants in 
human clinical research.219–221 It came under intense scrutiny throughout the 1960s and 
1970s amid a series of research scandals, including the abuses revealed by Henri Beecher 
in 1966  and the fallout of the Tuskegee syphilis trial in 1972 that eventually led to the 
systematisation of institutional review boards (note: for a comprehensive and gripping 
historical account, see Capron 2018222). The recognition of the respect for autonomy as 
one of the basic tenets of clinical practice occurred much later, through a succession of 
high-profile legal cases and under the pressure of civil societies. While the right of 
competent patients to refuse treatments—even life-saving ones—was progressively 
guaranteed, the possibility to withdraw treatments and to turn off life-supporting 
measures in unconscious (and thus incompetent) patients remained problematic.223 
In the United States, the case of Karen Quinlan, a 21-year-old woman in a persistent 
vegetative state following a drug overdose, was a turning point.224 In 1976, after a much 
publicised and commented trial, the New Jersey Supreme Court decided that Karen 
Quinlan’s father, acting as her legal guardian, had the right to withdraw artificial 
ventilation provided that her physician could determine the irreversibility of her condition 
and that the hospital’s ethics committee give its approval.225 A few months later, two 
major hospitals in Boston (Beth Israel and Massachusetts General Hospital) paved the 
way for more transparent institutional policies regarding the termination of life support 
by publishing their own internal guidelines in The New England Journal of Medicine.226,227 
This initiative was considered as an important milestone (“the hospitals are coming out 
of the closet!”, Fried celebrated in an accompanying editorial228). It should nevertheless 
be noted that national CPR standards published in 1974 already explicitly recommended 
against resuscitation attempts in patients with very poor prognosis, and advised that do-
not-resuscitate (DNR) orders should be documented in the patient’s medical records.229 
The notions that mechanical ventilation could be withdrawn without fear of criminal 
charges or legal liability and that surrogates could make decisions on incompetent a 
patient’s behalf were subsequently recognised230 and gradually gained consensus in the 
medical community.231–234 The right to forgo life-supporting treatments was then 
progressively extended to other measures such as artificial nutrition and hydration.235–239 
Moreover, the necessity to place patients at the centre the decision-making process has 
become an essential precept in clinical practice.234,240–242 This change of ethical paradigm 
has been described as “a shift from the primacy of beneficence to the primacy of 
autonomy”.243,244 To enforce the preferences of patients with advanced illness regarding 
the continuation or discontinuation of treatments at the end of life and to enable 
healthcare professionals to provide goal-concordant care, a special task force at the 
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Center for Ethics in Health Care at Oregon Health and Science University developed 
the Physician Orders for Life-Sustaining Treatment (POLST) Programme. It was 
implemented throughout Oregon in 1995 and extended to other states in 2004.245 The 
POLST programme is part of a wider effort to promote advance care planning as a way 
for patients to preserve their decisional autonomy, should they become incapable of self-
determination later.246–248 
In Sweden, although the delegation for medical ethics of the Swedish Society of Medicine 
(Swedish: Läkaresällskapets) already recognised in 1978 that life support could be 
withdrawn when death was imminent,249 official guidelines from the National Board of 
Health and Welfare were not published before 1992250 (these guidelines have been 
updated and reinforced in 2011251,252). In England, the British Medical Association 
released its first position statement in 1999, after a long consultation process.253–255 In 
France the Leonetti law was passed in April 2005, in the wake of the public debate 
prompted by the tragic death of Vincent Humbert.256,257 This legislation, which was 
updated in 2016, grants the right for patients with advanced disease to obtain the 
withholding or withdrawal of any treatment that was deemed “useless, disproportionate 
or having no other purpose than the artificial preservation of life.” It also enables patients 
to write advanced directives and to appoint a surrogate decision maker. 
Tragic choices: medical decisions before death 
Under the combined influence of progress in acute medical care, legal and judicial 
recognition of decisions to forgo treatments, and increasing appreciation of the right for 
patients and their surrogate to decline or stop life-prolonging therapy, the number of 
deaths preceded by a medical decision increased considerably in the late 1980s and 
throughout the 1990s. “Now that medical technology has teased apart the dying process, 
we have had to select a time of death when many signs of life do, in fact, remain”, Stuart 
Youngner noted.258 The first large-scale investigation, conducted from July 1987 to June 
1988 in two intensive care units affiliated to the University of California San Francisco, 
revealed that out of 224 deceased patients 114 (51%) died after support was withheld or 
withdrawn. In this landmark study, Nicholas Smedira et al. also showed that only a 
minority of these critically ill patients for whom a medical decision was made at the end 
of life were capable of participating in the decision themselves.259 Five years later, the 
proportion of deaths following a medical decision in the same two ICUs reached 
90%.260,261 Other observational studies have reported rates of end-of-life decisions in 
intensive care units ranging from 40% to 70%.262–264  
In Europe, findings from the EURELD study shed light on the frequency of end-of-life 
decisions in the general population in six different countries. In 2003, Van der Heide et al. 
reported that, out of 20 480 deceased individuals included in the analysis, death was 
anticipated in two-third of cases and was preceded by a medical decision in 23% of cases 
in Italy, 36% in Sweden, up to 51% in Switzerland.265 Decisions to alleviate pain or other 
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distressing symptoms while accounting for the possible hastening of death as a 
secondary, unintended consequence (‘double effect’) were the most common. Decisions 
to withhold or withdraw life-sustaining or potentially life-prolonging treatments were 
found in 33% of decedents in Sweden and affected primarily medications, artificial 
hydration or nutrition, and artificial ventilation.266 In addition, a do-not-resuscitate 
decision was enacted in over 70% of all non-sudden deaths.267 These decisions occurred 
not only in intensive care units or in acute care hospital wards, but also in the community 
and, increasingly, in nursing homes (where the proportion of older adults with severe 
cognitive impairment and limited decisional capacity is high). In Belgium, Chambaere et 
al. recently examined end-of-life decisions among older adults with dementia. They found 
that 28% of deaths followed treatment withholding or withdrawal, and 37% were 
preceded by a decision to intensify analgesics or sedatives.268 It has also been recently 
shown that the frequency of treatment withdrawal decisions among persons with 
dementia has increased substantially between 1998 and 2013 (from 20 to 35%).269 In sum, 
a large proportion of people now die as the direct or indirect result of a medical decision 
regarding treatments, whether this decision is to withhold a potentially life-saving 
therapy, to discontinue a drug that was prescribed to prevent adverse clinical events, or 
to withdraw an apparatus without which vital functions cannot be maintained. These 
decisions are, for the most part, the unforeseen consequence of the provision of high-
intensity care for patients with advanced illness near the end of life. 
The rising intensity of care at the end of life 
Countless studies have investigated the provision of care during the final months of life, 
most often to emphasise the intensity of disease-oriented treatments.59,270,271 Briefly, 
three main themes emerge from the current literature. First, ICU admissions close to 
death seem increasingly frequent.272,273 In the United States, the proportion of Medicare 
fee-for-service decedents admitted to ICUs during their last month of life rose from 24% 
in 2000 to nearly 30% in 2015.274 This is far more than any other countries. In an 
international study comparing seven developed nations, Bekelman et al. showed that 
among older patients with cancer, the proportion admitted in intensive care during their 
final month of life varied from 7–11% (Belgium, Canada, The Netherlands) to 27% in the 
United States.275 This comes with a sizeable number of individuals with tracheostomy and 
invasive mechanical ventilation initiated near the end of life. One explanation for this high 
ICU admission rate is the substantial number of older adults with limited life expectancy 
who, in the U.S., undergo inpatient surgery within three months before death.272,276  
Second, studies conducted in Northern America and Europe have found that 
approximately 20% of patients with advanced cancer receive chemotherapy, targeted 
therapy, or immunotherapy during the last month before death.277–282 There are, 
however, wide cross-national differences in chemotherapy use at the end of life. The 
above-mentioned international study led by Bekelman et al. reported that the proportion 
of lung cancer patients who used chemotherapy during their last 30 days of life varied 
37 
from 17% in Germany to 12.1% in the United States, down to 6% in Canada.283 In Sweden, 
Näppa et al. showed that among cancer patients who died in 2008, 23% had been treated 
with chemotherapy during the last month before death.281 In Belgium, 17% of all people 
who died from cancer in 2012 received chemotherapy during their last month of life, 3.3% 
had disease-oriented surgery, and 2.6% were admitted to an ICU.284 In France, a series of 
large retrospective cohort studies revealed that out of 110 631 hospitalised older adults 
(≥75 years) who died from metastatic cancer in 2010-2013, 10% received chemotherapy 
during their last month of life.279 Moreover, the rate of chemotherapy use was only 
marginally associated with the assumed chemosensitivity of the tumours; hospitalised 
patients with metastatic pancreatic cancer, melanoma, mesothelioma, soft-tissue 
sarcoma or biliary tract tumours—all known for their poor response rate to IV 
chemotherapy—had surprisingly high rates of chemotherapy close to death.285  
Third, the use of feeding tubes and artificial nutrition for critically ill patients or in older 
adults with terminal cancer or advanced dementia has come under scrutiny. Among 
critically ill patients in the United States, the incidence of gastrostomy tube placement 
has increased from 12 to 29 per 100 000 person-years between 1994 and 2014, with a 
parallel increase in the proportion of patients discharged to long-term care facilities.286 
Kempf et al. described that patients with metastatic oesophageal or stomach cancer had 
decreasing rates of chemotherapy but increasing rates of artificial nutrition near the end 
of life, despite clinical guidelines that unambiguously recommend limiting the use of 
artificial nutrition in the context of advanced cancer and limited life expectancy.287 The 
European Society for Clinical Nutrition and Metabolism (ESPEN) states that, near the end 
of life, “treatment needs to focus on symptomatic support including alleviating hunger 
and thirst, while all additional nutritional support may do more harm than good.”288 The 
ESPEN also explicitly recommends that “older persons with low nutritional intake in the 
terminal phase of illness shall be offered comfort feeding instead of enteral nutrition.”238 
In the context of advanced dementia, Mitchell et al. found that, in 1999, 34% of U.S. 
nursing home residents with severe cognitive impairment had feeding tubes.289 Although 
there has been a notable decrease in the incidence of percutaneous endoscopic 
gastrostomy in this population since 2000,290,291 artificial nutrition with feeding tubes 
remains frequent despite explicit clinical guidelines advising against it.238,292–294 
Transitions between care setting and final place of death 
Late hospitalisations and in-hospital deaths are one of the most visible consequences (or, 
some would argue, one of its latent causes) of the medicalisation of the dying process. 
Both elective and non-elective hospital admissions are frequent during the months 
before death. In the United States, Teno et al. calculated that among the 251 229 
Medicare fee-for-service older adults who died in 2015, 54% had been hospitalised during 
the last 30 days of life, 7% had been hospitalised at least three times during the last 90 
days, and 11% had transitioned from one place of care to another.274 Older adults with 
advanced illness and multimorbidity often follow a complex sequence of care transitions 
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during their last year of life.295 Important disparities across countries have been noted. 
Among older cancer patients, the proportion of individuals hospitalised during their last 
month of life varies from 45% in the Netherlands and Germany, to 50% in the United 
States, up to 60% in Canada and Norway.283 It has also been demonstrated that a 
substantial share of nursing home residents are hospitalised near the end of life, 
oftentimes prompted by the onset of potentially avoidable condition.296 In Sweden, we 
recently reported that 22% of older adults had at least one elective hospitalisation during 
their last month of life and that 51% had at least one non-elective hospitalisation, with 
substantial socioeconomic differences.297The proportion of individuals hospitalised 
during any given day increases at a faster pace during the last three months before death 
than during the preceding months, especially among older adults with cancer (Figure 5). 
These findings fit well with the state of knowledge published in other countries.298–303 
Figure 5. Percentage of individuals hospitalised throughout the last year of life, by age and illness 
trajectory (Sweden, 2015) 
Source: National Cause of Death Register and National Patient Register, Swedish Board of Health and Welfare. A 
total of 78 226 older adults (≥65 years) who died in Sweden between 1 January and 31 December 2015 were 
included. Trajectories of functional decline were derived from multiple cause of death data, using a methodology 
described elsewhere.43 The percentage of individuals who were hospitalised throughout the last year of life 
(28 630 716 person-days) was calculated from data from the National Patient Register, by using the dates of 
admission and discharge of every inpatient hospitalisation. 
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As a consequence, a large number of older persons die in hospitals or long-term care 
facilities rather than in the community. In practical terms, Haider Warraich writes, “the 
vast majority of people die in places where inert tones provide the palette, disinfectant 
the aroma, alarm bells the soundtrack, and open-back johnnies the wardrobe.”116 In 
Sweden, among decedents aged 65 years and over, 41% died in hospitals, 42% in nursing 
homes, and 16% at home. The proportion of death occurring in nursing homes increases 
dramatically with age, from 18% among decedents aged 65–74 years to 67% among those 
aged 95 years and older (Table 3). Moreover, hospitals are the most common place of 
death for people who died with cancer, organ failure, or sudden causes, while nursing 
homes are by far most common among decedents with dementia. These proportions are 
consistent with findings from other European and North American countries. 
The percentage of in-hospital deaths among people who die from conditions amenable 
to palliative care has been found to vary from 38% in the United States, to 45-50% in Italy 
and England, up to 60-65% in France, Spain, and Canada.304 These proportions are 
typically higher among cancer patients305, and lower among persons with dementia.306,307 
In the United States, Teno et al. have reported a substantial reduction of in-hospital 
deaths between 2000 and 2015 (from 33% to 20%), and a clear increase in home and 
hospice deaths. The proportion of older adults dying in nursing homes, on the other 
hand, remained stable at 25% of all deaths.274,308 Similar patterns have been found in the 
United Kingdom, which has led public health researchers to conclude that, if current 
trends remain stable, the number of people who will need adequate end-of-life care in 
the community and in nursing homes will increase considerably during the next two 
decades.309 Therefore, new models of palliative care delivery are warranted to ensure 
appropriate support across care settings.  
 Home Hospital Nursing home Other 
All decedents 16.2% 40.6% 42.1% 1.1% 
Sex     
Men 18.8% 45.2% 34.5% 1.5% 
Women 13.9% 36.6% 48.8% 0.7% 
Age at time of death     
65–74 years 27.1% 52.7% 17.8% 2.4% 
75–84 years 17.6% 46.6% 34.5% 1.3% 
85–94 years 11.6% 34.8% 53.1% 0.5% 
95 years and older 10.5% 22.1% 67.2% 0.2% 
Illness trajectory     
Short and evident decline (e.g. cancer) 20.3% 45.8% 32.5% 1.4% 
Intermittent decline (e.g. organ failure) 18.7% 50.8% 29.6% 0.9% 
Slow and gradual decline (e.g. dementia) 7.3% 16.5% 76.1% 0.1% 
Sudden death (e.g. injury, sepsis) 20.2% 54.1% 22.2% 3.4% 
Table 3. Places of death among older people in Sweden (2015) 
Source: National Cause of Death Register, Swedish Board of Health and Welfare. Out of 79 473 older adults aged 
65 years and over who died in 2015, the place of death was not reported for 1817 (2.3%) individuals. These 
percentages are thus calculated for a total of 77 656 decedents. 
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1.3 THE COMPLEX BURDEN OF MORBIDITY NEAR THE END OF LIFE  
Multimorbidity in old age 
Multimorbidity is defined as the co-occurrence of multiple chronic diseases in the same 
person.310,311 This notion differs from that of comorbidity, which is defined in reference to 
an index disease.312 A systematic review conducted in 2011 identified 39 different 
multimorbidity indices, 18 of which were weighted indices designed specifically to predict 
adverse health outcomes.313 The authors found considerable heterogeneity in the 
definition and selection of chronic diseases, and the data source used to capture these 
diseases, leading to large variability in prevalence estimates (from 55 to 98% among older 
adults).314–319 To overcome this predicament and improve the comparability of future 
epidemiological studies, Calderón-Larrañaga et al. developed a clinically-driven 
consensus classification of chronic diseases.320 This methodology enable us to detect a 
comprehensive set of chronic diseases that either have a long-lasting impact on older 
adults’ autonomy and quality of life, or that require enduring contacts with healthcare 
services. It can be implemented with both population-based survey data and routinely 
collected administrative data. Among older adults included in the Swedish National study 
of Aging and Care in Kungsholmen (SNAC-K), 89% had at least 2 chronic diseases and 56% 
were living with at least 4 co-existing chronic diseases.320  
Few studies have investigated the prevalence of multiple chronic diseases among older 
adults near the end of life. Rosella et al. have described the increasing burden of chronic 
conditions and multimorbidity among adult decedents in Ontario, Canada, between 1994 
and 2013.321 To our knowledge, this is to date the only large-scale published study on this 
topic. However, it well established that chronic multimorbidity is closely associated with 
mortality in old age.322 In a pooled analysis of more than 698 000 individuals enrolled in 
91 distinct prospective cohort studies, researchers found that the combination of three 
diseases (diabetes mellitus, stroke, myocardial infarction) was associated with a 15-year 
reduction of life expectancy at age 60.323 Recently, it has been shown that multimorbidity 
is the single most important factor of shortened survival among older persons, 
accounting for 7.5 years of life lost.324 Using routinely collected data for a random sample 
of 100 000 individuals drawn from the total Swedish older population aged 75 years and 
older, Figure 6 demonstrates the strong correlation between the number of co-existing 
chronic diseases, the risk of death within an year, and the remaining life expectancy. For 
instance, while older men with a single chronic disease can expect to live for another 16.1 
years, those with 5 concomitant conditions have a life expectancy of 13.1 years.  
Several published studies have also modelled the life expectancy of older adults with 
multiple chronic diseases. In Germany, Tetzlaff et al.325 recently reported the results of a 
study based on administrative claims data investigating the proportion of life expectancy 
spent with chronic multimorbidity defined as the presence of ≥6 chronic diseases and ≥5 
chronic medications.326 Years of life with multimorbidity account for one third of the total 
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life expectancy at age 60 (e.g. 7.9 out of 24.7 years for women). At age 70 and 80, this 
proportion rises to 40% and 45%, respectively. Using a 5% sample of Medicare 
beneficiaries without a history of cancer (n= 407 749), Cho et al.327 found that the life 
expectancy of American men at age 75 varied from 13 years among those without chronic 
diseases to 7 years among those with a high burden of chronic diseases (compared with 
10 years in the average U.S. population). Correlatively, their results demonstrate that the 
survival probability of women with high morbidity at age 75 is similar to that of women 
aged 81 years in the total U.S. population. DuGoff et al.328 reached similar conclusions 
based on a large dataset combining the 5% Medicare sample with data from the Chronic 
Condition Warehouse developed by the Centers for Medicare and Medicaid Services.329 At 
age 75, older adults with 5 chronic diseases can expect to live 5 years less than those with 
no chronic disease. These findings have two important clinical consequences. First, they 
suggest that there is a substantial burden of chronic diseases during the final years of 
life, which may come with an equally important number of medications. Second, it implies 
that chronological age is of limited value to estimate the remaining life expectancy of 
older persons with multiple chronic diseases, and thus to determine whether treatments 
are likely to achieve their benefit in a timeframe that is meaningful for patients. 
Figure 6. Multimorbidity, mortality risk and remaining life expectancy in old age 
Source: National Patient Register and National Prescribed Drugs Register, Swedish Board of Health and Welfare. 
A random sample of 100 000 older adults (≥75 years) living in the community on 1 June 2013 was drawn from the 
total population. These individuals were followed-up until 31 May 2014. Chronic diseases were captured by using 
the list proposed by Calderón-Larrañaga et al.320, based on ICD-10 codes reported for all inpatient and specialised 
outpatient care admissions, ATC codes for prescribed drugs, and free-text drug indications reported during a 5-
year period before baseline. Panel A shows the estimated hazard ratio for 1-year mortality as a function of the 
number of co-existing chronic conditions (reference: 1). These estimates were calculated with Cox proportional 
hazard regression analysis after adjustment for age, by using restricted cubic splines with 5 knots placed at 1, 3, 
5, 7 and 11 chronic conditions. The histogram at the bottom of panel A represents the distribution of individuals 
according to the number of co-existing chronic conditions (median: 5, interquartile range: 3–7). Panel B illustrates 
the remaining life expectancy of men and women aged 75 years according to their number of co-existing chronic 
conditions. To estimate the number of years of remaining life expectancy, period life tables were constructed 
based on the observed mortality rates at each subsequent attained age. The overall life expectancy of community-
dwellers at age 75 was 15 years for women and 12 years for men. 
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Physical frailty and vulnerability 
In combination with chronic multimorbidity and disability, frailty contributes to the 
complexity of older persons’ clinical profile near the end of life.59,308 Frailty can be broadly 
defined as a state of high vulnerability in which relatively minor stressors can cause 
disproportionate adverse health outcomes. The inability to return to homeostasis is the 
consequence of a progressive decline in multiple organ systems and of impaired 
physiological reserve.330 Numerous definitions of frailty have been proposed, based 
either on the notion of accumulated deficits331,332 or on a specific phenotype.333 This 
second approach laid the foundation to build a large consensus about the notion of 
physical frailty, “a medical syndrome […] characterized by diminished strength, 
endurance, and reduced physiologic function that increases an individual’s vulnerability 
for developing increased dependency or death.”334 The prevalence of physical frailty in 
the general older population is estimated to be 10-20% among community-dwellers335,336 
and above 50% among nursing home residents,337 with great heterogeneity across 
studies. Although frailty is a transitional, non-absorbing state, trajectories of worsening 
disabilities are more common than trajectories of durable improvement.338 Hence, at age 
75 women can expect to live 5.5 years with physical frailty out of 14 years of total life 
expectancy.339 Therefore, the burden of morbidity directly attributable to frailty is 
substantial near the end of life.340 In a prospective study of community-dwelling older 
adults in Connecticut, Gill et al. found that frailty was the most common condition leading 
to death, accounting for 28% of all deaths (n=107/383).39 A large retrospective cohort 
study based on a sample of 57 753 deceased patients enrolled in the Veteran Affairs 
health system recently showed that 18% of older adults had a primary diagnosis of 
frailty.341 Similar estimates were calculated in the Health and Retirement Study (15%, 
n= 7204 decedents).342 In Catalonia, advanced frailty was found to be the most common 
underlying condition of older adults in need of palliative care (31%), before dementia 
(23%) or cancer (13%).343 
The transition from fit to pre-frail or from pre-frail to frail is often prompted by the 
progression of an underlying disease.344–346 However, findings from multiple studies 
suggest the existence of iatrogenic transitions, namely incident impairments attributable 
to the utilisation of healthcare services (e.g. excessive bed rest during hospital stays, 
overuse of diapers and urinary catheterization, inappropriate drug prescribing, use of 
physical restraints).347–349 Repeated hospital admissions near the end of life have also 
been found to play an important role in the worsening of functional decline in frail 
individuals.350 Among older patients with cancer, systemic treatments and invasive 
interventions (e.g. surgery, chemotherapy, radiation therapy) can also challenge 
physiological reserve and trigger a spiral of decline.351 After summarizing the evidence 
from 20 observational studies that included 2916 older patients with solid or 
haematological malignancies, Handforth et al. reported a median prevalence of frailty of 
42%, and found that frailty was associated with a 4-fold increased risk of chemotherapy 
intolerance and severe postoperative complications within 1 month.352 
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Frailty often overlaps with disability and multimorbidity.353,354 However, geriatricians have 
called for a shift in the understanding of frailty in old age, suggesting to move past the 
predominantly disease-centric approach of geriatric care355 and to tailor health 
interventions for older adults with impaired physical functioning but no disability.356–358 
This is particularly relevant in the context of end-of-life care, since the natural course of 
frailty with no underlying advanced disease is often hardly predictable.359,360 For instance, 
Gill et al. could not find any obvious pattern in the disability trajectories during the last 
year of life of frail older persons.39 Likewise, although earlier reports suggested a more 
homogeneous clinical course of disability in frail older people near the end of life, no 
study could identify clear and consistent trajectories of functional decline combining 
multimorbidity, disability and physical frailty in a foreseeable manner.361,362 However, 
public health researchers at the University of Newcastle have recently demonstrated that 
older adults at highest risk of dying had a distinct trajectory of frailty during their last year 
of life. They suggested that routinely collected data at the population level can be 
leveraged to facilitate the identification of individuals at high risk of frailty near the end 
of life.363 They also argued that while frail older patients are often more inclined to 
express a preference for minimally invasive medical treatments at the end of life, these 
preferences are susceptible to shift during critical phases of care.364 Clinicians caring for 
frail older adults thus face important challenges, including the timely recognition of the 
palliative phase, the management of symptoms associated with frailty (e.g. weight loss, 
weakness, fatigue, musculoskeletal pain), and the coordination of multiple professional 
caregivers scattered across different care settings.365,366 All these factors can make the 
prescribing process even more difficult at the end of life.  
Prevalence of distressing symptoms near the end of life 
Many older adults experience distressing symptoms during the final months before 
death, which adds to the existing burden of morbidity due to multimorbidity, disability, 
and frailty. Several systematic reviews and meta-analyses have been published over the 
past decade, documenting the high prevalence of physical and psychological symptoms 
at the end of life (Table 4). Overall, the most common symptoms are pain, fatigue, 
dyspnoea, dry mouth, cough, nausea, constipation, anorexia, depressed mood, anxiety, 
delirium and insomnia. In a systematic review and meta-analysis focused on the 
prevalence of symptoms in older cancer patients receiving palliative care, Van Lancker et 
al.367 found that fatigue (78%), urinary incontinence (71%), asthenia (66%), pain (66%), and 
constipation (52%) were frequent at the end of life. However, it is a misconception that 
only cancer patients experience distressing symptoms at the end of life. Older persons 
who die from end-stage heart failure, renal failure, COPD, Parkinson’s disease, or 
dementia also express significant discomfort.368 Stow et al. recently reported the results 
from a systematic review showing that older adults with frailty often experience pain, 
nausea, shortness of breath, fatigue, and drowsiness. These findings highlight the 
considerable burden that physical and psychological symptoms exert on older people’s 
well-being near the end of life, regardless of their cause of death. 
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Author,  
year 
Inclusion criteria 
and target population 
No.  
studies 
No.  
persons 
Summary of main findings 
Janssen, 
2008369 
Quantitative studies reporting 
the prevalence of symptoms in 
patients with end-stage chronic 
organ failure (CHF, COPD, 
ESRD) at the end of life 
39 NR Daily symptom burden was high in end-stage 
chronic organ failure, irrespective of the 
underlying disease. Burdensome symptoms 
included fatigue, dyspnea, insomnia, pain, dry 
mouth, cough, anorexia, depression, anxiety, 
constipation, nausea, and delirium. 
Mitchell, 
2011370 
Quantitative, interview-based 
studies reporting the 
prevalence of depression in 
adult patients with cancer in 
palliative care settings 
24a 4007 Pooled prevalence of depression was 16.5% (95% 
CI, 13.1–20.3) according to DSM or ICD criteria. 
Prevalence of major depression was 14%. 
Prevalence of all types of depression combined 
was of 24·6% (95% CI 17.5–32.4). 
Moens, 
2014368 
Quantitative studies reporting 
the prevalence of symptoms 
among patients with advanced 
cancer, AIDS, chronic heart 
failure, COPD, ESRD, MS, PD, 
and dementia 
143 78 469 Largest number of published studies for 
advanced cancer (n=57) and end-stage renal 
disease (n=47). Four symptoms (pain, fatigue, 
anorexia, and dyspnea) had a prevalence rate 
≥50% for all studied diagnostic groups. Other 
common symptoms included nausea, insomnia, 
constipation, depression and anxiety. 
Murtagh, 
2007371 
Quantitative studies reporting 
the prevalence of symptoms 
among adult patients with end-
stage renal disease 
61b NR Commonly reported symptoms included fatigue 
(71%), pruritus (55%), constipation (53%), 
anorexia (49%), pain (47%), sleep disturbance 
(44%), anxiety (38%), dyspnea (35%), nausea 
(33%), and depression (27%) 
Solano, 
2006372 
Quantitative studies reporting 
the prevalence of symptoms 
among patients with advanced 
or terminal cancer, AIDS, heart 
disease, COPD, or renal failure. 
64 NR Prevalence of 11 symptoms was reported, with 
important heterogeneity across studies and 
across diseases. Three symptoms (pain, 
breathlessness, and fatigue) had a prevalence 
rate ≥50% for all five diseases. Dyspnea was also 
common (10–95%). 
Teunissen, 
2007373 
Quantitative studies reporting 
the prevalence of symptoms 
among adult patients with 
incurable cancer. 
44c 25 074c The authors report the prevalence of 37 
symptoms assessed in at least five studies. Five 
symptoms (fatigue, pain, weakness, and appetite 
loss) had a prevalence ≥50% 
Van den  
Beuken, 2016374 
Quantitative studies reporting 
the prevalence of pain in 
patients with advanced cancere 
24d 9653 Pooled prevalence rate of pain in patients with 
advanced, metastatic, or terminal cancer was 
66% (95% CI, 58–75). 
Van Lancker, 
2014367 
Quantitative studies reporting 
the prevalence of symptoms in 
older adults (≥ 65 years) with 
cancer receiving palliative care 
17 652e A total of 32 symptoms were identified, of which 
16 were included in the meta-analysis. Symptoms 
reported by >1 study included fatigue (pooled 
prevalence 78%), incontinence (71%), weakness 
(67%), pain (66%), constipation (52%), nausea 
(35%), anorexia (41%), dyspnea (33%). 
Table 4. Prevalence of symptoms near the end of life: overview of published systematic reviews and meta-
analyses (2000-2019) 
Abbreviations: AIDS, acquired immune deficiency syndrome; COPD, chronic obstructive pulmonary disease; ESRD, end-stage 
renal disease; PD, Parkinson’s disease; MS, multiple sclerosis; NR, not reported. Note: this overview does not include the 
systematic review by Lokker et al.375, which included only quantitative studies (n=29) reporting the prevalence of death rattle 
in the dying phase of adults (n=8280). aMitchell et al. also report the prevalence of depression and related mood disorders in 
70 additional studies with 10 071 individuals in oncological and haematological settings. bThese 61 studies were reported in 
64 different articles c Including 6 studies (n= 2219 patients) about symptom prevalence during the last 1-2 weeks of life. dOut 
of a total of 122 studies included in the review. eMaximum number of participants included in the pooled prevalence rates. 
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1.4 DRUG UTILISATION IN OLD AGE AND NEAR THE END OF LIFE 
One more pill for every ill 
With the advent of evidence-based medicine in the mid-1990s—the term was first coined 
by Gordon Guyatt in 1991376,377—clinical practice guidelines have progressively become 
one of the cornerstone of modern medicine. Clinical practice guidelines are defined by 
the Institute of Medicine as “recommendations intended to optimize patient care that are 
informed by a systematic review of evidence and an assessment of the benefits and 
harms of alternative care options.”378 They are used by physicians and patients to make 
decisions about the use of diagnostic, preventive, and therapeutic interventions. The 
tools and criteria used to assess the quality of the evidence upon which clinical guidelines 
are built (e.g. Grading of Recommendations, Assessment, Development and Evaluations 
[GRADE] rating framework379) give considerably more weight to randomised controlled 
trials and meta-analyses than observational studies, owing to the risk of confounding bias 
and—among other issues—immortal time bias, performance bias, and detection bias 
that often plague the latter. Randomised clinical trials are, in their vast majority, designed 
to measure the effect of a single intervention on a single health problem; for instance, 
the efficacy and safety of a specific drug treatment for the management of a specific 
disease. Moreover, trial participants are typically sampled from a population of 
individuals who only have the disease of interest, with no or few comorbidities.380–383  
As a result, because the available evidence only allows for drawing inference about one 
treatment-disease pair at a time, recommendations embedded into clinical practice 
guidelines address single diseases. For certain chronic diseases such as hypertension, 
heart failure or diabetes, a carefully vetted combination of several therapies is sometimes 
recommended to maximise benefits and minimise adverse outcomes. Energetic 
implementation policies from medical specialty societies and pay-for-performance 
programmes or similar value-based models initiated by healthcare authorities aim at 
increasing physicians’ adherence to guideline-recommended treatments. In many cases, 
this disease-specific approach can lead to remarkable improvements in the management 
of isolated conditions. One pitfall of this silo-based model, however, is the situation of 
multimorbid patients, who account for a substantial fraction of the older population. For 
these patients, the application of single-disease clinical practice guidelines can lead to an 
exponential number of prescribed drugs and increasingly complex regimens.384–386 Boyd 
et al. estimated that, if all applicable recommendations were followed, a hypothetical 79-
year-old woman with five concomitant chronic conditions (hypertension, diabetes, 
osteoporosis, osteoarthritis, and COPD) would be treated with 12 different prescription 
drugs, requiring 19 doses per day taken during 5 distinct dosing times.387 Okeowo et al. 
recently reiterated this simulation exercise, with similar results.388 In sum, multimorbidity 
leads to an accumulation of treatments recommended for the compartmentalised 
management of a specific health problem, which may have conflicting pharmacological 
targets, cause harmful interactions, and set off hazardous prescribing cascades. 
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Polypharmacy and inappropriate drug use in the general older population 
Polypharmacy is the concurrent utilisation of several medications by a single individual. 
There is currently no consensual operationalisation of polypharmacy. However, previous 
studies have frequently relied on a cut-off point of ≥5 medications to measure its 
prevalence in the older population.389–391 Estimates from the National Health and 
Nutrition Examination Survey in the United States suggest that 39% of community-
dwellers aged ≥65 years are exposed to polypharmacy.392,393 In Sweden, recent findings 
indicate that the prevalence of polypharmacy in the community rises up to 42% and that 
the incidence rate is 20 per 100 person-years.394 Among older adults living in nursing 
homes, a cross-national study conducted in Europe showed that polypharmacy affected 
about 75% of residents.395 A review of the literature showed that the proportion of older 
adults with polypharmacy is increasing worldwide.396 As discussed previously, the high 
prevalence of polypharmacy mirrors the prevalence of multimorbidity in old age, which 
partly explains the observed association with age (Figure 7). 
The prescribing of many different drugs may often be justified by the necessity to 
properly manage multiple chronic diseases and symptoms.397–399 In other words, 
polypharmacy is not necessarily inappropriate.400 However, it poses important clinical 
challenges as it comes with increased risk of negative health outcomes.401–406 
Polypharmacy has, for instance, been found to be associated with a substantial rise in 
potentially harmful drug-drug interactions407,408 and serious adverse drug reactions.409–417 
Figure 7. Polypharmacy in relation to multimorbidity and age among older adults in Sweden 
Source: Cross-sectional data from the Swedish Prescribed Drugs Register, linked at the individual level with the 
Total Population Register and the National Patient Register. Random sample of 100 000 older adults living in the 
community (i.e. not institutionalised) on 1 June 2013. In panel A,  chronic diseases were captured by using the list 
proposed by Calderón-Larrañaga et al.320 The curve corresponds to the polynomial (degree 3) fit of the number 
of prescribed drugs according to the number of chronic diseases. In panel B, the stacked bars represent – for 
each given age – the distribution of the population according to the number of prescribed drugs. 
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Furthermore, recent studies have suggested that the mere number of drugs may 
increase the risk of injurious falls, beyond the effect of specific pharmacological classes 
known to induce imbalance, sleepiness, reduced vigilance, or mobility difficulties.418–420 
Older adults with polypharmacy are also less likely to maintain adequate adherence to 
chronic treatments.421,422 Finally, the number of medications used concomitantly by a 
person is the single most important predictor of potentially inappropriate drug use423–426, 
which further amplifies the risk of serious drug-related adverse events.427 
The ageing process is characterised by important changes in body composition and organ 
functions.428–431 These modifications not only alter the absorption, distribution, 
metabolism and excretion of drugs (pharmacokinetics) but also enhance the sensitivity 
of older adults to specific drugs (pharmacodynamics), which in turn increases the risk of 
adverse drug reactions.409,413,431–433 Therefore, some drugs with a favourable benefit–risk 
ratio in the general population are contraindicated for older adults. In the geriatric 
pharmacology literature, drugs are considered potentially inappropriate when the risk of 
harmful effects outweighs their expected benefit, or when there exist a safer, better 
tolerated or more effective alternative.434 Inter-individual variation in the risk of adverse 
drug-related event makes the selection of appropriate and inappropriate medications 
challenging. To guide clinicians in their prescription, multiple instruments have been 
developed over the past 25 years (Table 5). Although some of these assessment tools are 
based on the implicit judgment of prescribers,435–438 most have been constructed around 
explicit criteria defined through literature reviews and expert consensus methods.439–441 
Existing criteria present major differences in their content and methodology.442 
In a nationwide, cross-sectional study of 1.3 million older adults aged ≥65 years in 
Sweden, we found that the prevalence of potentially inappropriate drug use varied from 
16% to 24% depending on the assessment tool we used.424 Despite this variability, the 
rate of potentially inappropriate drug use in the community (15-22%) was very similar to 
the pooled estimates previously reported in two distinct systematic review of the 
literature (20-23%).443,444 Among nursing home residents, we found that between 36% 
and 51% of the individuals living in institutions received potentially inappropriate drugs. 
We later confirmed this finding through a meta-analysis of 43 published studies 
(weighted average prevalence: 43.2%).445 Across different criteria, the most commonly 
reported inappropriate drug classes are long-acting benzodiazepines (e.g. diazepam), 
tricyclic antidepressants (e.g. amitriptyline) and other medications with anticholinergic 
properties (e.g. hydroxyzine, oxybutynin), nonsteroidal anti-inflammatory drugs, digoxin, 
and long-term use of proton-pump inhibitors. 
A considerable body of literature has investigated the role of potentially inappropriate 
drug use in the occurrence of negative health outcomes. In a meta-analysis of three 
observational studies accounting for a total of 1.8 million older people in the United 
States,446–448 researchers recently showed that incident use of inappropriate drugs was 
associated with a 60% relative increase of 1-year mortality.470  
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Criteria, year Country Target population Content 
Beers, 2019449 United  
States 
Older adults (≥ 65 years), 
excl. palliative care 
114 single drugs or drug classes to avoid; 
71 drugs or drug classes to avoid in older 
adults with specific diseases or syndromes; 
16 medications to be used with caution; 13 
clinically important DDIs; 20 drugs to avoid 
or to adapt according to the renal function. 
EU(7)-PIM450 Europe Older adults (≥ 65 years) 282 drugs considered potentially 
inappropriate (including 72 identified as 
“most frequent”) 
EURO-FORTA, 
2018451 
Europe Older adults (≥ 65 years) 264 items organised into 26 main 
indication groups, and graded from “A  
(Absolutely) : indispensable drug” to “D 
(Don’t): avoid in older people.” 
Laroche, 2007452 France Older adults (≥ 75 years) 34 criteria, including 29 single drugs or 
drug classes to avoid and 5 drugs or drug 
classes to avoid in older adults with specific 
diseases or syndromes. 
Maio, 2010453 Italy Older adults (≥ 65 years) 23 criteria, including 17 drugs that should 
always be avoided, 3 drugs that are rarely 
appropriate, and 3 drugs that may have an 
indication but are often misused. 
McLeod, 1997454 Canada Older adults (≥ 65 years) 38 criteria, including 18 drugs generally 
contraindicated for elderly people, 16 
drug–disease interactions and 4 drug–drug 
interactions. 
NORGEP, 2009455 Norway Older adults (≥ 70 years) 
in general practice 
36 criteria, including 21 single drugs and 15 
drug combinations considered potentially 
inappropriate for older adults. 
NORGEP-NH, 
2015456 
Norway Older adults (> 70 years) 
in nursing homes 
34 criteria, including 11 single drugs and 14 
drug combinations that should be avoided, 
as well as 8 drug classes that should be re-
assessed and possibly deprescribed 
PRISCUS, 2010457 Germany Older adults (≥ 65 years) 83 single drugs considered potentially 
inappropriate. 
STOPP/START, 
2014 458 
United 
Kingdom 
Older adults (≥ 65 years) 114 criteria, including 80 drugs and drug-
disease combination considered 
potentially inappropriate (STOPP) and 34 
drugs considered appropriate and 
indicated for older adults (START). 
STOPPFrail, 
2017459 
United 
Kingdom 
Frail older adults  
(≥ 65 years) with  
limited life expectancy 
27 criteria, including 2 implicit criteria 
suggesting to deprescribe any medication 
without a proper indication or with too 
poor compliance, and 25 drugs or drugs 
classes that are considered potentially 
inappropriate  
Swedish Board of 
Health and 
Welfare, 2017 460 
Sweden Older adults (≥ 65 years) 34 criteria, including 8 drug classes and 
drug combinations that should be avoided 
in older adults.  
Table 5. Selected list of explicit criteria for inappropriate drug use in older adults 
Note: The first version of the Beers criteria was published in 1991461 and aimed to identify potentially inappropriate 
medication use among nursing home residents. It was first revised in 1997462 and made applicable also for 
community-dwelling older people. The list was thereafter revised in 2003463, 2012464, 2015465, and more recently in 
2019449. The EURO-FORTA list is an extension of the FORTA (Fit fOr The Aged) initiative which was initially released in 
2013466, validated with an expert consensus in 2014467, and updated in 2015468. The Laroche list (2007) is currently 
being updated in France. The first version of the STOPP/START criteria was published in 2008469, and updated in 
2014458. The Swedish criteria were first introduced in 2004, and were updated in 2010 and 2017460. 
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Others studies reported a substantial rise in the risk of non-elective hospitalisation471–475 
and hip fracture,476 with particularly deleterious effects among older adults with 
dementia.477,478 However, previously developed criteria (e.g. Beers, STOPP–START, 
NORGEP) are of limited clinical value to evaluate the quality of drug prescribing in the 
context of end-of-life care. Drug classes considered potentially inappropriate because of 
their side effects (e.g. opioids, benzodiazepines, scopolamine) may for instance be 
indicated for the management of distressing symptoms during the final weeks of life. On 
the contrary, drugs deemed appropriate for older adults in general may have no 
substantial benefit and present a higher risk of harmful effects during the final months 
of life. As noted by Spinewine et al., “much of the published work has condensed the 
notion of appropriateness to simply pharmacological appropriateness, i.e. whether a 
drug is seen as safe and effective, or sometimes cost-effective.”434 A number of studies 
have emphasised the need to look beyond pharmacology and to adopt a broader view of 
the quality of prescribing in older adults.479–482 There is a need to reconsider what 
constitutes ‘potentially inappropriate prescribing’ in older adults at the end of life.483–487 
Overtreatment and low-value care 
The challenge of drug prescribing for older persons during the final months before death 
is not only to avoid serious adverse events and to ensure optimal symptom management, 
it is also to avoid overtreatment, namely providing medical resources that present a trivial 
or no benefit during a patient’s lifetime.488,489 Some authors favour the expressions non-
beneficial treatments or low-value care to express the disproportion between the intensity 
and the potential harms of treatments on the one hand, and the expected benefit in 
terms of health improvement, survival, or quality of life on the other hand.270 
As mentioned earlier, considerations about the use of potentially futile treatments near 
the end of life have first surfaced in the field of intensive care in the late 1980’s and early 
1990’s. Debates were fuelled by growing concerns that life-sustaining interventions for 
critically ill persons (e.g. use of mechanical ventilation or cardiopulmonary resuscitation 
for patients in a persistent vegetative state) may have no clinical benefit and only serve 
to prolong the dying process with substantial discomfort.490,491 The appropriateness of 
treatments in the context of limited life expectancy has also been questioned in medical 
oncology.492–497 Over the past three decades, ground-breaking progress of anticancer 
therapy has indeed been accompanied by the increased aggressiveness of disease-
targeted treatments during the final months and weeks of life of terminally ill 
patients.277,282,498,499 This has raised serious questions for the quality of end-of-life cancer 
care due to the lack of benefit of chemotherapy close to death, its potentially disastrous 
toxicity, and its negative impact on quality of life.500,501 As a result, the American Society 
of Clinical Oncology (ASCO) has included the use of chemotherapy for patients with 
advanced cancer and low performance status in its top-five list of “tests, procedures and 
treatments whose common use and clinical value are not supported by available 
evidence.”502 
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The issue of overtreatment extends far beyond end-of-life care and patients with serious 
illness. It is a widely acknowledged challenge for modern healthcare systems503–505 and 
has received considerable attention from the medical profession and the lay public.506–509 
Overtreatment is often the consequence of overdiagnosis, that is the diagnosis of a 
condition or physiological abnormality that, if unrecognised, would not have caused 
symptoms or harms in the first place.510–512 Overdiagnosis includes, for example, routine 
electrocardiograms in patients with no history of cardiovascular disease,513 screening for 
abdominal aortic aneurysm,514 or screening for breast cancer in women aged 75 years or 
older with less than 10 years of remaining life expectancy.515–518 The overuse of diagnostic, 
preventive, and therapeutic interventions can have unintended negative consequences 
and trigger a cascade of downstream services.519,520 Korenstein et al. recently proposed a 
conceptual map that classifies the harms of overdiagnosis and overtreatment in six 
different domains: physical (e.g. pain, injuries, disability, infections, adverse drug 
reaction), psychological (e.g. anxiety, stress, depression), social (e.g. disruption of familial, 
intimate, and social life), financial (direct and indirect economic costs), treatment burden 
(e.g. pill burden, INR testing), and dissatisfaction with care.521 
The provision of low-value medical services is well documented504 and has become 
commonplace. In the United States, Schwartz et al. estimated that in 2009 between 25% 
and 42% of patients covered by Medicare (≥65 years) received at least one of 26 examined 
low-value care procedures. Low-value care amounted to $1.9–$8.5 billion in healthcare 
expenditures nationally.522 In Canada, about 30% of older adults aged 75 years and over 
had received at least one of 10 low-value services.523  
These findings are problematic for three main reasons. First, because overtreatment 
exposes patients to unwarranted harm, either as a direct result of healthcare encounters 
and treatment uptake or indirectly through the use of downstream health services. In a 
recently published systematic review and meta-analysis of the literature (n=70 studies), 
Panagioti et al. calculated that 6% of patients were affected by preventable medical harm, 
most often involving drugs (25%) and other treatments (24%).524 Older persons are 
particularly vulnerable to adverse drug reactions; drugs that are usually well tolerated 
can cause serious harms that outweigh the benefit of the pre-existing treatment regimen. 
Second, because the overuse of non-beneficial treatments can paradoxically lead 
prescribers to omitting necessary treatments whose clinical value is well established, thus 
creating situations of undertreatment.421,525–530 Third, because overtreatment is the cause 
of considerable healthcare expenditures, generated not only by the treatments 
themselves but also by the resources needed to manage their iatrogenic effects. These 
healthcare costs could instead be dedicated to other patients who may need the 
treatments in question (economic transfer between patient groups to advance social 
justice) or to effective healthcare interventions that currently not readily available 
(economic transfer across medical services to optimize cost-effectiveness). The overuse 
of medical treatments has come under particularly close scrutiny in the context of 
advanced illness, limited life expectancy, and palliative goals of care.  
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Rationalising drug prescribing at the end of life 
Initially focused on medical interventions considered particularly invasive, concerns 
about the lack of meaningful clinical benefit and the potential for harm among patients 
at the end of life have since been extended to a broader range of treatments, including 
prescription drugs.531,532 In a 2004 article published in the British Medical Journal, 
Stevenson et al. examined the issues surrounding the decision to continue or discontinue 
medications prescribed for the management of chronic comorbidities in patients with 
life-limiting illness.481  “As prognosis worsens”, they wrote, “the challenge is to balance the 
diminishing benefits with the increasing side effects.” The difficulty is also to predict the 
appropriate time for gradually shifting the therapeutic objectives from predominantly 
preventive and curative treatments to predominantly palliative and symptomatic care.533 
Non-symptomatic drugs prescribed to older people with limited life expectancy are 
sometimes deemed ‘inadequate’ or ‘unnecessary’ based on their insufficient 
effectiveness and the high risk of undesirable effects that they can cause.534–537 This 
approach is characterised by a probabilistic view of what constitute adequate treatments 
near the end of life: medications are evaluated based on the likelihood that they will 
provide a significant benefit in terms of symptom control or survival vs. the likelihood that 
they will have side effects. A second model relies on a modified version of the Medication 
Appropriateness Index, a set of implicit criteria focused on the quality of the prescribing 
process (namely the existence of a clear indication for the drug, the appropriateness of 
the dosage, the absence of duplicates, and the risk of drug-drug interactions).436,538,539  
A third approach has been developed by Holmes et al.,540,541 that builds on the pillars of 
the two above-mentioned prescribing models but incorporates two additional elements. 
First, clinicians should carefully compare the time needed for the treatment to achieve its 
benefit (‘time to benefit’542,543) and the patient’s remaining life expectancy. Long-term 
preventive drugs that typically yield a measurable absolute risk reduction only after a few 
months or a few years may for instance be of little value for an 85-year-old patient with 
metastatic non-small cell lung cancer and five chronic comorbidities, whose life 
expectancy does not extend beyond 6 months and who will most likely die before the 
benefit of the drugs can accrue. Second, Holmes argues, the therapeutic outcome that 
the treatment is expected to achieve should remain aligned with the goals of care 
established with the patient. In other words, drug treatments should be prioritised 
according to their ability to obtain a health outcome that the patient values as important. 
This patient-centric approach to drug prescribing provides a useful roadmap to re-
examine the notion of benefit when discussing the appropriateness of drugs near the end 
of life. The proposed framework is also well in keeping with the American Geriatrics 
Society’s guiding principles on the care of older adults with multimorbidity,544 and is 
closely aligned with recent initiatives aiming at reducing wasteful clinical practices such 
as the Choosing Wisely campaigns in the United States and 19 other countries.545–549 
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Lack of evidence to estimate the burden of inadequate drugs at the end of life 
Despite mounting interest in geriatric medicine and in the palliative care community, only 
a handful of studies investigating drug prescribing patterns among older adults at the 
end of life were published before this thesis started in June 2015. A review of the literature 
(Appendix Table) suggests that a large proportion of persons at the end of life is exposed 
to polypharmacy539,550–565 and that the number of drugs often increases as death 
approaches.551,558,566 Furthermore, previous studies have suggested that the continuation 
of preventive medications is commonplace during the final months and weeks before 
death.534–536,538,567–578 Some authors also reported that drug-drug interactions were highly 
prevalent.539,552,556 One study indicates that the anticholinergic load rises near the end of 
life, partly because of the increasing use of medications for symptom management (e.g. 
oxycodone, morphine, fentanyl, scopolamine).579 
However, the available evidence stemmed mostly from studies conducted in selected 
populations, which were defined either based on an index disease (e.g. cancer, dementia) 
or on a specific care setting (e.g. nursing home). The generalisability of these findings was 
therefore limited, and large-scale epidemiological studies were warranted to examine the 
patterns of drug prescribing near the end of life at the population level. 
In addition, high-quality evidence from randomised clinical trials or well-designed, 
prospective observational studies about the effectiveness and safety of drug treatments 
in older persons with advanced illness and limited life expectancy is lacking. As a result, 
clinical guidance regarding the initiation, continuation, and discontinuation of drugs is 
limited. The development of consensus-based criteria to identify drugs that are most 
likely adequate, questionable, or inadequate for older adults at the end of life could thus 
represent an important step towards providing clinicians with tools to help them 
rationalise drug prescribing in this context.580 Such criteria would also enable researchers 
to generate comparable epidemiological evidence across patient groups, care settings, 
regions, and countries.
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2. AIMS AND RESEARCH QUESTIONS 
2.1 OVERALL AIM 
The overarching aim of this doctoral thesis was to evaluate the quality of drug prescribing 
in older adults near the end of life. We set out to examine drug utilisation patterns during 
the last year of life of older adults, to propose consensus criteria for evaluating the 
adequateness of drug treatments for older adults at the end of life, and to investigate the 
prevalence, determinants, and cost of potentially inadequate drugs in this setting. 
2.2 RESEARCH QUESTIONS 
The overall aim was examined in four individual studies, which addressed specific 
research questions. 
Study I: How does the burden of prescription drugs among older adults develop 
throughout their last year of life?   
In the first study we aimed to measure longitudinal changes in the number of prescribed 
drug treatments and in the prevalence of polypharmacy, and to identify the most 
commonly used drugs and drug classes during the last months before death in a cohort 
of older adults who died from any cause. 
Study II: Do older adults who died with solid cancer continue to receive preventive 
drugs near the end of life? What are the costs of these preventive drugs? 
In the second study, we focused our attention on older adults who died with solid 
malignancies. Our objective was to evaluate the uptake of preventive drug therapy 
between the 12th month before death and the final month of life, and to estimate the 
direct costs of these treatments across different cancer types. 
Study III: What drugs and drug classes are most often of limited clinical benefit for 
older adults at the end of life? 
The purpose of the third study was to develop consensus criteria for identifying drugs of 
limited clinical benefit for older people at end of life, through a Delphi survey involving 
European experts in palliative care, geriatrics, general practice, and pharmacology. 
Study IV: Are drugs of limited clinical benefit often continued or initiated near the 
end of life? 
In the fourth and last study, we aimed to measure the proportion of older adults with life-
limiting illness who either continued or initiated potentially inadequate drugs during their 
last months of life, according to the criteria developed in Study III.
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3. MATERIALS AND METHODS
3.1 DATA SOURCES 
All studies included in the present thesis (except Study III) are based on routinely collected 
administrative and healthcare data, that is data collected as part of a standard 
administrative or care process independently of specific a priori research purposes.581,582 
Total Population Register 
The Total Population Register (Swedish: registret över totalbefolkningen) was established in 
1968 by Statistics Sweden, based on computerised records from the local population 
registers. Individuals are assigned a unique personal identity number, which was first 
introduced in 1947. The register is maintained continuously and updated 5 times per 
week with data from the Swedish Tax Agency. It covers all persons registered as Swedish 
residents, including immigrants. A detailed account of the Total Population Register and 
its use in medical research is available elsewhere.583 
National Cause of Death Register 
The Swedish National Cause of Death Register (Swedish: dödsorsaksregistret) is 
administered and curated by the National Board of Health and Welfare. It is deemed 
complete since 1952, although detailed data about causes of death are available at the 
national level since 1911.584 Sweden has a long and well established tradition of collecting 
high-quality mortality data, with nationwide statistics dating back to 1751.585,586  
Death certification follows a 2-step procedure. First, the physician who pronounces death 
must notify the Swedish Tax Agency without delay. After this first notification, the medical 
death certificate is sent to the National Board of Health and Welfare within 3 weeks by 
the family physician or by the physician who last saw the patient either on paper (Figure 
8) or electronically. Causes of death are coded with the International Statistical
Classification of Diseases and Related Health Problems, 10th revision (ICD-10). For each
decedent, up to 48 distinct causes of death can be recorded. In keeping with the ICD-10
rules for mortality coding, the underlying cause of death is defined as “the disease or
injury which initiated the train of morbid events leading directly to death, or the
circumstances of the accident or violence which produced the fatal injury.”587 Electronic
classification systems have been used since 1987 to facilitate the selection and coding of
the underlying cause of death (ACME software from the U.S. NCHS). With the adoption of
the Iris system in 2012 and the switch to Iris v5 in 2017, the selection of the underlying
cause of death is now based on the Multicausal and Unicausal Selection Engine (MUSE).
About 1% of all deaths have no reported underlying cause of death. Out of ~90 000
deaths annually, 5000 undergo a specific forensic investigation (i.e. 7% of deceased
women and 15% of deceased men). Swedish residents who die abroad are accounted for.
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Figure 8. Standard death certificate in Sweden (unofficial English translation) 
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Swedish Prescribed Drug Register 
The Swedish Prescribed Drug Register (Swedish: läkemedelsregistret) was implemented in 
July 2005.588,589 Data about all prescription drugs dispensed at pharmacies in Sweden are 
transferred on a monthly basis to the National Board of Health and Welfare. 
Approximately 85% of all dispensed defined daily doses (DDDs) are covered by the 
register. Over-the-counter medications (12% of DDDs), drugs administered in hospitals 
(3% of DDDs) are not included. Vaccines and drugs dispensed in nursing homes with a 
drug storeroom are only partially covered. Between 2005 to 2015 the Swedish Prescribed 
Drug Register collected data about 660.7 million prescriptions drugs dispensed to 2.8 
million persons aged 65 years and older. 
National Patient Register 
The National Patient Register (Swedish: patientregistret) was started in 1964 and has full 
national coverage for inpatient care since 1987. It includes all inpatient admissions in 
Sweden from both public and private providers, with >99% completeness for somatic and 
psychiatric hospital discharges. Clinical diagnoses are coded according to the ICD 
classification (ICD-10 since 1997). The validity of these diagnoses has been found to be 
very high, with a positive predictive value greater than 95% for acute and severe 
conditions.590 It also collects data about specialised outpatient care since 2001, including 
day surgery and psychiatric care. The coverage of outpatient diagnoses is typically lower 
than for inpatient data but remains above 80% overall. The National Patient Register does 
not contain information about primary care. 
Social Services Register 
In Sweden, elderly care is primarily funded by local taxes and government grants to 
municipalities (>95%). While medical care is organised by county councils, the 
responsibility for social and long term care lies with the 290 municipalities, which have a 
legal obligation to provide adequate care and housing for older people and people with 
disabilities.591 Social care is a universal right provided based on needs assessment and 
largely subsidised.592 The Social Services Register (Swedish: registret över 
socialtjänstinsatser till äldre) collects individual-level data about the provision of care 
services to older persons and persons with functional impairments. It was first launched 
in 2007 and has been implemented in routine since 2013. The register contains data 
about persons who live in nursing homes and residential care homes, persons who have 
been granted home care help or assistance for their activities of daily living in the 
community, and persons who are admitted into short-term nursing facilities. The status 
of each individual is reported on the last day of each month (e.g. 31 October). The overall 
quality of the data is good, but some municipalities have lower-than-average reporting 
rates. On average, about 5% of persons aged ≥65 years (n= 82 000) live permanently in 
nursing homes. 
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Swedish Register of Education 
The Swedish Register of Education (Swedish: utbildningsregistret) was first established in 
1985. It contains data from the 1970 and 1990 population and housing censuses, as well 
as annual updates from Statistics Sweden from 2000 to 2014. Data are reported directly 
by educational institutions, thereby increasing the validity of the register. Educational 
attainments are coded with the SUN2000 nomenclature, which is adapted to the 
International Standard Classification of Education (ISCED-97).593 
Longitudinal integration database for health insurance and labour market 
studies (LISA) 
The LISA database was established in 1990 (and expanded considerably in 2004) to track 
workers’ health in relation with their professional occupation.594 It includes all individuals 
aged ≥16 years registered in Sweden on 31 December of each year. In this thesis, 
disposable income was defined as the total income received during the year prior to the 
year of death minus taxes. Disposable income includes earning (e.g. salaries), business 
income, sickness allowances, disability pensions, unemployment benefits, retirement 
and old-age pensions (National Retirement Pension Scheme), and general social support 
provisions. The disposable income of each individual was equivalised by dividing the total 
household disposable income by the number of consumption units in the household, in 
keeping with the OECD modified scale (first adult = 1.0, second adult = 0.51).595,596 
Database Population covered Information available 
Total Population 
Register (RTB) 
All persons aged ≥65 
years registered in 
Sweden 
Sex, date of birth, country of birth, municipality of 
residence, living arrangement, civil status, year of first and 
last immigration, year of last emigration 
Swedish Education 
Register 
All persons aged ≥65 
years registered in 
Sweden 
Highest educational attainment 
LISA All persons aged ≥65 
years registered in 
Sweden 
Disposable income, source of income 
National Cause of 
Death Register 
All decedents aged ≥65 
years at time of death 
Sex, date of birth, underlying and contributing causes of 
death (ICD-10), place of death, civil status 
National Patient 
Register (inpatient 
and specialised 
outpatient care) 
All persons aged ≥65 
years in Sweden 
Sex, age, date of admission and discharge, 
planned/unplanned admission, main diagnosis, secondary 
diagnoses, injuries, medical or surgical procedures, 
department of admission, provenance, destination. 
Social Services 
Register 
All persons aged ≥65 
years eligible under  
the Social Service Act 
Sex, age, provision of home care help (with type of ADL-
help and number of hours per month), housing in a nursing 
home, date of enforcement 
Swedish Prescribed 
Drugs Register 
All persons aged ≥65 
years in Sweden with at 
least 1 drug prescription 
Sex, age, date of prescription, date of dispensing, type of 
dispensing (e.g. multi-dose), total dose, prescribed daily 
dose (free text), number of DDDs dispensed, ATC code, 
generic name, costs, characteristics of prescribers 
Table 6. Summary of data sources used in Study I, Study II, and Study IV 
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3.2 STUDY DESIGNS AND POPULATIONS 
All studies but Study III were register-based, nationwide retrospective cohort studies, 
where older adults were selected at time of death from the National Cause of Death 
Register and followed-back over 1 year to reconstruct their healthcare utilisation history 
near the end of life. Table 7 presents an overview of the four studies. 
The first study included all older adults who died at age ≥66 years between 1 January 2007 
and 31 December 2013 in Sweden, notwithstanding those who had no reported cause of 
death, and/or no prescription drug history during their last 3 months of life. Out of 
545 212 older persons who died during the study period, 511 843 decedents (93.9%) met 
the inclusion criteria. Among them, 39 610 (7.7%) died from sudden causes of death. 
In the second study, we focused our attention on older people who died with solid 
tumours, a set of conditions often associated with a rapid functional decline marked by 
a short and clear terminal phase. We included older people aged ≥65 years who died 
between 1 January 2007 and 31 December 2013 in Sweden and who had a diagnosis of 
solid cancer (ICD-10 codes C00–C76 and C80) reported in the National Patient Register 
during the last 2 years of life or in the National Cause of Death Register as either the 
underlying or one of the contributing causes of death. Decedents were excluded from 
the study population if they were diagnosed with a concomitant haematological 
malignancy near the end of life, if  they had no reported cause of death; if they had no 
prescription drug history during the last 6 months before death; or if they remained 
hospitalised continuously during the last 3 months before death. Of the 545 212 
decedents identified during the study period, 151 201 were eligible. 
The third study was based on a consensus panel of European experts, who participated 
in a web-based Delphi survey. This methodology is often used by researchers to elicit 
opinions from a group of experts about a subject for which there is insufficiently robust 
factual evidence to generate consensus. More details about this approach are provided 
hereafter (see 3.7 Delphi consensus). Among the 58 geriatricians, palliative care physicians, 
Study Population Design Outcomes 
Study I Older adults (≥65 years) 
who died in 2007–2013 
Retrospective cohort  
of decedents 
Polypharmacy, most commonly 
prescribed drugs 
Study II Older adults (≥65 years) 
who died with solid cancer 
in 2007–2013 
Retrospective cohort  
of decedents 
Use and costs of preventive drugs 
Study III Panel of European experts Delphi consensus survey Adequate, questionable and 
inadequate drugs at the end of life 
Study IV Older adults (≥75 years) 
who died in 2015 from 
conditions amenable to 
palliative care 
Retrospective cohort  
of decedents 
Continuation and initiation of 
potentially inadequate drugs 
Table 7. Overview of the four studies included in the thesis 
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general practitioners, pharmacists, pharmacologists and psychiatrists who were invited 
to contribute, 40 (69%) agreed to participate and were thus included. 
In the fourth study (follow-back cohort of decedents), we included all older adults aged 
≥75 years who died between 1 January and 31 December 2015. Only those individuals 
who died from non-sudden conditions potentially amenable to palliative care were 
eligible for inclusion, and decedents were further stratified according to their most likely 
trajectory of functional decline at the end of life based on the clinical conditions leading 
to death (Table 8).  We excluded individuals with no exact date of death or no reported 
cause of death, as well as those who had no prescription drug history during the last 6 
months before death. Out of 64 715 older adults aged 75 years and over who died in 
2015, a total of 58 415 (90.3%) met our eligibility criteria.  
Illness trajectory, conditions ICD-10 codes 
Trajectory 1. Short decline with evident terminal phase 
Solid tumours  
and haematological malignancies 
C00-C26, C30-C34, C37-C41, C43-C58, C60-C85, C88, 
C90-C97, D00-D09, D32, D33, D37-D48 
Trajectory 2. Long-term limitations with intermittent acute episodes 
Diabetes E10-E14, G590, G632, H360, M142, N083 
Other endocrinal diseases E70-E72, E75-E77, E84-E85 
Infectious and parasitic diseases  A520-A523, A527, A810, A812, B15-B19, B20-B24 
Diseases of the blood D60, D61, D69, D70, D752, D758, D86 
Diseases of the cardiovascular system 
(incl. cerebrovascular diseases) 
I231-I233, I238, I25, I50, I60-I67, I680-I682, I688, I69, 
G46, I27, I42, I43, I51, I520, I70, I73, I74, I792, I970, 
I971, I978, I980, I981, I988 
COPD and other respiratory diseases J40-J44, J47, J60-J62, J66, J701, J80, J841, J951-J953, 
J96, J980-J984, R060, R062-R065, R068 
Liver failure and other digestive diseases K44, K50, K51, K55, K56, K70-K77, K85, K86, K87, K90 
Diseases of the skin L305, L40-L42, L44, L93, L945 
Diseases of the musculoskeletal system M360, M361, M05, M06, M13, M15, M21, M30-M35, 
M40-M43, M45-M51, M53, M54, M638, M80, M81, 
M820, M821, M843, M844, M86-M88, M907, M961 
Renal failure and genitourinary diseases N02-N05, N11, N12, N136, N160, N18, N19, N25, 
N312, N318, N319, N82 
Other (incl. congenital conditions) Q01-Q06, Q078, Q079, Q20-Q28, Q31, Q33, Q40-
Q45, Q60-Q68, Q714, Q75-Q79, Q850, Q86-87, Q89-
Q93, Q95-Q97, Q99 
Trajectory 3. Prolonged dwindling with progressive loss of physical and cognitive capacities 
Alzheimer’s disease G30-G32 
Dementia and mental disorders F00, F01, F02, F03, F05, F06, R54 
Parkinson’s disease G20-G23 
Multiple sclerosis G35-G37 
Other diseases of the nervous system G10, G12, G70-G73, G03-G05, G07, G478, G518, 
G551, G608, G80-G83, G90-G99 
Trajectory 4. Sudden death, conditions not amenable to palliative care 
None of the conditions above N.A. 
Table 8. List of conditions potentially amenable to palliative care and categorisation into illness 
trajectories at the end of life
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3.3 ASSESSMENT OF DRUG EXPOSURE 
In drug utilisation research and pharmacoepidemiologic studies, the accurate estimation 
of drug exposure is crucial. In Sweden, drugs are dispensed for up to 90 days. The date 
of dispensing is thus not sufficient to estimate whether an individual was exposed to 
specific drugs during a given day or a given period of time (e.g. week, month). Since the 
number of days covered (number of days’ supply) when a prescription is filled is seldom 
reported in routinely collected data, the duration of drug exposure must often be 
calculated or predicted by using proxies.597–600 
To construct drug exposure periods in Studies I and II, we used information from the 
Swedish Prescribed Drug Register, which collected data about all prescription drugs 
dispensed at pharmacies in Sweden. Drugs are defined by their product name, a 7-digit 
Anatomical Therapeutic Chemical Classification (ATC) code, and a national drug code 
(Swedish: varunummer). The national drug code allows for identifying the manufacturer, 
the specific strength, pharmaceutical formulation and dosage form (e.g. tablet, capsules, 
liquid solutions, inhaler, suppository) of each drug, as well as the number of units and the 
number of defined daily doses per package. From July 2005 to December 2015, there 
were a total of 48 588 distinct pharmaceutical products authorised on the Swedish 
market, corresponding to 2520 chemical substances (5th level of the ATC classification). 
Figure 9. Estimation of prescribed daily doses and calculation of numbers of days covered 
In this example, an individual filled a prescription on 1 June 2010 and received 1 drug package containing the 
equivalent of 15 defined daily doses (DDD). Based on the dosage written by the prescriber, the algorithm 
determines that the prescribed daily dose is equal to 2 tablets of 250mg (i.e. 500mg). According to the national 
drug database, this dosage corresponds to 25% of the defined daily dose for this specific drug. Thus, the 
individual was covered for 15 ÷ 0.25 = 60 days, assuming that he or she used the drug as prescribed. 
Extraction of the 
dispensing date
Text parsing to estimate
prescribed daily dose (PDD)
Conversion PDD to DDD
through a lookup table
500mg ÷ 2g = 0.25 DDD
Calculation of the
number of days covered
1 DDD = 2g
“One tablet at 8 am and 
one tablet before dinner”
2 tablets per day
2 x 250mg per day
15 DDD ÷ 0.25 = 60 days
End date: 31 July 2010
(dispensing date + 60 days)
1 June 2010 Search drug ID numberin the lookup table
Dispensed amount
15 DDD
Step 1 Step 2 Step 3 Step 4
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For every dispensed drug, we calculated the duration of exposure by applying the 
procedure shown in Figure 9. First, we extracted the dispensing date and the total 
dispensed amount expressed as a number of defined daily doses. Second, a rule-based 
text parsing algorithm was used to transform the dosage reported by the prescriber in 
free text (e.g. “One tablet at 8am and one tablet before dinner”) into a numerical estimate 
of the prescribed daily dose (e.g. 2 x 250mg = 500mg). Third, this prescribed daily dose 
was converted to defined daily doses with a lookup table (e.g. 500mg = 0.25 DDD). In the 
fourth and final step of the process, assuming that patients took their drugs at the 
prescribed dosage, the total number of defined daily doses filled by the patient was 
divided by the prescribed daily dose to obtain an estimation of the number of days 
covered (e.g. 15 DDDs ÷ 0.25 = 60 days). Drugs dispensed in multidose disposable strip 
pouches were assumed to be prescribed for a duration of 14 days.601 
When no information was available regarding the actual dosage (Box 2), we imputed the 
prescribed daily dose by using the year-specific average in the population. Drugs 
prescribed as needed were assumed to have a dosage equal to 50% of the average daily 
dose in the population. Finally, we used the defined daily doses as a proxy for the 
prescribed daily dose of dermatological drugs and eye preparations.602 Once the number 
of days covered was estimated for each dispensing episode, periods of drug exposure 
were constructed with regards to the date of death of study participants. This enable for 
investigating changes over time in drug exposure, or to calculate the prevalence of a 
polypharmacy during a given period (Figure 10). In the first and second studies, we split 
the last year of life into twelve consecutive 30-day periods. In our fourth study, we 
considered 3-month time periods in order to calculate the proportion of older adults who 
continued/initiated drugs of limited benefit. 
To evaluate the completeness of dosage information in the Swedish Prescribed Drug Register, we 
extracted a random sample of 100 000 persons aged ≥65 years on 1 January 2013 from the total 
Swedish population. Among these individuals, 90 586 were dispensed at least one drug in 2012. They 
filled a total of 3.1 million drugs during that period, scattered across 9375 unique pharmaceutical 
products (national drug codes) and 1123 chemical substance groups (ATC codes). Of these, 1.22 million 
drugs (39.3%) were dispensed in multidose strip pouches covering 14 days at a time. Among the 
remaining 1.88 million drugs dispensed through community pharmacies, 2.9% were non-therapeutic 
products, 4.5% were eye preparations, 3.3% were dermatological drugs, 1.7% were Vitamin K 
antagonists (dosage is adjusted according to the target international normalized ratio [INR]), 1.6% were 
insulins and analogues (dosage is adjusted according to the targeted haemoglobin A1c and blood 
glucose levels), and 13.6% of drugs were prescribed “as needed” thus resulting in less precise estimates 
of the number of days covered. While only 0.9% drugs were dispensed with no information whatsoever 
about the prescribed daily dose, 2.1% did not have sufficient documentation to enable the text-parsing 
algorithm to extract a numerical estimate of the prescribed daily dose. In addition, ~1% of dispensed 
drugs were documented with complex dosage information that the text-parsing algorithm could not 
interpret (e.g. “4 tablets in 1 day for the first two weeks, thereafter 6 tablets per week for rheumatoid 
arthritis”). For the remaining drugs, the estimated number of days covered seems highly accurate: we 
obtained a 96% agreement when comparing our automated algorithm with manual calculations in a 
random sample of 1000 filled prescriptions. 
Box 2. Completeness of dosage information in the Swedish Prescribed Drug Register 
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Figure 10. Construction of drug exposure periods 
In this example, monthly periods of exposure are constructed for 6 different drugs. The thick vertical back 
represents the date of death. For each drug, the cap represents the date of dispensing, and the arrow the 
number of days covered. Hence, during the final month before death, this individual filled only 2 prescription 
drugs but potentially took 3 other drugs that he/she had filled before (total: 5 drugs). 
3.4 ESTIMATION OF DRUG COSTS 
In our second study, we investigated not only the use but also the costs of preventive 
drugs throughout the last year of life. Preventive drugs were defined on the basis of a 
recent systematic review by Todd et al.603, and included drugs for diabetes (ATC codes 
A10A, A10B), vitamins (A11), mineral supplements (A12), antithrombotic agents (B01A), 
antihypertensives (C02, C03A, C03B, C07, C08 excl. C08D, and C09), statins (C10AA), 
bisphosphonates (M05B), and medications for chronic anaemia (B03A). Drug costs were 
defined as the combined amount paid by the county council under the pharmaceutical 
benefits scheme and by the patient as out-of-pocket costs. The latter represents ~20% of 
the total costs of prescription drugs during the final year of life. To avoid artificially 
concentrating costs around the dispensing date, we distributed costs over time by 
following a 2-step approach depicted in Figure 11. 
Figure 11. Estimation of drug expenditures across exposure periods 
The costs of drugs dispensed during a given month are calculated as the sum of the total market price of each 
prescription drug filled during that month (e.g. 135 + 30 + 96 = $261 for Month-3). In contrast, the costs of 
drugs potentially taken during a given month are equivalised according to the number of days covered by each 
drug during that month (daily cost x number of days covered). Depending on the metric used, estimated drug 
expenditures vary substantially. Abbreviation: USD, US dollars. 
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First, we divided the total cost of each dispensed drug by the estimated number of days 
covered in order to obtain its daily cost – based on the assumption that patients used 
each drug at a constant dosage until the next purchase. Second, we multiplied the daily 
cost by the number of days covered during each of the 12 months before death to 
equivalise drugs expenditures according to the estimated duration of exposure. After 
summing up the estimated monthly costs of the drugs of interest, we standardised the 
obtained values by using the harmonised index of consumer prices (HICP) in order to 
correct for inflation between 2007 and 2013.604,605 Costs were then converted from 
Swedish Kronor (SEK) into US dollars (USD) based on Sweden’s Central Bank annual 
average exchange rate from 1 January to 31 December 2013 to facilitate international 
comparisons (1 SEK = 0.1535 USD). 
3.5 INDIVIDUAL CHARACTERISTICS 
Sociodemographic characteristics 
In Studies I, II, and IV, the sex and date of birth of decedents were extracted from the 
National Cause of Death Register and were cross-validated for quality control with data 
from the Total Population Register. To protect data anonymity and prevent the re-
identification of individual patients, the date of birth was truncated by removing the day 
of death and replacing it with the mid-month value (i.e. 15 or 16). The age at time of death 
was thus calculated as the difference between the pseudo birthday and the date of death. 
The level of education of decedents was assessed through deterministic record linkage 
with the Swedish Register of Education. We categorised their lifetime highest educational 
attainment according to the SUN2000 and ISCED-97 classification systems as primary, 
secondary or tertiary education.593,606 This categorisation is detailed in Table 9. Since 
primary schooling was made compulsory in Sweden in 1842 (with an extension from 6 to 
7 years in 1936-37)607 and since our cohort of older adults who died between 2007 and 
2015 was born between 1899 and 1950, we have no record of persons with no formal 
education. However, 25 838 out of 703 863 decedents (3.7%) had missing information 
about their level of education, ranging from 6.8% in 2007 to 2.2% in 2015. 
Level of education Categories ISCED97 SUN2000 
Primary education Primary education or first stage of basic education 1 100 
Secondary education Lower secondary education 2A 200-206 
Upper secondary education ≤ 2 years 3C 310-327 
Upper secondary education ≥3 years 3A 330–337 
Post-secondary, non-tertiary education <2 years 4C, 4A 410–417 
Tertiary education Tertiary education for practical/ technical occupations 5B 520–527 
Tertiary or academic education giving access to 
professions with high skills requirements 
5A 530–557 
Post-graduate education (licentiate/doctorate) 6 600–640 
Table 9. Categorisation of educational levels in the present thesis 
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Chronic diseases and multimorbidity 
Studies I, II and IV made use of the methodological approach proposed by Calderón-
Larrañaga et al. to identify chronic conditions and to appraise the burden of 
multimorbidity among older adults.320 Briefly, it consists of a clinically-driven list of 60 
chronic conditions selected by a multidisciplinary team of epidemiologists, geriatricians, 
and general practitioners, who defined as ‘chronic’ any long-lasting disease or conditions 
that leads to (1) residual disability or impaired quality of life or (2) a prolonged period of 
care, treatment or rehabilitation. This tool was primarily developed for the purpose of 
measuring multimorbidity in population-based cohort studies, where self-reported and 
clinician-reported clinical diagnoses, medical journals, and biological parameters are 
typically available. It has for instance been used with data from the SNAC-K cohort (~3000 
older adults ≥60 years followed since 2001) to identify clusters of chronic diseases or to 
investigate the potential role of various life experiences in the speed at which chronic 
diseases accumulate in old age.608,609 However, it can also be implemented in routinely 
collected administrative and healthcare data.610 
In Study I, we considered the full list of 60 chronic diseases, which we identified by using 
three distinct sources of information: the ICD-10 codes from the National Cause of Death 
(underlying and contributing causes of death), the ICD-10 codes reported in the National 
Patient Register for all inpatient admissions and specialised outpatient visits during the 
last 2 years before death, and ATC codes extracted from the Swedish Prescribed Drug 
Register for specific medications dispensed during the last 2 years before death. In Study 
II, we made two minor adjustments to this methodology: we first removed solid tumours 
and haematological malignancies from the list of chronic conditions (since the former 
was the main eligibility criteria and the latter was one of the exclusion criteria), and we 
then extended the lookback period to 3 years for capturing ICD-10 codes in the National 
Patient Register and in the Swedish Prescribed Drug Register.  
In Study IV, we further refined this approach to improve its sensitivity and increase the 
detection of chronic conditions. For this purpose, we extended the lookback period to 5 
years before death while excluding the last 3 months of life (since this was the time 
window used for assessing the outcomes). In addition, we discarded 5 conditions that we 
believe are more likely to be the symptoms of an underlying disease rather than distinct 
nosological entities (anaemia, asthma, chronic ulcer of the skin, colitis and diarrhoea, and 
sleep disorders) as well as 4 conditions that, in our experience, tend to be poorly reported 
in routinely collected data (allergies, dorsopathies, dyslipidaemia, and obesity). Finally, we 
supplemented ICD-10 and ATC codes with semi-structured information from the Swedish 
Prescribed Drug Register. A rule-based text parsing algorithm was developed to extract 
relevant clinical indications from the prescribed dosages mentioned by the prescribers in 
free text. This novel methodology has the advantage of capturing chronic diseases of 
mild-to-moderate severity that are likely to be underreported in hospital records (e.g. 
hypertension, COPD, atrial fibrillation, osteoporosis, depression). 
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Hospital Frailty Risk Score 
In Study IV, we computed the Hospital Frailty Risk Score of each individual based on 
inpatient and specialised outpatient care diagnoses reported during a period ranging 
from 5 years to 3 months before death. The Hospital Frailty Score was recently proposed 
by Gilbert et al. (United Kingdom) in an attempt to automatize the identification of older 
adults at high risk of adverse outcomes due to frailty syndromes, based solely on clinical 
diagnoses reported in inpatient electronic records.611 Briefly, this tool was developed in 3 
consecutive steps: (1) a data-driven cluster analysis was carried out to confirm that a ‘frail’ 
group of older patients could be delineated based on their ICD-10 codes, length of 
hospitalisation, and  hospital costs; (2) a risk score was calculated by using ICD-10 codes 
that were substantially over-represented in the ‘frail’ group and by weighting each of 
these codes proportionally to how strongly they predicted cluster membership based on 
logistic regression coefficients; (3) this weighted score was applied in two distinct 
validation datasets. First, the association between the Hospital Frailty Risk Score and 
various outcomes (e.g. 30-day mortality) was assessed based on Hospital Episode 
Statistics (HES) data in a national cohort of older adults aged ≥75 years who experienced 
a non-elective admission in 2014–2015. Second, the authors used a local database linked 
to HES data to test whether older adults identified as frail according to the Hospital Frailty 
Risk Score overlapped with those captured when using a validated, clinician-administered 
frailty scale (either the Fried phenotype333 or the Rockwood Frailty Index332). Although in 
this study the Hospital Frailty Risk Score itself showed only moderate performance to 
predict 30-day mortality and a fair degree of correspondence with other frailty 
assessment tools, its implementation from ICD-10 codes rather than primary care Read 
codes (used to calculate the electronic frailty index363,612) is a key advantage. Moreover, 
some of our recent work suggests that this score can be useful to stratify older adults 
according to their risk of adverse event or nursing home admission (Table 10). 
Hospital Frailty Risk Score Incidence rate (95% CI) Crude HR Adjusted HR (sex, age) 
All-cause mortality    
Low risk (<5) 40 (39–41) 1 1 
Moderate risk (5–15) 109 (104–114) 2.74 (2.58–2.91) 2.32 (2.19–2.46) 
High risk (>15) 201 (182–222) 5.07 (4.56–5.64) 3.96 (3.56–4.41) 
Non-elective hospitalisation    
Low risk (<5) 230 (226–233) 1 1 
Moderate risk (5–15) 530 (517–542) 2.29 (2.22–2.35) 2.09 (2.03–2.15) 
High risk (>15) 926 (875–980) 3.96 (3.73–4.20) 3.46 (3.26–3.67) 
Nursing home admission    
Low risk (<5) 29 (28–30) 1 1 
Moderate risk (5–15) 109 (104–114) 3.75 (3.52–4.00) 2.99 (2.80–3.18) 
High risk (>15) 257 (234–282) 8.82 (7.97–9.76) 6.49 (5.85–7.18) 
Table 10. Association between baseline Hospital Frailty Risk Score and selected outcomes  
Cohort of 100 000 community dwellers selected randomly from the total Swedish population alive on 1 June 2013 
and followed-up for 1 year or until the occurrence of a censoring event. Hazard Ratios (HR) were calculated with 
Cox proportional hazard regression models and are reported with 95% confidence intervals (CI). 
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Living arrangement 
The living arrangement of individuals during their last year of life was defined as 
community-dwelling or nursing home, based on data from the Social Services Register. It 
is notoriously challenging to establish whether various institutional care facilities for older 
adults can be labelled as ‘nursing homes’ as there is much ambiguity around this term in 
the international literature.613,614 In Sweden, municipalities are primarily responsible for 
organising social care services and elderly care. This leads to much heterogeneity in what 
‘special housing facilities’ (Swedish: särskilt boende) actually refer to depending on their 
geographical location.615,616 However, all of these facilities meet the basic criteria 
proposed in 2015 by Sanford et al.617: (1) they provides 24-hour functional support for 
older adults who require assistance with activities of daily living and have complex health 
needs and/or moderate-to-severe cognitive impairment; (2) they are staffed with trained 
health care professionals; (3) they provide  long-term care as part of hospital avoidance 
or to facilitate early hospital discharges; (4) they are not hospital-based and do not 
function as hospital wards; (5) they provide palliative care at the end of life.618  
In the first and second studies, we categorised as nursing home residents any decedent 
who had been admitted into a nursing home either before the final year of life or during 
one of the last 12 months of life, excluding older persons who died shortly after their 
admission (<15 days). In the fourth study, the living arrangement of decedents was 
defined by using a lookback period ranging from 12 to 3 months before death. This was 
done not only because the quality of the Social Services Register was substantially 
improved in 2015 compared with 2007–2013 (there was, therefore, no need to extend 
the lookback period beyond 12 months), but also because the last 3 months of life were 
used to assess the outcomes of interest. 
Place of death 
On Swedish death certificates, the place of death is defined as either ‘Home’, ‘Hospital’, 
‘Nursing Home’, or ‘Other’. This variable was however missing for 7.7% of all decedents 
aged ≥65 years (2007–2015), declining from 10.3% in 2007 to 5.0% in 2015. By cross-
referencing data from the National Cause of Death Register with information from the 
National Patient Register and from the Social Services Register, we reduced missing 
values to 5.3% overall (2.0% in 2015). In Study II, for clarity, we grouped the places of 
death into ‘Usual place of living’ (i.e. home or nursing home) and ‘Hospital facility’. 
Marital status 
The marital status of decedents was only available to us for the fourth and final study. It 
was ascertained with data from the National Cause of Death linked to the Total 
Population Register. Individuals were categorised as ‘Married’, ‘Single or divorced’ or 
‘Widowed’. Missing values (< 0.01%) were completed through record linkage by using the 
spouses’ unique identifier to capture recent, unreported cases of spousal loss. 
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3.6 STATISTICAL ANALYSES 
Overall 
In all four studies, the participants’ characteristics were reported by using absolute 
numbers and percentages, or means and standard deviations (SD), when appropriate. 
Statistical analyses were performed with SAS JMP® versions 12.1, 13.0, and 14.1 (SAS 
Institute, Cary, NC) and Stata® version 14.1 (StataCorp, College Station, TX) software. 
Polypharmacy and number of drugs throughout the last year of life 
We calculated the monthly prevalence of polypharmacy as the proportion of individuals 
who were exposed to ≥10 different drugs during each of the last 12 months before death. 
In addition, we computed the average number of prescription drugs over the course of 
the last year of life. Descriptive results comparing community-dwellers and nursing home 
residents were standardised for both sex and age, based on the structure of the total 
study population (direct standardisation approach). The prevalence of the 20 most 
commonly prescribed drugs and drug classes was calculated for the 12th month, the 6th 
month, and the last month before death. 
To examine trends in polypharmacy throughout the last year of life, we first calculated 
the relative change in the prevalence of polypharmacy between the 12th month and the 
final month before death. Second, logistic regression models were fit to estimate the 
odds of being exposed to ≥10 drugs during the final month before death compared with 
12 months before, with time as the sole independent variable. We used robust standard 
errors to account for correlation of observations within individuals.  
We identified the factors associated with the magnitude of change in the number of 
prescription drugs throughout the last year of life by fitting generalised estimating 
equation (GEE) models with a factor ´ time interaction term. These models produce 
population-averaged effect estimates for panel data, where the b coefficient for the 
interaction term can be interpreted as the rate of change over time conditional on a given 
set of parameters (e.g. the rate of change among women compared with that of men, 
while adjusting for age and end-of-life illness trajectory). GEE models were specified with 
a Gaussian distribution, an identity link function, and unstructured within-group 
correlation. Results are presented as adjusted b coefficients with their 95% confidence 
intervals (CIs). In sensitivity analyses, the same models were computed by removing 
analgesics from the total number of drugs. 
Preventive drugs among older adults with cancer at the end of life 
Variation in the use of preventive drugs over the course of the last year of life of older 
adults with solid cancer was first assessed by calculating, for each drug class separately, 
the absolute change in the prevalence rate between the 12th month and the final month 
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before death. Absolute change was reported in percentage points with 95% CIs. We also 
examined the continuation and initiation of preventive drugs during the last year of life. 
Continuation rate was calculated as the percentage of older adults who were exposed to 
a given drug class of during the last month before death among those already exposed 1 
year before. The initiation rate was calculated as the percentage of decedents who were 
dispensed a given drug class during the last year of life (namely, between the 11th and the 
final month before death) among those not exposed during the 12th month before death. 
The overall costs of prescription drugs and the costs of preventive drugs per capita were 
calculated according to the procedure detailed earlier (see page  62) and stratified by 
cancer type. Because healthcare cost data tend to be highly skewed to the right (i.e. 
gamma-shaped distribution, where most data points fall to the left of the mean)619,620, we 
reported the median and interquartile range of drug costs rather than their mean for 
descriptive purposes. In addition, the proportion of the total drug costs dedicated to 
preventive drugs was calculated for the entire last year of life, the 12th month and the 
final month before death. 
We used quantile regression models to analyse drug costs across cancer types while 
adjusting on sex, age, number of chronic comorbidities, living arrangement and level of 
education. While linear regression allows for modelling the mean of an outcome of 
interest, quantile regression is used to model it quantiles (e.g. median).621,622 The 
b coefficients obtained from quantile regressions can be interpreted as the adjusted 
median difference (AMD) in costs compared with the reference group. To ensure that the 
average median effects were concordant – in both direction and magnitude – with the 
average mean effects, we compared our results with estimates calculated by fitting 
Generalised Linear Models (GLM) with a log link function and a gamma distribution. GML 
models have the advantage of being more flexible than ordinary least square regressions, 
they do not require a log transformation of the outcome (which, by nature, makes it 
impossible to account for observations with zero costs and thus leads to biased 
estimates), and they correct for heteroscedastic errors.623,624 The b coefficients were 
reported together with their 95% CIs. Two sets of sensitivity analyses were performed to 
mitigate the risk of bias due to the potentially unpredictable time of death of older adults 
with cancer, which would explain why preventive drugs were continued until the very end 
of life. First, we excluded patients whose underlying cause of death suggested an acute 
and potentially unpredictable fatal event (e.g. stroke with no prior history of ischemic 
heart disease). Second, we stratified our analyses according to the lag between cancer 
diagnosis and death, thereby differentiating older adults who were diagnosed >12 
months before death from those who died within 6 months after their diagnosis. 
Individuals with missing data regarding the time between diagnosis and death (n= 7863 
patients; 5.2%) were excluded from this sensitivity analysis. We tested for the difference 
in the median cost of preventive drugs according to the timing of diagnosis by using non-
parametric Wilcoxon rank sum test. 
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Use of drugs of questionable clinical benefit at the end of life 
In the fourth and final study of the present thesis, drugs of questionable clinical benefit 
near the end of life were defined according to the set of consensus-based criteria 
developed in Study III (see section 3.7 below). Although this list also encompasses drugs 
deemed ‘questionable’ for use among older adults with a remaining life expectancy of <3 
months, we restricted our study to drugs considered ‘often inadequate’ and—out of 
caution—referred to them as drugs of questionable clinical benefit. 
The main outcomes were the continuation and the initiation of drugs of questionable 
clinical benefit during the last 3 months of life. Continuation was defined as the 
dispensing of at one such drug during the 91-day period before death, among older 
persons who had initiated the treatment before. Initiation was defined as the dispensing 
of at least one drug of questionable clinical benefit during the 91-day period before death 
among individuals who had not been treated with the same drug during the 9-month 
period prior (i.e. between 365 and 92 days before death). Individuals who were potentially 
exposed to drugs of questionable clinical benefit during the last 3 months of life but did 
not refill their prescription were considered as having discontinued their treatment. 
To identify factors independently associated with the continuation or the initiation of 
drugs of questionable clinical benefit near the end of life, we fitted log-binomial 
regression models (i.e. GLM models with log link function and binomial distribution). Log-
binomial models have the advantage of estimating risk ratios (RR) rather than odds ratios 
(OR), and thus to avoid overestimating the effect estimates in cohort studies when the 
outcome of interest is common.625 RRs and 95% CIs were adjusted for sex, age at time of 
death, illness trajectory, number of chronic diseases, Hospital Frailty Risk Score, living 
arrangement, marital status, and level of education. Decedents with missing data about 
their level of education (2.2%) were excluded from multivariable analyses. 
We carried out a series of sensitivity and subgroup analyses. First, much like in Study II, 
we removed older adults whose underlying cause of death suggested an acute and 
potentially unpredictable fatal event from the study population. This was done to 
examine whether the observed patterns of drug utilisation near the end of life were 
substantially different among older adults whose death may not have been anticipated 
despite the presence of a life-limiting disease (e.g. pneumonia, accident, suicide). In 
subgroup analyses, we examined patterns of continuation and initiation of drugs of 
clinical benefit at the end of life across illness trajectories and living arrangements. 
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3.7 DELPHI CONSENSUS 
Objectives of the Delphi consensus survey 
The third study of the present thesis (Study III), we aimed to develop consensus-based 
criteria to identify prescription drugs most likely ‘adequate’, ‘questionable’ or ‘inadequate’ 
for older persons aged ≥75 years with an estimated life expectancy of 3 months or less. 
More specifically, we set two specifications for these criteria: (1) they should provide 
guidance for prescribers caring for older patients nearing the end of life; and (2) they 
should be easily applicable in routinely collected healthcare and administrative data. 
The Delphi methodology 
The Delphi method is an approach developed in the late 50s and early 60s by the U.S. 
non-profit think tank RAND as a structured, systematic, interactive, and iterative method 
for eliciting and refining expert opinion in order to provide long-range forecasting and to 
improve decision-making process on topics for which empirical evidence is either lacking 
or inconsistent.626,627 Olaf Helmer-Hirschberg, one of its architects, defined it as “a 
systematic procedure for obtaining the opinions of experts on a particular subject.”628  
In practical terms, the Delphi procedure relies on a panel of experts who have extensive 
knowledge of the area of interest (in this case, drug prescribing for older adults near the 
end of life) and who are asked to formulate a judgment about a set of questions or items 
over two or more rounds. The procedure has three key features: (1) anonymity, not only 
to reduce the influence that the authority, reputation or personality of some participants 
may have on the opinion that other participants express, but also to allow respondents 
to deviate from dominant theories, beliefs or views; (2) controlled feedback, namely 
providing participants with a summary of the results after each round in order to give 
them the opportunity to revise their own opinion iteratively; (3) the statistical group 
response is defined a priori, which reduces the pressure for conformity and ensures that 
the judgment of every panel participant is accounted for.627 Contrary to nominal group 
discussion techniques and consensus development conferences, the Delphi method 
does not require face-to-face meetings. This methodology has been used previously to 
develop consensus-based lists of potentially inappropriate drugs for older adults, 
including earlier versions of the Beers criteria, the STOPP/START tool, or more recently 
the EURO-FORTA list (see Table 5, page 48).629–632 More generally, the Delphi technique is 
a commonly used for developing and selecting healthcare quality indicators.633 
Selection of tentative criteria 
To identify drugs and drug classes deemed potentially adequate or inadequate for use 
among older adults in the context of palliative and end-of-life care, we first conducted a 
scoping review of the literature to update the findings from Todd et al. (which were first 
published on 5 January 2016).603 This review included original, quantitative studies 
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published between January 1990 and March 2016. We later updated the search to include 
studies published until June 2017. Methodological details are presented in Table 11. 
Overall, our review included 47 articles, 9 of which were published after March 2016 (see 
Appendix Table). Based on this material, a preliminary list of 49 drug classes was 
prepared by our multidisciplinary research team, consisting of two clinical 
pharmacologists, one pharmacist, one geriatrician, and one pharmaco-epidemiologist. 
We included pharmacological subgroups (e.g. drugs for peptic ulcer and gastro-
oesophageal reflux) rather than individual drugs (e.g. omeprazole). Since this study was 
focused on prescription drugs, other types of medical treatments such as herbal 
products, mechanical ventilation, or tube feeding were not included. 
Selection of panellists 
The Delphi panel consisted of European clinicians and researchers with a high degree of 
expertise about drug prescribing for older adults with limited life expectancy. Only 
healthcare professionals with clinical experience in either palliative medicine, geriatrics, 
family medicine, or pharmacology were eligible for inclusion. Potential participants were 
identified through a literature review, selecting principal investigators and corresponding 
authors of recent original studies on the same topic. To broaden the panel of experts and 
avoid ‘academic homogamy’, we also asked key informants to provide the name and 
contact information of potentially eligible clinicians. Overall, 58 experts from 10 different 
European countries were invited to participate. Age, gender, occupational, and 
geographical balance were ensured during the panel selection. Eligible panellists were 
sent an email invitation, which presented the aims of the study and the main features of 
the Delphi procedure. Those who agreed to participate were required to sign an 
electronic consent form and were informed that they could withdraw from the Delphi 
survey at any time. Their anonymity was ensured throughout the procedure, and 
panellists could choose whether they want to be acknowledged for their participation or 
not. No financial incentive was provided.  
Aims To investigate the use of medications among adult patients with life-limiting 
conditions near the end of life, and to identify potentially adequate and 
inadequate drugs in this context. 
Inclusion criteria Original, quantitative studies published between January 1, 1990 and March 30, 
2016, describing the use of drug treatments among adult patients at the 
advanced stage of a serious and incurable disease with limited life expectancy. 
Exclusion criteria Narrative studies, reviews or original studies published before 1990. Publications 
in another language than English were not considered. 
Search strategy MEDLINE/PubMed search, combining MeSH terms with specific keywords. This 
online database search was completed by a manual screening of previous 
systematic reviews (Maddison, 2011634; Todd, 2017603; Leblanc, 2015635) 
Table 11. Summary protocol of the scoping review undertaken prior to the Delphi survey 
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Delphi survey 
The tentative list of drug classes established based on the literature was submitted to the 
panellists through a web-based interactive survey, hosted on a secure platform (Artologik 
Survey&Report® software, version 4.3). Panellists were asked to consider the situation of 
older adults aged ≥75 years with an estimated life expectancy of 3 months or less, 
regardless of their underlying condition and regardless of the clinical indication of the 
drug. They were explicitly instructed to take into account the need to ensure impeccable 
symptom management, the obligation to minimise the risk of adverse drug-related event, 
and the potential futility of drug treatments in the context of very limited life expectancy. 
For each drug class, we distinguished two scenarios: (1) the continuation of a drug class 
that was previously prescribed, and (2) the initiation of a new drug. Panellists were asked 
the following question: “In your opinion, in older adults (≥75 years) with an estimated life 
expectancy of 3 months or less, how adequate or inadequate are the continuation and 
initiation of the following drugs or drug classes?”. They provided their answer by using a 
5-point, non-numerical Likert scale (‘Always inadequate’, ‘Often inadequate’,
‘Questionable’, ‘Often adequate’, or ‘Always adequate’). They also had the opportunity to
suggest breaking down large drug classes into specific drugs or adding drugs or drug
classes that were not included in the preliminary list, and to leave comment in free text.
The first round took place between 1 June and 31 August 2016. Participants were 
informed that consensus would be achieved if at least 75% (30 out of 40) panellists rated 
a given drug class as either ‘Always/often inadequate’ or ‘Always/often adequate’. Drugs 
for which consensus was reached at this stage were not reviewed again during the 
subsequent rounds. The second round took place between 1 November and 31 
December 2016. The panellists were provided with controlled feedback consisting of 
aggregated results for each drug class evaluated during the first round as well as 
comments and suggestions from the other participants. Based on this feedback, they 
were asked to re-evaluate the drug classes for which consensus had not been achieved, 
and to provide their expert opinion about the drugs or drug classes suggested by the 
participants. They were also invited to leave any comment or suggestion about the 
different items (Figure 12). 
We analysed the results from the second round by calculating the degree of agreement 
for each criterion. Drugs and drug classes that were rated as ‘Always’ or ‘often adequate” 
by ≥75% of the respondents were included in the list and labelled as ‘Often adequate’. 
Likewise, drugs rates as ‘Always’ or ‘often inadequate” by ≥75% of the respondents were 
included in the list and labelled as ‘Often inadequate’. The remaining drugs and drug 
classes were defined as ‘Questionable’ if they were rated either ‘questionable’, ‘often’, or 
‘always inadequate’ by ≥75% of respondents. Drugs with a moderate (65–74%) or low 
(<65%) level of agreement were not included in the final list. This study adheres to the 
CREDES guidelines on conducting and reporting Delphi studies in palliative care.636 
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Figure 12. Example of controlled feedback and second round of Delphi procedure 
In this example, panellists were asked to rate the adequateness or inadequateness of anti-dementia drugs. In the 
upper part of the questionnaire, the drug or drug class of interest is described with its ATC code in order to prevent 
any ambiguity. In the second part, a stacked-bar graph shows the aggregated results of the first round of the 
Delphi survey. It appears that while the panellists’ opinion was heterogenous regarding the continuation of anti-
dementia drugs near the end of life, there was a high degree of agreement to consider initiation either ‘often’ or 
‘always’ inadequate (36 / 40 = 90%). Therefore, only the continuation of anti-dementia drugs was submitted for 
review during the second round. The panellists also suggested to break down the drug class ‘anti-dementia drugs’ 
into more precise items: acetylcholinesterase (AChE) inhibitors on the one hand, and memantine (a NMDA 
receptor antagonist) on the other hand. During the second round, the respondents were therefore presented 
with the possibility of rating both drug classes separately. They could also provide free-text comments and 
suggestions. 
In your opinion, in older adults (≥75 years) with an estimated life expectancy of 3 months or less, 
how adequate or inadequate is the initiation of the following drugs or drug classes?
*Please note that clicking on any ATC code gives you a direct access to the ATC classiﬁcation (WHOCC website).
Anti-dementia drugs
(ATC codes N06DA, N06DX01)
Results from the ﬁrst Delphi round:
Conclusions from the ﬁrst round:
(a) Regarding the continuation of this drug class: no consensus yet
(b) Regarding the initiation of this drug class: consensus (initiating anti-dementia drugs is often inadequate)
0 5 10 15 20 25 30 35 40
(b) Initiation
(a) Continuation
Number of respondents (total= 40)
Always adequate
Often adequate
Questionable
Often inadequate
Always inadequate
Suggestions from the respondents:
        Consider anticholinesterases (e.g. donepezil, rivastigmine, galantamine) and memantine separately
Second Delphi round:
Anticholinesterases (N06DA)
Memantine (N06DX01)
Always
inadequate Questionable
Always
adequate
Often
adequate
Often
inadequate
Initiating this drug (or drug class) is...
You can write your comments, remarks, and suggestions here:
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3.8 ETHICAL CONSIDERATIONS 
The four studies that compose the present thesis were all approved by Stockholm’s 
Regional Ethical Review Board (Table 12). Studies I, II, and IV are based on de-identified, 
routinely collected administrative and healthcare data. The use of such data for academic 
research purposes raises two important ethical issues: the lack of informed consent from 
the persons included in the studies, and the need to protect health and personal privacy. 
Informed consent is a tenet of medical research. It is of paramount importance in clinical 
trials and other interventional studies, since the participants must be able to make their 
own assessment of the risks associated with the experiment.637,638 In other words, the 
obligation to obtain informed consent from research participants matches the bioethical 
principle of respect for personal autonomy.639,640 However, since routinely collected 
administrative and healthcare data require, by definition, no ad hoc intervention or data 
collection, study participants are not exposed to the potential harms of physically or 
psychologically invasive procedures that usually come with biomedical research. This 
argument alone could potentially justify waiving the obligation of informed consent, 
provided that adequate mechanisms are in place to allow individuals to opt-out if 
desired.641,642 In addition, requiring written informed consent from each person whose 
personal data were collected in a national register would often prove unfeasible or 
prohibitively expensive. This is particularly true for retrospective cohort studies of 
decedents, which is the case of Study I, Study II, and Study IV. 
In fact, it could be argued that collecting data specifically for research purposes (i.e. 
prospective or retrospective study by questionnaire or face-to-face interviews) would 
prove more invasive for the study participants or their relatives, less reliable in terms of 
data quality, and more prone to selective participation. By conducting research after the 
death of the individuals with routinely collected data, epidemiologists make sure that 
their investigation does not have any direct or indirect incidence on the persons, namely 
that it doesn’t interfere with the provision of care and the psychological wellbeing of the 
patient and his/her relatives). A recent qualitative study in the United Kingdom suggests 
that there is a strong support from patients and family members regarding the secondary 
use of de-identified electronic health records in research, provided that data were not 
shared with for-profit organisations and were handled in a secure manner.643 These 
findings resonate with the increasing scrutiny of stakeholders644,645 and with the pressing 
societal demand for transparency and trust in the use of big data.646–648 
Health and personal privacy are of particular concern when dealing with sensitive data.649  
The personal integrity of individuals included in a registry could for instance be 
compromised if their anonymity was not ensured.650 This risk was mitigated by the 
register holders (Socialstyrelsen and Statistics Sweden), who de-identified the records. The 
pseudo-identifiers used by our research team did not allow for tracing back the 
information to a given individual. In addition, some individual data have been aggregated 
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into categories to prevent any attempt of backward-identification: detailed zip codes 
were for instance not available, and the exact birthday was replaced by a dummy value 
(YYYY-MM-15).  
In Study III, study participants were physicians and pharmacists who agreed to take part 
in a Delphi consensus panel. Before the survey was conducted, all participants signed an 
electronic consent form that explicitly mentioned the aims of the study, the procedure, 
the possibility to withdraw at any time, the means and methods used to analyse and 
safely store all data material, the confidential nature of their personal data, and the 
opportunity to be acknowledged in the ensuing publication if desired. No financial 
incentive was offered. 
All studies included in the present thesis comply with the Ethical Principles for Medical 
Research Involving Human Subjects stated in the World Medical Association Declaration 
of Helsinki, and with the “Good research practice” guidelines of the Swedish Research 
Council (Swedish: Vetenskapsrådet). 
Study Title of the application Date application Date decision DNR reference 
Studies I & II Drug use as risk, protective or 
predictive factor for care utilisation, 
dementia and mortality: a register-
based project  
2013-11-05 2013-12-04 2013/1941-31/3  
Studies I & II Amendment to DNR 2013/1941-31/3  2015-08-03 2015-08-19 2015/1319-32 
Study III Läkemedelsbehandling i livets 
slutskede 
2015-08-03 2015-09-02 2015/1341-31/1 
Study IV Frisk till livets slut? Hälsa, 
funktionsförmåga, vård och 
läkemedelsbehandling hos äldre 
2016-05-09 2016-06-08 2016/1001-31/4 
Table 12. Overview of ethical permits 
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4. MAIN FINDINGS
4.1 GENERAL CHARACTERISTICS OF THE STUDY POPULATION 
Between 1 January 2007 and 31 December 2015, a total of 703 863 persons aged ≥65 
years died in Sweden. Of them, 671 754 (95.5%) met our general eligibility criteria. 
Women accounted for 53.9% of the decedents and the mean age at death was 84.1 (SD 
8.2) years. The most commonly reported underlying causes of death were ischaemic 
heart diseases (17%), dementias (9%), cerebrovascular diseases (9%), digestive cancers 
(7%), and heart failure (5%). Over time, there was a subtle yet evident increase in the 
proportion of older adults who died from cancer or neurodegenerative diseases, as well 
as a noticeable decrease in the proportion of those who died from organ failure (Table 
13). The proportion of decedents who had only attended compulsory primary school 
declined substantially, from 58.5% in 2007 to 46.5% in 2015. The proportion of hospital 
deaths remained stable (~41%). 
A striking characteristic was the substantial burden of chronic multimorbidity at the end 
of life. On average, older adults who died in 2015 had 6.6 (SD 3.2) co-existing chronic 
conditions, and nearly 18% had 10 or more chronic diseases diagnosed at time of death. 
This multimorbidity was primarily fuelled by the high prevalence of cardiovascular 
diseases, solid tumours, depression, diabetes, and dementia (Figure 13) 
As mentioned earlier (see 3.2 Study designs and populations), specific eligibility criteria 
were applied in each study. The first study included 511 843 older persons who died 
between 2007 and 2013 of any cause. The second study included 151 201 older persons 
diagnosed with solid cancer who died during the same period. The fourth study included 
58 415 individuals aged ≥75 years who died from conditions potentially amenable to 
palliative care. Their characteristics are reported in the corresponding articles. 
2007 2008 2009 2010 2011 2012 2013 2014 2015 
Women, % 54.6% 54.3% 54.0% 53.9% 53.9% 54.0% 53.9% 53.4% 53.3% 
Age in years, median 84.9 85.0 85.1 85.2 85.3 85.4 85.2 85.2 85.3 
Level of education, % 
Primary 58.5% 57.2% 55.8% 54.4% 53.1% 51.6% 49.7% 48.1% 46.4% 
Secondary 32.9% 33.9% 34.8% 35.7% 36.8% 37.7% 38.9% 39.9% 41.4% 
Tertiary 8.6% 8.9% 9.3% 9.9% 10.1% 10.7% 11.4% 12.0% 12.2% 
Illness trajectory, % 
Cancer 27.8% 27.9% 28.3% 28.6% 29.0% 28.8% 29.3% 30.1% 29.9% 
Organ failure 40.8% 40.5% 39.8% 38.8% 38.0% 37.6% 37.2% 36.7% 36.4% 
Prolonged dwindling 23.5% 23.7% 24.2% 25.2% 25.7% 26.3% 26.1% 26.0% 26.3% 
Sudden death 7.9% 8.0% 7.7% 7.4% 7.3% 7.3% 7.4% 7.2% 7.4% 
Hospital deaths, % 41.6% 42.0% 41.8% 41.4% 41.0% 41.2% 41.8% 41.9% 41.1% 
Table 13. Main characteristics of older adults (≥65 years) who died in Sweden in 2007–2015 
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Figure 13. Prevalence of the 30 most common chronic diseases among older adults (≥65 years) 
who died in 2015, by number of co-existing conditions 
Source: National Cause of Death Register, National Patient Register and National Prescribed Drugs Register 
(Swedish Board of Health and Welfare). N= 78 226 older adults aged 65 years and over who died in 2015. A total 
of 51 chronic diseases were identified during the 5-year period preceding death (see methods page 64). 
4.2 POLYPHARMACY OVER THE COURSE OF THE LAST YEAR OF LIFE 
In Study I, we first found that, throughout their last year of life, older adults (n=511 843) 
used an increasing number of prescription drugs. The average number of drugs rose 
from 7.6 (SD 4.4) during the 12th month before death to 9.6 (SD 4.7) during the final month 
(Figure 14). During the same period, the proportion of older adults exposed to ≥10 drugs 
increased by 55.9%, from 30.3% to 47.2%. This upward trend in the burden of drugs was 
especially pronounced among individuals aged 66–74 years, among community dwellers, 
and among those who died with only 1 or 2 chronic conditions. The likelihood of being 
exposed to polypharmacy during the final month of life compared with 12 months before 
30. Peripheral vascular disease
29. Other neurological disease
28. Parkinson’s disease
27. Other psychiatric disease
26. Autoimmune diseases
25. Cardiac valve diseases
24. Osteoarthritis
23. Other musculoskeletal disease
22. Other genitourinary disease
21. Chronic kidney disease
20. Glaucoma
19. Bradycardias
18. Osteoporosis
17. Inflammatory arthropathy
16. Thyroid disease
15. Prostate disease
14. Gastrointestinal disease
13. Other cardiovascular disease
12. COPD, chronic bronchitis
11. Other eye disease
10. Diabetes
09. Dementia
08. Cerebrovascular disease
07. Atrial fibrillation
06. Cataract, lens disease
05. Depression or mood disease
04. Solid neoplasm
03. Heart failure
02. Ischemic heart disease
01. Hypertension
Chronic condition
(Rank)
0% 20% 40% 60% 80%
Number of 
co-occurring conditions:
≤1 2 3 4 5 ≥6
Prevalence by number of comorbidities
% of all deceased individuals
6.2%
7.0%
7.3%
7.9%
8.0%
9.1%
9.7%
10.1%
11.2%
11.4%
12.4%
12.7%
13.2%
13.2%
13.5%
14.1%
14.9%
15.8%
16.7%
22.1%
22.8%
26.3%
27.3%
30.3%
31.5%
35.3%
37.7%
39.3%
40.7%
71.5%
Prevalence
rate (%)
98.0%
95.6%
94.3%
94.3%
96.3%
97.9%
96.1%
96.4%
95.7%
98.4%
95.0%
97.8%
95.7%
97.6%
93.8%
94.1%
95.1%
95.1%
93.7%
97.7%
96.0%
85.0%
93.9%
97.3%
96.3%
92.3%
84.8%
95.7%
93.9%
91.5%
≥3 comorbidities
(% of cases)
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was also substantially higher among cancer decedents (OR 3.34, 95% CI 3.29 to 3.39) than 
among older adults who died from organ failure (OR 1.73, 95% CI 1.71 to 1.76) or 
dementia and other neurodegenerative disorders (OR 1.74, 95% CI 1.71 to 1.77). While 
adjusting for sex, age, multimorbidity, level of education, and illness trajectory, we found 
that the number of drugs increased at a slower rate among nursing home residents than 
among community dwellers (b coefficient -0.90, 95% CI -0.92 to -0.87). Cancer decedents 
had the steepest escalation in the number of prescribed medicines, even after analgesics 
were excluded from the analysis. Of note, a higher level of education was independently 
associated with a greater increase in the burden of drugs near the end of life (b 0.09, 95% 
CI 0.05 to 0.12). 
4.3 MOST COMMONLY PRESCRIBED DRUGS AT THE END OF LIFE 
In addition, Study I showed that the growing proportion of older adults exposed to 
polypharmacy near the end of life was fuelled not only by symptomatic drugs but also by 
the sustained prevalence of long-term preventive treatments and medicines prescribed 
for the management of chronic diseases that may otherwise lead to short-term 
complications (e.g. insulin and oral blood glucose-lowering agents). 
The use of opioid analgesics and paracetamol increased substantially (38.5% and 49.2% 
during the last month of life, respectively), as did the prescribing of drugs for constipation, 
anxiolytics, hypnotics and sedatives, antidepressants (Table 14). However, cardiovascular 
drug treatments remained impressively stable over time: there was no or only a minimal 
decrease in the use of vitamin K antagonists, antiplatelet drugs, diuretics, beta-blockers, 
ACE inhibitors, ARBs, statins, and calcium channel blockers. During their last month of 
life, patients aged ≥85 years received on average 2.4 different cardiovascular drugs, 
including 9.2% treated with statins, 28% with ACE inhibitors or ARBs, 40% with beta 
blockers, 47% with low-dose aspirin, and 16% with calcium channel blockers. 
Figure 14. Change in the number of prescription drugs and polypharmacy 
Study population: 511 843 older adults (≥66 years) who died from any cause in 2007–2013 in Sweden. 
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12th 
month 
9th 
month 
6th 
month 
3rd 
month 
Last 
month 
Antithrombotic agents 52.5 53.2 53.5 53.9 53.8 
Vitamin K antagonists 7.9 7.9 7.7 7.4 6.7 
Heparin group 1.6 1.9 2.5 3.6 5.2 
Platelet aggregation inhibitors 44.3 44.8 44.9 45.1 44.9 
Diuretics 47.1 48.2 49.2 50.8 53.1 
Low-ceiling diuretics 6.0 5.9 5.7 5.5 5.2 
High-ceiling diuretics 37.2 38.6 40.1 42.5 45.6 
Potassium-sparing agents 13.2 13.5 13.6 14.0 14.8 
Analgesics 40.2 42.6 45.9 51.9 60.8 
Opioids 17.5 19.0 21.4 26.9 38.5 
Other analgesics 35.0 36.9 39.6 44.2 49.2 
Psycholeptics 39.5 41.0 42.8 45.9 51.2 
Antipsychotics 7.8 8.3 8.9 9.9 11.5 
Anxiolytics 16.7 17.6 18.8 21.1 26.6 
Hypnotics and sedatives 28.1 28.8 29.9 31.8 34.5 
Beta blockers 39.4 40.0 40.3 40.8 41.1 
Renin-angiotensin agents 31.8 32.0 31.9 31.5 30.6 
ACE inhibitors 21.6 21.8 21.9 21.8 21.4 
Angiotensin II receptor blockers 10.9 10.8 10.7 10.4 9.8 
Anti-anaemic preparations 30.6 31.8 32.9 34.1 34.6 
Iron preparations 7.8 8.3 8.9 9.8 10.4 
Vitamin B12 and folic acid 25.9 26.8 27.5 28.2 28.2 
Psychoanaleptics 27.4 28.4 29.5 31.1 32.6 
Antidepressants 24.5 25.5 26.6 28.3 30.1 
Anti-dementia drugs 5.4 5.5 5.4 5.3 5.0 
Drugs for acid related disorders 23.8 25.3 27.4 31.1 35.1 
Cardiac therapy 22.2 22.7 23.0 23.6 24.3 
Cardiac glycosides 7.9 8.0 8.0 8.1 8.3 
Vasodilators 15.5 15.9 16.2 16.7 17.4 
Emollients 22.1 23.7 25.3 27.1 28.7 
Lipid modifying agents (incl. statins) 18.7 18.5 18.1 17.4 16.3 
Calcium channel blockers 17.8 17.5 17.1 16.4 15.4 
Mineral supplements 17.6 18.1 18.7 19.7 20.5 
Calcium 12.6 12.8 13.0 13.2 12.9 
Potassium 5.6 5.9 6.3 7.1 8.1 
Drugs used in diabetes 15.1 15.2 15.3 15.4 15.4 
Insulin and analogues 8.8 9.1 9.4 9.8 10.3 
Blood glucose lowering drugs 8.6 8.4 8.2 7.8 7.4 
Ophthalmologicals 14.7 15.0 15.2 15.4 15.3 
Drugs for COPD and asthma 12.5 12.8 13.3 13.9 14.9 
Inhalants 12.0 12.3 12.7 13.3 13.9 
Drugs for systemic use 1.3 1.4 1.5 1.6 2.1 
Antibiotics for systemic use 11.5 12.1 13.1 15.8 20.0 
Tetracyclines 1.1 1.2 1.3 1.6 2.1 
Beta-lactam antibiotics 5.1 5.4 5.9 7.5 10.3 
Trimethoprim and sulfonamides 1.4 1.5 1.6 1.9 2.3 
Quinolones 1.7 1.8 2.1 2.7 3.6 
Thyroid therapy 10.5 10.6 10.8 10.9 10.9 
Corticosteroids for systemic use 9.4 10.4 11.8 14.7 18.1 
Table 14. Twenty most common drug classes throughout the last year of life (%) 
Corresponding ATC codes are provided in the article of Study I. Low-ceiling diuretics include both thiazides (e.g. 
Bendroflumethiazide, hydrochlorothiazide) and sulfonamides (e.g. metolazone). Potassium-sparing agents include 
combinations with hydrochlorothiazide. Other analgesics consist almost exclusively of paracetamol.  Angiotensin-
converting-enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) include combinations with 
diuretics and calcium channel blockers. Beta-lactam antibiotics include both penicillin and cephalosporins. 
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4.4 USE AND COSTS OF PREVENTIVE DRUGS DURING THE LAST YEAR OF 
LIFE OF OLDER ADULTS WITH SOLID CANCER 
In Study II, we found that older adults who died with solid cancer (n=151 201) often 
continued to receive preventive drugs until the very end of life. These drugs account for 
~20% of the total drug expenditures, and there exist substantial variations across cancer 
types that age and multimorbidity can only partly explain. 
Between the 12th month before death and the final month, there was little change in the 
receipt of antihypertensive agents (absolute change -0.3%, 95% CI -0.6 to 0.0), vitamin K 
antagonists (+1.5%, 95% CI 1.1 to 1.9), antiplatelet agents (-1.5%, 95% CI -1.8 to -1.2), 
statins (-4.7%, 95% CI -5.0 to -4.4), bisphosphonates (-0.3%, 95% CI -0.4 to -0.2), or vitamins 
(+1.0, 95% CI 0.8 to 1.2). We found that the proportion of older adults who continued 
therapy until their last month of life ranged from 47.6% (95% CI 46.7 to 48.5) for vitamin 
K antagonists to 65.0% (95% CI 64.4 to 65.5) for statins, up to 82.9% (95% CI 82.6 to 83.3) 
for beta blockers. Inversely, there was an overall low proportion of individuals initiating 
preventive drugs during the last year before death, with the notable exceptions of 
antiplatelet agents (13.4% initiators, 95% 13.2 to 13.6) and heparin (14.9%, 95% CI 14.6 to 
15.9), beta blockers (13.3%, 95% CI 13.1 to 13.6), and drugs for anaemia (17.6%, 95% CI 
17.4 to 17.8). We found substantial variation in the use of preventive drugs near the end 
of life across cancer types, also after balancing covariates (Table 15). 
During the last year before death, median drug cost per capita was $1482 (interquartile 
range [IQR] $700–2896), including $213 (IQR $77–490) for preventive treatments. Figure 
15 shows that the 25th, 50th, and 75th percentiles of costs for preventive drugs were 
largely a function of age and multimorbidity, with higher costs among younger 
individuals with multiple chronic comorbidities. This association was especially clear for 
the upper part of the cost distribution (75th percentile). Disparities between cancer 
types remained after controlling for age, multimorbidity, and other potential 
confounders in quantile regression models. Compared with older adults who died 
with lung cancer, those who died with gynaecological malignancies (adjusted median 
difference [AMD] $27, 95% CI $18 to $36), breast cancer (AMD $19, 95% CI $11 to $28), 
and pancreas or prostate cancer (AMD $13, 95% CI $5 to $20) had higher costs for 
preventive medications. Overall, there was no decrease—and in fact even a slight 
increase— in the cost of preventive drugs between the 12th month before death and 
the final month of life (median difference $0.78, 95% CI 0.60 to 0.95). 
In sensitivity analyses, excluding cancer patients whose underlying cause of death 
suggested an acute and potentially unpredictable fatal event from the analysis did not 
qualitatively alter our findings. The prevalence and costs of preventive drugs were similar 
to the main analysis. Also, stratifying the study population according to the delay between 
cancer diagnosis and death (>12 months, 6 to 12 months, and <6 months) had little 
influence over the results.
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Figure 15. Distribution of costs for preventive drugs during the final year of life of older adults who 
died with cancer, by age at death and number of chronic comorbidities (2007–2013) 
(A) Heatmaps represent the absolute value (in US dollars) of the 25th, 50th, and 75th percentiles of costs for
preventive drugs during the last year before death, by age at time of death and number of chronic comorbidities.
Cells are coloured according to a scale ranging from the lowest to the highest observed values for the percentile
of interest. For instance, the 25th percentile of costs (top-left panel) ranged from $0 to $425. (B) 3D scatterplots
show the association between age, number of comorbidities, and absolute values for the 25th, 50th, and 75th
percentiles of preventive drug costs. (C) Contour plots represent the proportion of decedents whose costs for
preventive drugs during the last year of life were greater than the population 25th, 50th, and 75th percentiles,
respectively. Areas are coloured according to a scale ranging from the lowest to the highest observed proportion
and divided into deciles to facilitate interpretation. Costs were standardised by using the harmonised index of
consumer prices (see methods page 62), and were converted from Swedish Kronor into US dollars based on
Sweden’s Central Bank annual average exchange rate in 2013 (1 SEK = 0.1535 USD).
 84 
4.5 ADEQUATE, QUESTIONABLE, AND INADEQUATE DRUGS FOR OLDER 
ADULTS NEAR THE END OF LIFE 
Out of 58 European experts invited to participate in Study III, 40 agreed to take part in the 
panel (including one person who dropped out before the second round). Participants 
were scattered across 10 different countries. There was a majority of women (n=23), aged 
45–54 years (n=12) or ≥55 years (n=11), with more than 10 years of clinical experience 
(n=34). Most panellists were geriatricians (n=13) or palliative care physicians (n=12), but 
there were also 7 GPs, 7 pharmacologists and pharmacists, and 1 psychiatrist. After two 
Delphi rounds consensus was reached on 14 drugs or drug classes deemed ‘often 
adequate’, 28 drug classes deemed ‘questionable’, and 10 drug classes deemed ‘often 
inadequate’ for continuation among older adults aged ≥75 years with a life expectancy of 
3 months or less. Panellists were also in agreement to consider the initiation of 10 drug 
classes ‘often adequate’, 23 drug classes “questionable”, and 23 drug classes ‘often 
inadequate’ in this context. To improve clarity and readability, these drug classes were re-
combined in a smaller number of homogenous groups in Table 16. 
Drug classes that were rated as ‘often adequate’ are predominantly prescribed for 
symptom management and to ensure comfort care near the end of life. It is for instance 
the case of opioid and non-opioid analgesics, drugs for constipation, antiemetics and 
antinauseants (including glucocorticoids such as dexamethasone, e.g. for cancer patients 
with refractory symptoms), metoclopramide (a prokinetic mainly prescribed to relieve 
chemotherapy-induced nausea and vomiting, but also for the management of delayed 
gastric emptying, inoperable GI obstruction without colic, intractable hiccup, drug-
induced ), anxiolytics, antiepileptics, and butylscopolamine (also known as hyoscine 
butylbromide), which is widely used in palliative care as an antispasmodic and as an 
antisecretory drug for death rattles. While the continuation of levodopa, thyroid 
hormones, and inhaled salbutamol was deemed ‘often adequate’, their initiation wasn’t. 
Among the drugs and drug classes considered ‘questionable’ for use near the end of life, 
a large majority are prescribed for the long-term management of non-life-threatening 
chronic conditions (e.g. oxybutynin, anti-gout medications, drugs for prostate 
hypertrophy) or for the secondary prevention of chronic diseases that may otherwise 
lead to adverse events (e.g. antiplatelet agents, VKA, antihypertensives, blood glucose 
lowering drugs). Some drugs are also commonly prescribed to prevent the secondary 
effects of other pharmaceutical treatments (e.g. drugs for acid-related disorders). Drugs 
that panellists consensually defined as ‘often inadequate’ encompasses mostly drugs and 
supplements prescribed for primary prevention or as part of a long-term strategy of 
secondary or tertiary prevention. For instance, vitamin D, calcium supplements, 
bisphosphonates, statins, antidementia drugs. This third category of drugs deemed ‘often 
inadequate’ for older adults at the end of life was substantially longer when considering 
the initiation of new drugs rather than the continuation of treatments prescribed before.
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Continuation of drug therapy  Initiation of drug therapy 
Often adequate Often adequate 
Butylscopolamine Butylscopolamine  
Antiemetics and antinauseants Antiemetics and antinauseants 
Drugs for constipation Drugs for constipation 
Glucocorticoids for systemic use Glucocorticoids for systemic use 
Thyroid hormones Metoclopramide 
Analgesics (including opioids) Analgesics (including opioids) 
Antiepileptics Antiepileptics 
Anxiolytics: benzodiazepines Anxiolytics: benzodiazepines 
Hypnotics and sedatives: benzodiazepines 
Levodopa Questionable 
Salbutamol, inhalant Drugs for acid-related disorders, excl. PPIs 
Glucocorticoids, inhalants  Intermediate-acting and combined insulin 
Ipratropium bromide, inhalant Blood glucose-lowering drugs 
Unfractionated heparin 
Questionable Low molecular weight heparin 
Drugs for acid-related disorders, excluding PPIs Antiplatelet agents 
Blood glucose-lowering drugs, excluding metformin Blood products 
Vitamin K antagonists Digitalis glycosides 
Unfractionated heparin Low-ceiling diuretics 
Antiplatelet agents High-ceiling diuretics, excluding furosemide and torasemide 
Novel oral anticoagulants Potassium-sparing agents 
Other anticoagulants Beta-blockers 
Antianemic preparations Calcium channel blockers, excluding verapamil 
Blood products Oxybutynin 
Digitalis glycosides Drugs for prostate hypertrophy, excluding finasteride 
Other cardiac glycosides Anti-thyroid drugs and iodine therapy 
Alpha-blocker antihypertensives Anti-gout medications, excluding colchicine 
Low-ceiling diuretics Anti-Parkinson drugs, excluding levodopa 
Potassium-sparing agents, excluding spironolactone Hypnotics and sedatives other than benzodiazepines 
Non-selective beta-blockers Tricyclic antidepressants and monoamine oxidase inhibitors 
Calcium channel blockers  Systemic drugs for obstructive airway diseases 
Angiotensin-converting-enzyme (ACE) inhibitors 
Angiotensin II receptor blockers (ARBs) Often inadequate 
Finasteride Vitamin D 
Iodine therapy  Calcium supplement 
Antineoplastic drugs (including chemotherapy) Vitamin K antagonists 
Endocrine therapies Novel oral anticoagulants 
Immunosuppressants Other anticoagulants 
Anti-gout drugs, excl. allopurinol and colchicine Iron preparations and erythropoietin 
Systemic drugs for obstructive airway diseases Vitamin B12 and folic acid 
Cardiac glycosides, excluding digoxin 
Often inadequate Other cardiac stimulants 
Vitamin D Antihypertensives 
Calcium supplement Peripheral vasodilators 
Cardiac stimulants other than glycosides Verapamil 
Antihypertensives, excluding α-blockers Angiotensin-converting-enzyme (ACE) inhibitors 
Peripheral vasodilators Angiotensin II receptor blockers (ARBs) 
Lipid-modifying agents Lipid-modifying agents 
Immunostimulants Drugs for incontinence, excl. oxybutynin 
Bisphosphonates and other osteoporosis drugs Finasteride 
Antidementia drugs (AChEI and memantine) Antineoplastic drugs (including chemotherapy) 
Endocrine therapies 
Immunostimulants and immunosuppressants 
Bisphosphonates and other osteoporosis drugs 
Antidementia drugs (AChEI and memantine) 
Table 16. Consensus criteria regarding the continuation and the initiation of drug therapy for older 
adults (≥75 years) with an estimated life expectancy of 3 months or less 
Antiepileptics and antidepressants included in this list do not encompass drugs prescribed for the management of 
neuropathic pain (e.g. gabapentin, pregabalin, amitriptyline, duloxetine, venlafaxine). For clarity, a few pharmacological 
subgroups have been combined together to form homogenous categories. The detailed list of drugs and drug classes 
included in each of these categories is available in the published article, together with the corresponding ATC codes. 
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Consensus remained unachieved regarding the continuation of 53 drugs and drug 
classes (29 obtained only a moderate level of agreement [65–74%], and 24 had a low 
[<65%] level of agreement), and regarding the initiation of 40 drugs and drug classes (15 
obtained a moderate level of agreement, and 25 had a low level of agreement). Hence, 
we found that panellists had widely diverging opinions about the continuation of proton-
pump inhibitors, anti-thyroid drugs, intermediate- and long-acting insulin, muscle 
relaxants, antipsychotics, olanzapine, or antidepressants (Table 17). There was also no 
consensus about the initiation of fast-acting insulin, furosemide, haloperidol, Z-drugs, or 
selective serotonin reuptake inhibitors (SSRIs). For these drugs, the level of agreement 
amongst panellists did not improve between the first and the second round. 
Continuation of drug therapy  Initiation of drug therapy 
Proton-pump inhibitors Proton-pump inhibitors 
Long-acting insulin Fast-acting insulin 
Intermediate-acting insulin Furosemide 
Combined insulin Mineralocorticoids (e.g. aldosterone) 
Torasemide Acetic acid derivatives (e.g. diclofenac) 
Mineralocorticoids Baclofen  
Anti-thyroid drugs Other muscle relaxants 
Acetic acid derivatives (e.g. diclofenac) Ketamine 
Propionic acid derivatives (e.g. ibuprofen) Haloperidol 
Muscle relaxants, excluding baclofen Levomepromazine 
Ketamine Other antipsychotics 
Levomepromazine Non-benzodiazepine anxiolytics (e.g. hydroxyzine) 
Other antipsychotics, excluding haloperidol Olanzapine 
Non-benzodiazepine anxiolytics (e.g. hydroxyzine) Zopiclone  
Olanzapine Zolpidem 
Eszopiclone Eszopiclone 
Tricyclic antidepressants Selective serotonin reuptake inhibitors 
Selective serotonin reuptake inhibitors Trazodone 
Trazodone Mirtazapine 
Mirtazapine Methadone 
Methadone Inhalants for COPD, excluding salbutamol and ipratropium 
  
Drugs for neuropathic pain: Drugs for neuropathic pain: 
Venlafaxine  Venlafaxine 
Lidocaine Lidocaine 
Duloxetine Duloxetine 
Tricyclic antidepressants Tricyclic antidepressants 
 Pregabalin 
Table 17. Drugs and drug classes for which consensus was not reached due to a low (<65%) level 
of agreement among panellists 
4.6 CONTINUATION AND INITATION OF DRUGS OF QUESTIONABLE 
CLINICAL BENEFIT AT THE END OF LIFE 
A total of 58 415 older persons who died from conditions potentially amenable to 
palliative care in 2015 were included in Study IV. Mean age at time of death was 87 (SD 
6.3) years, 56% were women, and 42% were living in nursing homes. Based on multiple 
cause of death records, 28% died from cancer, 40% from organ failure, and 32% followed 
a trajectory of prolonged dwindling (i.e. dementia and neurodegenerative diseases). 
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During their last three months of life, 32% of older adults who died from conditions 
potentially amenable to palliative care continued and 14% initiated at least one drug of 
questionable clinical benefit (i.e. drugs deemed “often inadequate”, see list page 85). In 
contrast, 58.6% of decedents neither continued nor initiated such drugs. As shown in 
Figure 16, the proportion of individuals who continued to receive drugs of questionable 
clinical benefit near the end of life decreased with age and was somewhat higher among 
women (adjusted RR 1.08, 95% 1.05–1.11). Higher age was also associated with a lower 
likelihood of initiating drugs of questionable clinical benefit. We found that the proportion 
of patients who continued drugs of questionable benefit was substantially lower among 
cancer decedents (26%) than among those who died from organ failure (35%) or 
dementia (34%). The latter group had the lowest probability of initiating such drugs.  
Figure 16. Continuation and initiation of drugs of questionable clinical benefit during the last 3 
months of life, by sex and age 
The number of co-existing chronic diseases was independently associated with an 
increase in the probability of both continuing (RR 1.10, 95% CI 1.09–1.11) and initiating 
(RR 1.05, 1.04–1.06) drugs considered ‘often inadequate’ near the end of life. Compared 
with older persons with a low risk of frailty, those with a high risk were more likely to 
continue questionably beneficial drugs during their last 3 months of life (RR = 1.27, 95% 
CI = 1.23–1.31). However, they were significantly less likely to initiate these drugs (RR = 
0.83, 95% CI = 0.78–0.89). While continuation was equally frequent among community 
dwellers and nursing home residents (31% and 33%, respectively), initiation was less likely 
among nursing home residents (RR = 0.56, 95% CI = 0.53–0.59). In sensitivity analyses, we 
found that excluding older adults who died from acute and potentially unpredictable fatal 
events (n= 9918 [17%]) led to a qualitatively irrelevant albeit statistically significant 
reduction in the proportion of individuals exposed to drugs of questionable clinical 
benefit near the end of life (-1 to -1.5 percentage point difference). 
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During the last three months of life, statins were the most commonly continued drugs of 
questionable clinical benefit near the end of life, followed by calcium supplements, 
antidementia drugs, bisphosphonates and vitamin D (Table 18). Drugs for anaemia, ACE 
inhibitors and angiotensin II receptor blockers, novel oral anticoagulants, statins, and 
vitamin K antagonists were the most frequently initiated. Overall, both continuation and 
initiation were more common among older adults who died from organ failure than 
among those who died from cancer or dementia and neurodegenerative diseases. 
No. / No. at risk  % 
Continuation during the last 3 months of life 
At least one drug of questionable clinical benefit 18 681 / 58 415  32.0% 
Statins and other lipid-lowering agents 8394 / 12 875  65.2% 
Calcium supplements 6855 / 9856  69.6% 
Antidementia drugs 4463 / 5459  81.8% 
Bisphosphonates and other drugs for osteoporosis 1581 / 2668  59.3% 
Vitamin D 1225 / 1905  64.3% 
Immunostimulants 32 / 75  42.7% 
Peripheral vasodilators 0 / 0  0.0% 
Antihypertensives, excluding α-blocker 42 / 62  67.7% 
Cardiac stimulants other than glycosides 65 / 185  35.1% 
Initiation during the last 3 months of life 
At least one drug of questionable clinical benefit 8180 / 58 415  14.0% 
Drugs for anaemia  2090 / 35 959  3.6% 
ACE inhibitors or angiotensin II receptor blockers 1333 / 35 858  2.3% 
Statins and other lipid-lowering agents 686 / 45 540  1.2% 
Vitamin K antagonists 680 / 51 042  1.2% 
Novel oral anticoagulants 848 / 56 396  1.5% 
Other anticoagulants 5 / 58 414  0.0% 
Antineoplastic drugs 259 / 57 613  0.4% 
Endocrine therapies 264 / 54 883  0.5% 
Immunostimulants 21 / 58 340  0.0% 
Immunosuppressants 117 / 57 586  0.2% 
Finasteride 0 / 58 415  0.0% 
Vitamin D 432 / 56 510  0.8% 
Calcium supplement 1002 / 48 559  2.1% 
Cardiac glycosides, excluding digoxin 0 / 58 415  0.0% 
Other cardiac stimulants 21 / 58 230  0.0% 
Antihypertensives 56 / 57 913  0.1% 
Peripheral vasodilators 0 / 58 415  0.0% 
Verapamil 24 / 57 941  0.0% 
Drugs for urinary incontinence, excluding oxybutynin 200 / 57 090  0.4% 
Antidementia drugs 359 / 52 956  0.7% 
Bisphosphonates and other osteoporosis drugs 286 / 55 747  0.5% 
Table 18. Prevalence of the most commonly prescribed drugs of questionable clinical benefit for 
older adults near the end of life 
The proportion of older adults who continued or initiated at least one drug of questionable clinical benefit during 
the last 3 months before death was calculated as a fraction of the entire study population (n=58 415). For specific 
drugs and drug classes, the population at risk (denominator) was defined as follow: (a) continuation, individuals 
already treated with each specific drug class between 12 and 3 months before death; (b) initiation, individuals who 
were not previously treated and had at least one refill during the last 3 months before death. Drugs for anaemia 
include iron supplements, vitamin B12, folic acid and erythropoietin. Antidementia drugs include both 
acetylcholinesterase inhibitors (donepezil, rivastigmine and galantamine) and memantine. The list of Anatomical 
Therapeutic Chemical (ATC) codes corresponding to the different drugs and drug class is available in 
Supplementary Table 9 and Supplementary Table 10 of the published article for Study IV. 
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5. DISCUSSION 
5.1 SUMMARY OF THE MAIN FINDINGS 
In this doctoral thesis, we investigated changes in the number and type of drugs 
prescribed throughout the final year of life of older adults in Sweden, we described the 
use and costs of preventive therapy among older people with cancer at the end of life, 
we developed a set of explicit criteria for identifying drugs of limited clinical benefit at the 
end of life, and we examined the continuation and initiation of these drugs in the Swedish 
population. Our main findings can be summarised as follow: 
1. During their last year of life, older adults are prescribed an increasing number of 
drugs. Half of the decedents were exposed to ≥10 different drugs during the last 
month before death. Polypharmacy was fuelled not only by the initiation of 
symptomatic drugs but also by the continuation of drugs for chronic conditions. 
2. Among older adults who died with solid cancer, preventive drugs are frequently 
continued until the very end of life. During the last year before death, the median 
drug cost per capita was $1482, including $213 for preventive therapies. 
Disparities between cancer types remained after controlling for age, 
multimorbidity, and other potential confounders. 
3. A Delphi consensus panel allowed to create a set of criteria differentiating drugs 
and drug classes deemed ‘often adequate’, ‘questionable’, and ‘often inadequate’ 
for use in older persons aged ≥75 years with a life expectancy of three months or 
less. However, consensus remained unachieved for a substantial number of drugs 
commonly prescribed at the end of life (e.g. proton-pump inhibitors, 
antipsychotics, antidepressants). 
4. Upon applying the above-mentioned criteria on a population of older adults who 
died from conditions potentially amenable to palliative care, we found that 32% 
continued and 14% initiated at least one drug considered ‘often inadequate’.  
The specific findings from each of these four studies have been discussed in the 
corresponding published articles. However, certain aspects deserve further discussion, 
as they transcend the individual studies and articles. In our opinion, the necessity to 
rationalise and improve drug prescribing for older adults near the end of life can be 
understood from three different yet intertwined perspectives: biological (accounting for 
the profound alteration of pharmacokinetic parameters at the end of life), clinical 
(reconsidering the notion of benefit), and ethical (minimising the risk of harm). We then 
discuss the reasons that may, at least partly, explain the prescribing of drugs deemed 
‘often inadequate’ at the end of life. Finally, we review the main methodological 
limitations of the present thesis, and we reflect on future research perspectives.   
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5.2 OPTIMIZING DRUG THERAPY IN OLDER PEOPLE AT THE END OF LIFE 
The biological perspective: altered pharmacokinetics and pharmacodynamics 
Older adults who reach the end of life experience physiological changes that go beyond 
normal age-related modifications. The pharmacokinetic processes and pharmaco-
dynamics of drugs can thus be considerably altered as death approaches. Despite the 
scarcity of data to shed light on the impact of physiological changes near the end of life, 
all four pharmacokinetic processes are likely to be affected, thereby increasing the risk of 
adverse drug reaction.651–654 
The absorption of medications administered per os can be influenced by gastrointestinal 
symptoms. Hence, constipation can either decrease the absorption rate by delaying the 
dissolution of the drugs (thus affecting the time to peak concentration), or on the contrary 
increase the overall extent of absorption by prolonging the time of contact with the 
intestinal mucosa. Additionally, diarrhoea can decrease the bioavailability of drugs by 
accelerating the bowel transit time, thus affecting the initial peak concentration and total 
exposure. Optimal absorption is also compromised among patients with gastric or 
colorectal cancer who undergo surgical resection of their gastrointestinal tract, and 
among patients with artificial enteral nutrition. Finally, impairments to the gut wall 
function induced by cachexia or inflammation (frequent among cancer patients) may lead 
to changes in drug absorption.655 To our knowledge, it is unknown whether the reduction 
of first-pass metabolism observed among older adults is accelerated near the end of life. 
The volume of distribution of drugs can be affected by changes in body composition 
resulting from the progression of the disease, for instance weight loss, loss of total body 
water due to dehydration or volume depletion, ascites, oedema, and loss of muscle mass. 
In advanced cancer and dementia, extreme weight loss and cachexia can occur, which 
results in subcutaneous and visceral adipose tissue depletion and thus decrease the 
volume of distribution of lipophilic drugs and—mechanically—increase their peak serum 
concentration.655 Decrease in the volume of distribution should mainly be accounted for 
when prescribing medications with a rapid onset such as analgesics and sedatives, since 
it affects the initial peak concentration. Alterations of plasma protein binding (typically 
hypoalbuminemia and increased alpha1-acid glycoprotein654) can also influence the 
volume of distribution, although it is unlikely to be clinically relevant.410,431 Among older 
adults with advanced dementia, the enhanced permeability of the blood-brain barrier 
increases the risk of serious neurological adverse drug reactions.651 
Metabolism, namely the transformation of drug compounds into metabolites, can be 
altered by the decline in the ability of the liver to extract drugs from the blood.656 Two 
mechanisms are potentially at play: a reduced liver blood flow (frequent among patients 
with congestive heart failure657), and a decreased intrinsic clearance function due, for 
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instance, to liver metastases, chemotherapy-induced hepatic toxicity (e.g. sinusoidal 
obstruction syndrome caused by the combination of oxaliplatin with 5-fluorouracil in 
FOLFOX chemotherapy regimens), or reduced cytochrome P450 3A activity.658 
The excretion of drugs is often compromised, particularly for older adults with renal 
impairment. Reduced kidney clearance can lead to an accumulation of parent drugs or 
active metabolites during the final days of life and cause adverse effects (e.g. delirium, 
myoclonus).654 Of note, estimating the actual glomerular filtration rate in the population 
of terminally ill or very frail older adults can be difficult, as the usual methods based on 
creatinine levels show limited accuracy among patients with low or decreasing muscle 
mass.651,659 
As noted by Franken et al., “the pharmacokinetics of drugs in terminally ill patients can 
be complex […], and limited evidence exists on guided drug use.”652 Even less is known 
about the pharmacodynamics of drugs in the context of end-of-life care. While 
pharmacokinetics refers to the various effects that the organism has on ingested drugs, 
pharmacodynamics describes how the drugs affect the organism. More specifically, 
pharmacodynamics corresponds to the set of interactions that occur between the drugs 
and their receptors in the target organ (signal transduction mechanisms) and the 
homeostatic regulatory processes that preserve the functional equilibrium of the 
organism. Although the exaggerated sensitivity to drugs and the higher risk of toxicity are 
well documented in clinical studies, pharmacodynamics processes are notoriously 
difficult to predict in individual cases.660,661 In a review focused on older people with 
dementia, Reeve et al. emphasised the hazards of central nervous system drugs and 
anticholinergics but also pointed out the lack of research investigating the effect of frailty 
on pharmacodynamics.651 Moreover, because of their low baseline functional status and 
reduced homeostatic mechanisms (which, one may assume, tend to worsen near the end 
of life), older adults with advanced illness are more susceptible to develop drug-induced 
orthostatic hypotension, dehydration, hypokalaemia, or hyponatraemia.662  
Beyond strictly physiological parameters, the hazard of prescribing drugs to older adults 
at the end of life is further complicated by the exponentially increasing risk of drug-drug 
interactions that comes with polypharmacy.407,663 In a large, multicentre cohort study in 
11 European countries, Kotlinska-Lemieszek et al. found that a majority of patients with 
advanced cancer were exposed to potentially harmful drug-drug interactions.559 In 
Australia, Morgan et al. reported that 72% of adult patients referred to specialist palliative 
care were at risk of drug-drug interaction and stressed the importance of implementing 
tailored computerised prescribing alerts and developing close collaborations with clinical 
pharmacists to detect potentially serious drug-drug interactions and adverse drug 
reactions.552 In sum, clinicians prescribing for older adults near the end of life must apply 
utmost caution and carefully consider the risk-benefit ratio of continuing or initiating a 
new drug and personalise the dose to minimise the burden of side effects. 
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The clinical standpoint: reconsidering the benefit of medications 
Incorporating life expectancy in the assessment of treatment benefits  
Assessing the benefits and risks of preventive medicines for older people with advanced 
illness is challenging since measures typically derived from randomised clinical trials do 
not account for the amount of time that patients can expect to live. The number needed 
to treat (NNT) is a commonly used indicator of treatment effectiveness.664,665 It 
corresponds to the inverse of the absolute risk reduction (ARR) between patients enrolled 
in the ‘treatment’ group and those allocated to the ‘control’ or ‘placebo’ group, and it can 
be interpreted as the number of individuals who need to be treated to avoid one 
occurrence of the outcome of interest. We illustrate this approach with an example. 
In a meta-analysis666 of 14 clinical trials investigating the effectiveness of statins for the 
primary prevention of cardiovascular diseases, statins were found to reduce the 
occurrence of coronary events over 5 years: 820/24 217 (3.4%) in the treatment group 
versus 1114/23 832 (4.7%) in the ‘placebo or usual care’ group. Although statistically 
correct, it would be somewhat misleading for clinicians and patients to describe this 
finding by saying that statins result in a 27% relative risk reduction (RR=0.73, 95% CI 0.67 
to 0.80) of CHD events. Instead, it is preferable to state that statins lead to a 1.3% (95%CI 
0.94 to 1.64) absolute risk reduction, or that 78 patients need to be treated for 5 years to 
prevent one coronary event among persons without a history of cardiovascular disease. 
Yet, although this would indicate  a substantial benefit of statins for the general older 
population, NNT over 5 years is of limited value for individuals with metastatic cancer or 
advanced dementia with a predicted life expectancy of less than 6 months.667–669 As noted 
by Stevenson et al., “the number needed to treat for a given treatment for a comorbidity 
will increase as the prognosis decreases.”481 However, since adverse outcomes are 
seldom distributed evenly over time and since the absolute risk reduction is rarely 
constant, scaling NNT for different periods of time is rather unhelpful and could lead to 
overly optimistic estimates. 
To tackle this issue and help clinicians prioritise medications offering the best chance of 
achieving their benefit during the patients’ remaining life expectancy, Holmes et al. have 
promoted the concept of time to benefit.540 It is defined as “the time until a statistically 
significant benefit is observed in trials of people taking a therapy compared to a control 
group not taking the therapy.”542 Since the number of weeks, months or years needed to 
observe the benefit of a therapy is hardly ever reported as such, several methods have 
been used to estimate time to benefit from published randomised controlled trials: 
comparing the absolute risk reduction observed in trials of different durations; using the 
median or mean follow-up time of individual patients by assuming right-censoring after 
the outcome of interest; or conducting a visual inspection of cumulative survival or failure 
curves to identify the earliest time of curve separation.542,668 However, it should be noted 
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that these methods present important caveats that make their generalisation 
challenging. Van de Glind et al. recently proposed a novel approach to overcome these 
difficulties. Their method relies on statistical process control to determine the time point 
after which the cumulative absolute risk reduction in adverse events become greater 
than the normal variability observed across treatment groups over time.670 Another 
approach has been proposed by Braithwaite et al. to estimate the time until the 
cumulative benefits of a medical intervention exceed its potential for harms according to 
the patients’ characteristics.671,672 This payoff time model was initially developed to inform 
policymakers and healthcare stakeholders about the time needed for preventive care 
guidelines to achieve a net benefit among older adults with multiple chronic diseases 
(compared with their remaining life expectancy). In a similar perspective, Lee et al. 
conducted a meta-analysis of 9 population-based, randomised controlled trials 
comparing the effectiveness of breast and colorectal cancer screening to assess the time 
until a significant survival benefit is observed.673 Using annual estimates of the mortality 
rate among screened and unscreened participants, they calculated the time required to 
obtain predefined cut-off values of absolute risk reduction. Their results show that it took 
11 years (95% CI 4.4–21.6) to prevent one death for every 1000 women who underwent 
breast cancer screening, and 10 years (95% CI 6.0–16.4) to prevent one death for every 
1000 persons who had colorectal cancer screening. These findings have been confirmed 
by other studies and demonstrate the necessity to account for the remaining life 
expectancy before recommending the use of preventive health interventions that may 
yield a significant benefit only years later.674–679  
Incorporating the time to benefit in the decisions to initiate, continue or discontinue 
treatments inevitably leads to reconsider what makes a therapy potentially beneficial in 
the context of limited life expectancy: the question is no longer “Is this medication 
effective?” but rather “Will this medication help the patient during his/her remaining 
lifespan?.” In that sense, the time to benefit is a tool to contextualise measures of benefit. 
The findings from Study I and Study II showing that a sizeable proportion of older adults 
with life-limiting illness continue to receive drugs for the long-term prevention of chronic 
diseases until their last month of life can, for instance, be interpreted critically in light of 
the apparent mismatch between the long lag time to benefit of these drugs and the short 
survival of these patients.  
Nonetheless, accounting for life expectancy may not be sufficient to ensure that drug 
prescribing is adequate. The time to benefit of a specific treatment depends on the 
outcome selected to judge whether this treatment has reached its intended target. For 
instance, what if the time to benefit for the primary endpoint (e.g. myocardial infarction) 
favours the treatment but the time needed to achieve the endpoint that is the most 
important for the patients (e.g. quality of life) does not? What if the intended benefit 
accrues at a time when the patient is no longer functional enough to find this benefit 
meaningful? These questions reveal the importance of aligning the treatment target with 
the patients’ personal preferences and goals of care.542,680 
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Targeting what matters: placing patient preferences at the centre 
Older adults often reconsider their preferences regarding the goals of care when the 
disease progresses, and the perspective of a remission becomes less and less likely. For 
instance, ensuring symptoms management and maintaining quality of life may become 
more important for the patient than extending survival.681 A survey conducted in the 
United States (n=1006) indicates that for 71% of the population “helping people die 
without pain, discomfort, and stress” should be the priority of healthcare at the end of 
life.682 When asked to rate the importance of different factors in thinking about their own 
situation, 85% stated that making sure their wishes for medical care were followed was 
“extremely important” or “very important.” Being comfortable and without pain (78%) was 
more often mentioned as important than living as long as possible (46%). Yet, in a post-
death interview study of 1212 family caregivers who lost a relative aged ≥65 years, 13% 
reported that the care provided during the final month of life was inconsistent with the 
decedent’s stated preferences.683 This reality had already been described in 2002 by Teno 
et al., who described that over one-third of seriously ill patients who had expressed a 
preference for comfort care received treatments that were not concordant with this.684 
The quality of care can be defined as “the extent to which health services for individuals 
and populations increase the likelihood of desired health outcomes.”685 In other words, 
the quality of a medical intervention should be judged according to the capacity of that 
intervention to achieve a goal valued as important by the person who should benefit from 
it.686 Because the priorities of people facing the consequences of a serious and incurable 
life-limiting illness are likely to be different from those of the general population, what 
constitutes a desired health outcome also differs.687 Therefore, treatment benefits should 
not only be defined according to the mere physiological effect that they produce but 
according to their ability to address the needs that the patient considers as important 
and meaningful.542,688,689 Maintaining a person-centred care plan also means that the 
benefits and potential harms of treatments should be discussed in the context of the 
patient’s anticipated health trajectory, to ensure that these treatments will remain 
meaningful throughout the course of the disease and in spite of a likely decline in ADL 
and mobility functions.544,690 Since the priorities of seriously ill patients nearing death 
have been found to vary over time,691 keeping the therapeutic target aligned with the 
goals of care requires good communication between the prescriber and the patient.  
The ethical point of view: “first, do no harm” 
In the previous section, we have demonstrated the necessity for clinicians to ensure that 
treatments provide a meaningful benefit and are in the patient’s best interest as they 
approach the end of life. It corresponds to the first principle of medical ethics: beneficence. 
A second principle governs decisions to initiate, continue or withdraw medical 
treatments: non-maleficence.639,640 This relates to the injunction “first do no harm” (Primum 
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non nocere), which dictates that the obligation of beneficence must always be weighed 
against the obligation not to cause harm. In other words, clinicians should abstain from 
providing treatments that are likely to do more harm than good.692–694 While certain drugs 
are well tolerated and present only a small risk of clinically relevant adverse events, other 
treatments are particularly prone to cause serious harm. Among older people treated 
with antidiabetic drugs, for instance, overly intensive glycaemic control often results in 
hypoglycaemia, which, in turn, increases the risk of injurious falls, physical frailty, and 
cognitive impairment.695,696 Insulins and oral blood glucose-lowering drugs have been 
found to be implicated in nearly 25% of all non-elective hospitalisations of older 
American.416 However, despite limited but convincing evidence that deintensification of 
glycaemic control is feasible, safe, and has the potential of reducing harms,697,698 less than 
one-third of patients with very low levels of haemoglobin A1c (HbA1c <6.0%) have their 
medications revised.699 Hamada et al. reported that only a small minority discontinue 
antidiabetics near the end of life,700 which our own findings confirmed. Another example 
would be that of anticoagulants for the management of cancer-associated deep-vein 
thrombosis at the advanced stage of the disease. Low-molecular-weight heparin and 
direct oral anticoagulants are effective treatments but come with a substantial risk of 
gastrointestinal and intracranial bleeding.701–703 In a recently published prospective 
cohort study of patients with cancer admitted to specialist palliative care units in the 
United Kingdom, White et al. showed that the prevalence of femoral deep vein 
thrombosis as assessed with ultrasonography at time of admission was high (34%) but 
incidence during the next two weeks was very low. “[These findings] suggest that 
thromboprophylaxis at this stage might be too late”, the authors concluded, adding that 
“the absence of observed association with survival, or symptoms or signs other than leg 
oedema questions whether thromboprophylaxis offers clinically meaningful benefit.”704 
Potential harms associated with a therapy are often measured through the number 
needed to harm (NNH), a correlate of the number needed to treat (NNT) described earlier. 
However, just like the NTT, the NNH does not estimate the time required for an 
intervention to cause harm. This means that as prognosis worsens and life expectancy 
diminishes, clinicians should not only balance the probability that the treatment will 
benefit against the probability that it causes harm, but also consider the probability that 
time-to-harm be shorter than time-to-benefit. One can, for instance, imagine a 
hypothetical trial evaluating the benefits and harms of a cardiovascular treatment 
intended to reduce the risk of 2-year mortality among older adults who experienced a 
serious sentinel event. Findings demonstrate a clinically significant decrease in the 
probability of dying among study participants who were allocated to the treatment arm, 
with an absolute risk reduction of 2.5% (NNT 40). But the results also show that those 
who received the treatment were at 2% higher risk of institutionalisation and incident 
ADL disability (NNH 50). Moreover, detailed analysis reveals that most of the benefit is 
observed after 1 year while most of the adverse effects are reported during the first 
months after enrolment. Hence, the authors find that the NNH is greater than the NNT 
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during the first 6 months, before the ratio gradually inverses and the benefits outweigh 
the harms. This scenario is not uncommon in published randomised controlled trials and 
should give pause in the context of limited life expectancy. While the abovementioned 
trade-off may seem acceptable for the general population of older adults (considering 
the favourable risk-benefit balance in the long term), it is questionable when considering 
the case of patients who are unlikely to survive longer than 1 year. These persons would 
indeed live long enough to experience the harms caused by the treatment, but not long 
enough to gain any substantial benefit. This example was recently embodied by a large 
observational study investigating the benefits and harms of beta-blocking agents among 
frail older adults after acute myocardial infarction.705,706 In a propensity-matched cohort 
of 10 992 older adults aged 84 years on average, Steinman et al. found that β-blockers 
were associated with a significant reduction of mortality (HR 0.74, 95% CI 0.67–0.83) but 
also with an increased risk of functional decline during the 3-month period after hospital 
discharge (OR 1.14, 95% CI 1.02–1.28). Furthermore, researchers reported that nursing 
home residents with moderate to severe cognitive impairment or severe ADL limitations 
at baseline were the most likely to experience further functional decline. In an 
accompanying editorial, Tjia et al. commented that these results “confirm that the 
practice of avoiding prescription of β-blockers in frail and highly vulnerable elders with 
functional impairment is reasonable. […] As clinicians, we must remember that the 
spectrum of good prescribing practices spans initiation to discontinuation of therapy. 
Initiation of therapy, in many ways, is the easy part of the prescribing spectrum. The more 
challenging part is considering the discontinuation of therapy.”707 
Physicians should consider withdrawing drugs when the potential for harm outweighs 
the benefits that patients can reasonably expect during their remaining lifespan, or when 
the treatment target is no longer aligned with the preferred goals of care. As life 
expectancy diminishes, the spectrum of drugs considered adequate should be gradually 
reduced (Figure 17). The process of deprescribing has gained traction in the field of 
geriatric medicine,708–711 and is considered as a potentially powerful instrument to reduce 
inappropriate drug utilisation, lower the prevalence of polypharmacy, and improve 
health outcomes in multimorbid older adults.712–717 In the context of end-of-life care, 
withdrawal of preventive drugs has recently come under the spotlight with the 
publication of a landmark randomised controlled trial by Kutner et al. evaluating the 
safety of discontinuing statin medications for patients in the palliative care setting.718 In 
this study, a total of 381 individuals (mean age 74 years) with advanced illness and ≤ 12 
months life expectancy were randomly assigned to either ‘continuing’ or ‘stopping’ 
statins. There was no clinically relevant difference in the risk of death or in the time to 
first cardiovascular event. Moreover, patients who discontinued statins reported a higher 
satisfaction with care and a better quality of life. Whether this conclusion is applicable to 
other drugs remains uncertain and warrant further research (see 5.6 Future 
perspectives).719–722  
97 
The clinical and ethical dilemma that results from the obligation of non-maleficence can 
be extended one step further. Prescribers should indeed balance the lack of benefit of a 
given drug with the potentially harmful effects of its withdrawal. For instance, the 
discontinuation of antidementia drugs raises important and unsolved questions. Despite 
their widely acknowledged ineffectiveness in the treatment of advanced dementia, 
discontinuation may lead to accelerated cognitive and functional decline and has been 
linked to a 2-fold increased risk of institutionalisation.723–725 Decisions about drug 
discontinuation near the end of life are also made more difficult by three factors: the 
prognostic uncertainty, the challenge of timely patient-physician communication, and the 
existence of cognitive biases that may distort the decision-making process. 
5.3 THE CHALLENGE OF DEPRESCRIBING AS DEATH APPROACHES 
Predicting the unpredictable 
Despite a considerable number of studies conducted over the past two decades, 
predictions about the remaining life expectancy of individual patients remain highly 
inaccurate. Kimbell et al. recently observed that “predicting how long an individual will 
live remains an inexact science in all diseases and is nigh on impossible when people 
have multiple advanced conditions.”726 Predictions made by physicians in routine clinical 
practice are often far more optimistic than the actual survival time of patients with life-
limiting diseases.727–730 A meta-analysis of 8 studies (n= 1563) published by Glare et al. in 
2003 showed that clinical predictions of survival in terminally ill cancer patients were 
accurate (less than 1-week difference) in 25% of the cases, but overestimated actual 
survival by at least 4 weeks in 27% of cases.731 Anecdotally, the predictions of 3-month 
survival for patients with advanced cancer have been found to be as (in)accurate as 5-day 
meteorological forecasting.732 Studies conducted in other patient groups (e.g. heart 
failure, COPD) showed equally unreliable physician733 and patient734 predictions. 
Figure 17. (De)prescribing model for older adults approaching the end of life 
Adapted from Holmes HM, et al. (2006). 
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Moss et al. developed the ‘surprise question’ to identify patients who might benefit from 
palliative care.735,736 This approach requires clinicians to assess whether they would be 
surprised if an individual patient died in the next 12 months. It should be noted that the 
initial aim of the surprise question is not to produce an accurate survival prediction, but 
rather to serve as a screening tool to emphasise the need for careful re-examination of 
the patient’s goals of care in light of the most likely limited life expectancy.737 Yet, several 
studies have investigated the predictive performance of the surprise question to estimate 
the probability of death within 6 to 18 months. Two recent systematic reviews and meta-
analyses show that this tool is insufficiently accurate to predict mortality (area under the 
curve 0.75–0.81), especially for patients with non-malignant diseases.738,739 
Efforts have also been made in various medical disciplines to develop more sophisticated 
predictive algorithms designed to estimate the remaining life expectancy of individual 
patients based on a broad range of demographic, clinical, and biological information. Yet, 
until now these instruments have hardly proven to be helpful at the bedside. Out of a 
total of 16 validated prognostic indices for older adults included in the systematic review 
published by Yourman et al. in 2012,740 the area under the curve ranged from 0.64 to 0.83 
– which mean that the outcome would be erroneously predicted in 1 out of 3 to 6 patients. 
Similarly, although several authors reported promising sensitivity/specificity values for 
various prognostic scores,741–744 the degree of inaccuracy remains too high to use them 
as standalone prognostic tools to support decision-making in routine clinical practice. 
This is particularly true for older adults at the advanced stage of dementia, a disease 
characterised by its frequently unpredictable clinical course.745–749 Hence, Mitchell et al. 
found that the Advanced Dementia Prognostic Tool (ADEPT)750 performed poorly at 
predicting 6-month mortality in a prospective cohort of 606 nursing home residents with 
advanced dementia, which led them to conclude that “care provided to these residents 
should be guided by their goals of care rather than estimated life expectancy.”751 
This raises challenging questions. How should older adults re-evaluate their goals of care 
if the information that they receive from their treating physician about their life 
expectancy is most likely inaccurate? What should guide the decision to initiate, continue, 
or discontinue a specific treatment if the comparison between the time-to-benefit and 
the remaining life expectancy is based on unreliable estimates? On the one hand, some 
anticipate that progress in statistical processing and a better utilisation of available 
information (e.g. machine-learning, medical imaging, biological markers) will eventually 
result in optimal prognostic algorithms with nearly perfect predictive performance. 
Others argue that instead of trying to purge the decision-making process of any form of 
uncertainty, decisions regarding the course of treatments should include a degree of 
ambivalence, and use it to help patients express their worries, fears, and 
priorities.726,752,753 For older people who live with an advanced, incurable, and progressive 
illness, uncertainty can be an opportunity to start discussing end-of-life issues; including 
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how different drug treatments can help them achieve the goals that are important for 
them and how the most bothersome side effects of drugs can be addressed.754–756 
End-of-life discussions and shared decision-making 
Aligning drug therapy with evolving goals of care near the end of life requires timely 
discussions between patients, physicians, and relatives.757–759 Good communication is 
ranked amongst the most important components of end-of-life care by patients and their 
informal caregivers.760 Although some people prefer to be kept at a distance from the 
decision-making process, a large majority of older adults want to be informed about the 
course of their illness, to discuss their options in terms of disease and symptom 
management, and to participate in decisions regarding the initiation, continuation or 
withdrawal of treatments.761–763 In a 2016 survey of the US population,682 92% of 
respondents stated that they would be “comfortable talking about their own end-of-life 
medical wishes with a healthcare provider”, and 87% considered that the wishes of 
patients and relatives should prevail in decisions about the continuation of medical 
treatments near the end of their lives. Interestingly, despite important cultural 
differences across countries the proportion of individuals who declare that physicians 
should be “completely honest even if there is little chance of recovery” with seriously ill 
patients is similar in Japan (80%), Italy (79%), the United States (88%), and Brazil (80%).764 
Patients themselves often expect their treating physician to cultivate open and honest 
discussions about their prognosis.765–768  
Contrary to popular belief, conversations about end-of-life issues do not seem to increase 
patient emotional distress, anxiety, depressive symptoms, or hopelessness.759,769,770 In a 
prospective study of 988 patients with ≤6 months life expectancy who underwent an 
initial interview about death, dying, and bereavement, 89% of patients and 90% of their 
relatives reported little or no stress afterwards.771 On the contrary, Fallowfield et al. noted 
that “the desire to shield patients from the reality of their situation usually creates even 
greater difficulties.”766 Consensus about the clinical benefit and the ethical obligation to 
discuss end-of-life issues has grown stronger in the medical community over the last two 
decades, which is in line with the earlier-mentioned shift from paternalism to patient 
autonomy.772 Yet, many clinicians are still hesitant (and even reluctant) to discuss this 
topic openly with patients and their caregivers.773–776 
A substantial share of patients with life-limiting conditions are not given the opportunity 
to discuss end-of-life issues with a physician.777–783 For instance, a prospective study of 
2155 patients with stage IV lung or colorectal cancer found that 27% of patients had no 
reported end-of-life care discussion.784 Among older adults with terminal heart failure, 
end-of-life issues are rarely (if ever) broached, conversations are mostly focused on 
disease-modifying therapy.785 In nursing homes, a growing number of observational 
studies report that residents are often not informed of their situation and are seldom 
involved in decisions regarding the continuation or discontinuation of treatments near 
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the end of life. In France, we showed that out of 674 older adults who died in nursing 
homes in 2013–2014, no discussion about end-of-life-related topics was reported with 
the resident or with the relatives in 32% of cases.786 In Norway, Gjerberg et al. reported 
similar findings, remarking that “most [residents] stated that they had not had an 
opportunity to discuss their values and preferences for treatment and care related to 
end-of-life with the nursing home staff.”787 
This lack of communication has important consequences for the quality of end-of-life 
care. Failure to disclose the prognosis and to discuss the progression of the disease can 
lead to unrealistic expectations on the part of the patients and their relatives towards the 
benefits of treatments. Among 1193 patients receiving chemotherapy for newly 
diagnosed metastatic lung or colorectal cancer, Weeks et al. found that between 69% 
(lung) and 81% (colon-rectum) of participants did not understand that chemotherapy was 
“not at all likely” to cure their cancer.788 Similarly, a meta-analysis of 34 studies showed 
that less than half of patients with advanced or terminal cancer had an accurate 
understanding of their prognosis, reflecting the poor quality of patient-physician 
communication in these difficult times.789 On the contrary, seriously ill patients who have 
the possibility to discuss end-of-life care issues with a physician have a better 
understanding of their remaining life expectancy and are more likely to receive care and 
treatments that are aligned with their preferences near the end of life.784,790–799 
Discussions about end-of-life related issues should not only cover prognosis and life 
expectancy, but also touch upon broader issues related to the fears and concerns of 
patients and relatives, the goals of care in the event of a sudden decompensation, the 
patient’s wishes for family involvement, and personal or religious preferences regarding 
value-laden medical decisions (e.g. continuous sedation, withdrawal of life-sustaining 
treatments).759,775,800 Timely discussion about the possibilities in terms of symptom 
management and palliative care offered by local hospitals, nursing homes, and 
community-based hospice programs is also essential to avoid the sense of abandonment 
that patients and relatives may experience while life-prolonging treatments are gradually 
discontinued. Patients should be reassured that transitioning to palliative goals of care 
does not amount to ‘giving up’.801–804 
Having these conversations can be exceedingly difficult for clinicians, who find it stressful 
and emotionally burdensome.773,805–807 Physicians often mention lack of time and 
patients’ and family members’ difficulty understanding the limitations of life-prolonging 
therapies as important obstacles to end-of-life discussions.808–811 Recent policy changes 
have been implemented in the United States to tackle this problem. For instance, the 
Medicare fee-for-service program now allows for the reimbursement of voluntary 
counselling sessions designed to promote end-of-life discussions and advance care 
planning.59,812–814 Another substantial barrier is the abovementioned difficulty in 
estimating time to death, and thus in determining when end-of-life discussions should be 
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started.815–818 Although this concern is related to clinicians’ desire to balance hope with 
realistic information,818–824 it often leads to delaying end-of-life conversations until very 
late in the course of the disease trajectory, at a time when it may be difficult to realign 
treatments with the patient’s preferred goals of care.66,825,826 
Some argue that shared decision-making is illusory, plagued by ever-changing 
preferences regarding treatments and by a profound aspiration from the patients and 
their relatives to avoid difficult decisions about future care plans.827 It is true that denial 
of the ineluctably fatal progression of the disease is common and that patients can 
sometimes feel overwhelmed by difficult decisions. However, these emotional reactions 
tend to be stronger when discussions about the end of life occur late, in a context of crisis 
(e.g. unplanned hospitalisation), or when they focus exclusively on treatment options and 
don’t include other non-medical issues.828 Maskrey et al. recently emphasised that “at its 
simplest, shared understanding may involve a one-off binary choice (e.g. take an 
antibiotic or have a surgical procedure), but often it involves a dialogue that must be 
maintained through the complexities of chronic or comorbid illnesses.”829 In other words, 
patient-physician dialogue should start early during the course of the disease, and broach 
the issue of end-of-life care progressively. 
Optimal communication and shared decision-making with seriously ill persons require 
skills for which physicians are rarely trained.830–832 Clinicians should be encouraged to use 
checklists, communication-priming leaflets, conversation guides, and video decision aids 
to ensure that important issues are discussed with patients when prognosis worsens and 
the continuation of disease-oriented treatments becomes questionable.833,834 The 
purpose of these tools is not only to support patient-centred approach to end-of-life care, 
but also to reduce cognitive biases that may alter the decision-making process. 
The therapeutic illusion 
In the context of reduced life expectancy, when physicians have reached the limits of 
modern therapeutic resources, medical decisions are often fuelled not by evidence-
based guidelines but rather by intuition, clinical experience, and emotions.807,823 This 
paves the way for various cognitive biases, which may distort the assessment of benefits 
and harms of treatments and thus encourage overtreatment. Both physicians and 
patients tend to overestimate the control that they can have on the course of the disease, 
exaggerating the effects of their own actions and underestimating the influence of factors 
that are outside their control.835 This illustrates a phenomenon recently described by 
palliative care physician David Casarett as a therapeutic illusion,836 also known by 
behavioural psychologists as the illusion of control.837–839 In Australia, Scott et al. have 
proposed a comprehensive overview of the cognitive biases that “steer clinicians towards 
continuing to believe in, and deliver, care that robust evidence has shown to be of low 
value.”840 In particular, the following cognitive biases may play an important role in the 
decision to prescribe preventive medications to older adults at the end of life. 
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The impact bias leads to overestimating the probability that an intervention will provide a 
benefit while underestimating the probability that it will cause harm.841,842 It relates to the 
extrapolation bias, i.e. expecting that the favourable impact of an intervention observed 
in a specific group of patients will be equally favourable in another population. The 
confirmation bias leads to choosing and remembering the facts that support one’s initial 
assumption while undermining or ignoring facts that contradict that assumption.843 The 
commission bias refers to the tendency of physicians to act out of a stronger desire to 
avoid the negative consequences that may result from the omission of an intervention 
(e.g. treatment, diagnostic test) than to avoid the harms that may result from providing 
that intervention.844,845 Believing in the effectiveness of an intervention based on a few, 
highly selected cases where favourable outcomes were previously obtained reflects an 
attribution bias. In medical oncology, rare situations of rapid and unexpected 
improvement after salvage chemotherapy are known as the ‘Lazarus effect’, and may 
accentuate the propensity of oncologists to suggest a new line of anticancer treatments 
against all odds.846,847 The framing bias is defined as the inclination of prescribers to 
present (‘frame’) the potential benefits associated with an intervention in a more 
appealing manner than the evidence suggests. For instance, a recent qualitative study 
revealed that oncologists often used implicit persuasive behaviours to convince patients 
to accept the therapeutic option that they believe is best.848 Finally, the endowment bias is 
characterised as the natural tendency to give a greater value to something (e.g. a 
treatment) that is expected to be discontinued or removed. Behavioural economists have 
found that people tend to attach a greater value to keep an object than they would to 
obtain it if they didn’t already own it.849 In healthcare decision-making, the endowment 
bias is mirrored by a common preference for status quo, i.e. continuing potentially 
unnecessary and harmful treatments to avoid the feeling of loss that would arise from 
discontinuation. 
To counter these commonly observed cognitive biases and reduce inappropriate drug 
utilisation in older adults with multimorbidity and limited life expectancy, deprescribing 
strategies should attempt to rationalise the evaluation of benefits and harms of 
treatments, and promote shared decision-making.533,714,850,851 More high-quality empirical 
evidence is also needed to curtail the use of ineffective drug treatments near the end of 
life. For instance, haloperidol is currently recommended as first-line treatment for 
delirium in palliative care,852 but a recent randomised controlled trial revealed that it has 
no proven benefit compared to placebo.853 It is likely that, in Study III of the present 
thesis, the lack of consensus about very commonly prescribed drugs at the end of life 
(including haloperidol) can be explained not only by the lack of robust empirical evidence 
but also by some of the cognitive biases described above. 
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Deprescribing in real-world clinical practice: easier said than done? 
Results from Study IV clearly demonstrate that a substantial fraction of older people 
continues to be prescribed drugs considered ‘often inadequate’ until the very end of life. 
Besides the difficulties discussed earlier, other challenges rooted in the daily clinical 
practice may explain the suboptimal rates of deprescribing at the end of life. A series of 
recent systematic reviews have been conducted on this topic, providing a detailed 
account of the barriers that hinder deprescribing efforts.850,854–856 In our view, three of 
these barriers deserve particular consideration. 
First, deprescribing in the context of end-of-life care is seldom about discontinuing a 
single drug in patients with a single disease. Most older adults with advanced illness live 
with multiple comorbidities that co-exist with a myriad of symptoms and geriatric 
syndromes. These health problems and their treatments form a complex nexus, which—
in some cases—may be in a state of equilibrium. The withdrawal or tapering of one drug 
because of insufficient short-term benefit can potentially affect the fragile equipoise that 
prevailed until then and thus prove unrewarding because of unintended collateral 
consequences. This line of thinking is behind the ‘Never change a winning team’ principle 
endorsed by Onder et al. in a recent editorial.857 This approach, they argue, differs from 
therapeutic inertia in the sense that is does not stem from a failure to act in the presence 
of side effects of goal-discordant care, but instead is the result of a clinical decision guided 
by a personalised assessment of the benefits and harms of continuing vs. stopping an 
otherwise well-tolerated treatment. 
Second, discontinuing drugs in seriously ill, multimorbid, symptomatic older patients 
requires what—in most care settings—are the two of the most sought-after resources: 
time and expertise. Deprescribing necessitates the presence of trained clinicians at the 
bedside and close collaboration with clinical pharmacist and pharmacologists, with 
careful monitoring of patients during the following days and weeks to ensure that no 
adverse effect is developing. Some treatments should also be tapered progressively to 
avoid withdrawal syndromes and rebound effect, which requires multiple encounters 
with the prescriber, sometimes over several weeks. This is the case, for instance, of 
benzodiazepines and zolpidem, antidementia drugs, antidepressants, beta-blockers, and 
other antihypertensives. Therefore, staff shortages and the lack of on-site 
pharmacological expertise may impede deprescribing in routine clinical practice. 
Third, because they can only afford to spend a limited amount of time with each patient, 
physicians have to make trade-off decisions between attempting to deprescribe drugs of 
limited clinical benefit on the one hand and managing the increasingly complex care 
needs of older people as they approach the end of life. This is especially an issue for GPs, 
whose average consultation time varies from 10 minutes in England and in the 
Netherlands, to 15 minutes in Belgium and France, up to 20 minutes in the United 
States.858 The same applies in nursing homes, where trained geriatricians are scant.859,860
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5.4 METHODOLOGICAL CONSIDERATIONS 
Study design 
Three of the four studies included in the present thesis rely on a retrospective cohort 
design, where older adults were selected at time of death and followed-back in time to 
reconstruct their drug utilisation history near the end of life. This design has been 
criticised by Bach et al., who argued that studies “resurrecting the treatment histories of 
dead patients” yield different results than studies based on a prospective cohort design 
where individuals are selected at the time when their prognosis worsens and followed-
up until death.861 Two mechanisms can indeed introduce bias.  
First, patients who die during a given period are not entirely similar to patients who had 
the same profile (e.g. sex, age, primary life-limiting condition, number of chronic co-
morbidities, level of ADL disability) but remained alive. In other words, studies examining 
decedents may leave out part of the population of interest. This selection effect has 
serious implications when it comes to discussing the potential benefits and harms of 
treatments: by design, people who did benefit from the treatments and did not suffer 
substantial harms are excluded from mortality follow-back studies. Also, considering the 
“last months of life” of patients who died leads to underestimating the prognosis 
uncertainty that these patients, their family caregivers, and healthcare professionals 
experienced at the time. We have tried to mitigate this risk of bias by stratifying older 
decedents according to their illness trajectory (Study I), by selecting patients whose death 
should have been anticipated at least a few months ahead (Study II), by selecting only 
people who died from conditions amenable to palliative care (Study IV), and by removing 
patients who died from an acute and potential unpredictable cause (Studies II and IV). 
Second, while prospective studies will only count as contributing time the period ranging 
from the diagnosis of a serious illness until death, retrospective cohorts of decedents will 
almost inevitably consider a fixed period before death irrespective of the timing of 
diagnosis. By pooling together months spent with and without a serious illness, the 
retrospective design may introduce immortal time bias. This is particularly true for older 
adults, who can expect to live fewer months after a diagnosis of serious illness and also 
experience a higher risk of death in the absence of a serious condition. However, in our 
view, immortal time bias would only arise if the outcome is dependent on the diagnosis 
(e.g. prescribing of chemotherapy for patients with metastatic cancer) or if the outcome 
of interest is cumulative over time (e.g. accumulated healthcare expenditures over the 
last year of life). In Study II, we found that stratifying the results according to the time 
from cancer diagnosis and death made little difference. In a study comparing deceased 
patients identified retrospectively with patients prospectively identified at high 
probability of dying at the time of hospital admission, Barnato et al. reported similar 
estimates for a range of healthcare utilisation indicators.862 
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Misclassification of drug exposure 
In pharmacoepidemiologic and drug utilisation studies, the exposure to drugs must be 
ascertained in a rigorous, reproducible, and accurate manner. Most databases contain 
the date of prescription, the date of dispensing, or both. Researchers typically use this 
information to define the beginning of a new exposure period or to determine the 
prolongation of an antecedent period. However, the number of days covered is seldom 
available in routinely collected data (Medicaid and Medicare Part D claims data being 
notable exceptions597,863). In the absence of explicit information about the number of 
days’ supply, the duration of drug exposure is often estimated by using proxies. Although 
many studies rely on defined daily doses to estimate windows of drug exposure, this can 
result in serious misclassification bias and is thus not a recommended approach.597 
Others have suggested using the distribution of the interval between prescription refills 
to predict the duration of a new exposure period, for instance by considering specific 
percentiles of the waiting time distribution for a given drug class in order to calculate the 
typical number of day until the next purchase.864–867  However, this method relies on the 
assumption that drugs prescribed for different clinical indications are used at the same 
rate and that refill patterns are constant over time, i.e. that there is no within-person 
change in the prescribed daily dose. The limitations of both methods have been 
demonstrated by Tanskanen et al.,599 who recently proposed a novel data-driven 
approach for estimating drug exposure periods.868 
In this thesis, we have used yet another methodology, based on the interpretation of 
written instructions for the prescribed daily dose (see 3.3 Assessment of drug exposure). 
We have established that the number of days’ supply estimated by using our algorithm is 
very close to that of a manual, line-by-line screening by a human operator. Moreover, the 
Swedish Prescribed Drug Register reports data about dispensed rather than prescribed 
drugs, which means that our results are not affected by primary non-adherence (i.e. 
treatments that are prescribed but not redeemed at pharmacies869,870). However, several 
shortcomings may have led to a misclassification of drug exposure for a fraction of 
individuals. First, this register only collects data on prescription drugs dispensed at 
community pharmacies. Over-the-counter (OTC) drugs, drugs administered in hospitals 
or in nursing homes with a drug storeroom are thus not included, leading to some degree 
of underestimation. To minimise the risk of bias that could arise from these ‘blind spots’, 
we excluded older adults who had no history of drug utilisation during the 3–6 months 
before death (~5% of decedents). Second, the estimated prevalence of polypharmacy, 
preventive drugs, and drugs of questionable benefit relies on the assumption that older 
adults used their treatments in keeping with the prescribed dosage, namely at the dose 
and frequency indicated by the physician at the time when the drug prescription was 
initiated or renewed. Our results may thus be affected by secondary non-adherence 
(drugs were dispensed but not ingested), dose tapering (the prescribed daily dose was 
reduced in the midst of an exposure period), and drug discontinuation (the drug regimen 
was stopped before the ‘end date’ calculated based on the number of days’ supply). These 
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three scenarios—to which the algorithm that we devised is blind—are most likely 
common near the end of life and could lead to overestimating the actual use of chronic 
drugs during the months before death. Further methodological developments are thus 
warranted to assess and improve the accuracy of routinely collected drug data in the 
context of advanced illness and end-of-life care. However, it is unlikely that our approach 
for estimating the duration of drug exposure leads to differential misclassification. 
Measurement errors and information bias 
Using routinely collected administrative and healthcare data for research purposes raises 
a number of methodological issues, not least the presence of upcoding errors, 
opportunistic coding practices, inconsistencies across geographical areas or care 
settings, and changes in coding strategies over time.871 For instance, the validity of 
dementia diagnoses in electronic health records, hospital discharge reports, and death 
certificates should be examined critically in light of recent studies demonstrating high 
specificity but overall low sensitivity.872,873 In Sweden, Rizzuto et al. showed that, in the 
general older population, only half of dementia cases were ever captured by the National 
Patient Register or the National Cause of Death Register; detected cases were recorded 
on average 5.5 years after the first diagnosis of dementia.874 In the studies included in the 
present study, we made all efforts to optimise the detection of chronic conditions by 
extending the lookback period up to 5 years, by considering not only ICD-10 diagnoses 
but also specific ATC codes for prescribed drugs, and by using an advanced text-mining 
algorithm to interpret clinical indications for drug treatments. It should be noted that 
while some chronic conditions are most likely underreported in national registers (e.g. 
hypertension, asthma, depression, gynaecological diseases) the more severe illnesses 
have been found to be very accurately coded (e.g. cancer, stroke, history of AMI, 
Parkinson’s disease). We also have reasons to believe that, prior to 2013, the monthly 
assessment of nursing home residence in the Social Services Register was suboptimal, 
which could have led to a misclassification of living arrangement for a fraction of 
decedents in Study I and Study II. We minimised the risk of bias by cross-referencing 
data from the Social Services Register with the place of death recorded in the National 
Cause of Death Register and with hospital discharge data from the National Patient 
Register (which contains information about the patients’ destination after discharge). 
Illness trajectories and patterns of functional decline at the end of life 
It has recently been demonstrated that, contrary to earlier assumptions, the condition 
leading to death (which we used to construct illness trajectories in the present thesis) was 
only weakly correlated with the actual course of disability near the end of life. In other 
words, people dying from a certain set of diseases may not experience a homogenous 
and predictable pattern of functional decline that would differentiate them from those 
who died from another set of diseases.39 By using prospective data from the Health, Aging 
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and Body Composition (Health ABC) study, Lunney et al. made it clear that there exists 
little overlap between illness trajectories and mobility or ADL disability41, and that 
longitudinal, within-person changes in health status or disability did not differ 
substantially according to the underlying disease.875 While physical functioning seems to 
oscillate to a greater extent among patients with congestive heart failure or COPD, which 
is reflected in their higher rate of non-elective hospitalisations at the end of life, there is 
no evidence a single trajectory of disability that would accurately describe a majority of 
decedents.876 In a large cohort study based on data collected prospectively by 115 
specialist palliative care services participating in the Palliative Care Outcomes 
Collaboration in Australia,877 Morgan et al. found that patients who died from cancer, 
solid organ failure, and cardiovascular diseases shared a similar profile of ‘precipitous 
deterioration of functional decline’ during their last 4 months of life, while patients with 
dementia and neurological conditions — including stroke — followed a largely common 
path of slow and prolonged decline.40 The authors interpret their findings as the logical 
consequence of effective medical interventions for life-limiting diseases (e.g. cancer 
immunotherapy, thrombolysis for acute ischemic stroke) and better management of 
chronic co-morbidities, which further extend the lifespan of seriously ill patients and tend 
to exacerbate the final drop in physical functioning shortly before death. Recent 
improvements in cancer treatments are currently transforming the landscape of 
supportive care in oncology, with a substantial proportion of older patients now surviving 
conditions that would have been lethal in the short term less than 10 years ago (e.g. 
metastatic melanoma, advanced lung cancer).878–880 Be that as it may, stratifying older 
adults according to the clinical conditions leading to death remains a useful approach to 
understand the heterogeneity in healthcare utilisation and palliative care needs near the 
end of life. In Study I and Study IV, we showed that drug prescribing patterns among 
people who die from cancer, organ failure, or dementia and neurodegenerative 
conditions are markedly different, and that decedents in each group shared distinct 
sociodemographic features. Moreover, operationalising these illness trajectories based 
not only on the underlying cause of death but also on contributing causes allows for a 
more nuanced assessment of the most likely course of disease at the end of life. 
Illness trajectory Cancer Organ failure Dementia 
Short and evident decline (e.g. cancer) 100% 39.70% 11.40% 
Intermittent decline (e.g. organ failure) 18.60% 100% 26.90% 
Slow and gradual decline (e.g. dementia) 11.50% 58.10% 100% 
Table 19. Overlap between illness trajectories at the end of life 
Percentages represent the proportion of decedents (≥65 years) whose multiple causes of death suggested 
overlapping illness trajectories. For instance, out of the 23 289 older adults who died with cancer, 39.7% also had 
a cause of death categorised as ‘organ failure’ and 11.4% had a cause of death categorised as ‘dementia’. To assign 
decedents to a single trajectory, we applied the hierarchy proposed by Gill et al.39 and Chaudry et al.44: cancer > 
dementia > organ failure > sudden death.  
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Generalisability and transportability 
An aspect of the validity of a study is the ability to extrapolate its results beyond the group 
of individuals that were empirically observed in order to draw inference about the target 
population. Generalisability—which is also referred to as external validity—can be 
affected by selective inclusion into the study, selective attrition during follow-up, selective 
assignment of the exposure, and non-random missing data about either the exposure, 
the outcome, or potential confounders.881 While modern epidemiology is mostly 
concerned with threats to externally valid causal effect estimates (e.g. ensuring that the 
average treatment effect observed in the study population is an unbiased estimator of 
the true average treatment effect in the population of interest882,883), in the three 
epidemiological studies included in this thesis we were mainly interested in providing 
descriptive and predictive results that would pertain to the entire population of older 
adults nearing the end of life. This issue can be approached from two different angles. 
First, are the findings observed in the sample population of each study unbiased 
approximations of what we would have found if we had been able to measure them in the 
whole target population under perfect conditions? The use of high-quality, routinely 
collected administrative and healthcare data with national coverage is key to avoid 
selection bias and attrition due to loss to follow-up that are often encountered in surveys 
and population-based studies. Our cohorts were constructed based on the Total 
Population Register and the National Cause of Death Register, which both cover the full 
Swedish population with virtually 100% completeness. This removes concerns about 
random (i.e. sampling) error. However, because we excluded older adults who died from 
unknown or unreported cause and date of death, those who had no history of drug 
dispensing during the months before death, and those who remained hospitalised 
continuously during their last 3 months of life, about 5% of decedents were not included. 
Doing so created a statistically perceptible but qualitatively trivial distortion between the 
sociodemographic characteristics of the entire cohort of decedents over the study period 
and those of the subjects included in the different studies (e.g. slight underrepresentation 
of younger-old decedents). We found no evidence that the study populations in Study I, 
Study II, and Study IV differed in meaningful ways from their hypothetical target 
populations with respect to sex, living arrangement, level of education, marital status, 
and final place of death. Moreover, the proportion of individuals with missing data for 
their educational attainment who were thus excluded from multivariable regression 
analyses ranged between 4.7% in Study I and 2.3% in Study IV. Although these data were 
clearly not missing at random (concentration around people aged 95 years and over), it 
is unlikely that the relative risks and adjusted median differences estimated in each study 
would have been noticeably different had these people been included in the analysis. 
Second, are these findings transportable to a broader population that does not entirely 
overlap with (and may even substantially differ from) the study population at hand? For 
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instance, can we make inference about the patterns of drug prescribing for older people 
at the end of life in other countries? In regions that share a social, economic, cultural, and 
healthcare environment similar to Sweden and (e.g. Nordic European countries, 
Germany, United Kingdom, France, Canada), one could expect to observe comparable 
rates of polypharmacy and potentially inadequate drugs during the last months of life. 
This assumption is supported by recent studies conducted in Ireland884, France885, 
Beligum886, New-Zealand887, and Australia888–890. However, our findings may not be 
entirely applicable to countries with vastly different healthcare systems. Cross-national 
studies have hitherto been limited, thus precluding reliable international comparisons. 
Some evidence suggests that the use of medications of questionable clinical benefit near 
the end of life may be more frequent among older adults with dementia in the United 
States570 than in Sweden568, Canada, or Taiwan573. A head-to-head comparison between 
two hospitals in the U.S. and in England also showed a greater burden of preventive drugs 
among American lung cancer patients than among their British counterparts.891 
Nevertheless, Zueger et al. found that older Medicare Part D-enrolled beneficiaries who 
died between 2008 and 2013 following hospice admission continued to receive 
preventive medications to the same extent as in Sweden.892,893 
Residual confounding 
Confounding refers to the bias resulting from the existence of common causes of both 
the exposure and the outcome. When “the apparent effect of the exposure of interest is 
distorted because the effect of an extraneous factor is mistaken for the actual effect of 
the exposure [on the outcome]”, Rothman writes, then the association between exposure 
and outcome is confounded and cannot be interpreted as a strictly causal relationship.881 
In other words, confounding arises if the direct path between the exposure X and the 
outcome Y (X ® Y) is seconded by an indirect path running through a common cause L 
(X ¬ L ® Y). In this case, association cannot be interpreted as causation because there is 
a lack of exchangeability between individuals exposed (X = 1) and unexposed (X = 0).  
This can be expressed in counterfactual terms by comparing the difference in the observed 
outcome between the exposed (Pr [Y = 1 | X = 1] and unexposed (Pr [Y = 1 | X = 0) with the 
difference in the potential outcome had everyone been exposed (Pr [Y x=1 = 1]) in contrast 
with a situation where nobody had been exposed (Pr [Y x=0 = 1]). If there is no confounding, 
then Pr [Y x=1 = 1] – Pr [Y x=0 = 1] = Pr [Y = 1 | X = 1] – Pr[Y = 1 | X = 0].894 This would be the 
expected setting in a well-designed randomised clinical trial, where individual participants 
have the exact same probability of receiving the treatment and are assigned to a 
treatment group by the flip of a coin. The randomisation procedure normally ensures the 
marginal exchangeability of study participants since there exists no common cause of X 
and Y. In observational research, however, exposures are seldom determined by chance 
and are usually driven by many factors L that can also influence the likelihood of 
experiencing the outcome of interest. To enable causal inference for the effect of X on Y, 
all indirect paths (‘backdoors’) must be blocked by conditioning on the covariates that 
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represent a common cause—in this case, either L itself or a proxy for L. These measured 
confounders can be accounted for by adjusting the analysis with either stratification-
based methods (e.g. stratification, restriction, matching, regression, propensity scores) or 
G-methods (e.g. G-formula, inverse probability weighting, G-estimation).895 
In the studies included in this thesis, our aim was not to establish causal relationships, 
but rather to identify independent determinants of specific patterns of drug prescribing 
at the end of life. We handled the issue of confounding by conducting various regression 
analyses adjusted for relevant covariates identified a priori based on expert-matter 
knowledge and information available in routinely collected data. We interpreted results 
from these regression models not as average causal effect estimates but as average 
predicted risk differences.896 In Study II, for instance, the b coefficients derived from 
quantile regression can be thought of as the estimated median difference in costs among 
older people who died from cancer A compared with those who died from cancer B if  
decedents in both groups had, on average, had the same sex, age, number of chronic 
diseases, living arrangement, and level of education. Nonetheless, whether they are used 
for prediction purposes or to make causal inferences, adjustment methods rely on the 
untestable assumption that the available covariates represent a set of confounders that 
is sufficient to block all indirect paths between exposure and outcome and that there is 
no unmeasured confounding. Although we have made every effort to control for 
sociodemographic characteristics, illness trajectory, chronic multimorbidity and (in Study 
IV) risk of physical frailty, we cannot rule out the presence of residual confounding. 
The granularity and the diagnostic accuracy of the data used in our studies are most likely 
insufficient to guarantee that the magnitude of the association observed between 
potential predictors and drug utilisation at the end of life is unbiased. For instance, the 
lack of information about the stage, the clinical characterisation, and the physiopathology 
of the underlying disease and about the severity of chronic comorbidities is a clear threat 
to the validity of our estimates. The Hospital Frailty Risk Score developed by Gilbert et 
al.611 is, by any standard, an imperfect surrogate for the actual level of frailty of older 
adults. Because ICD-10 codes are used to evaluate the case-mix of healthcare services 
and to construct Diagnosis-Related Groups (both of which are the cornerstone of current 
reimbursement procedures in the U.S. and in most European countries), they are 
notoriously affect by opportunistic coding practices. Some have argued that frailty-
related ICD-10 codes are not as well documented as the organ-related acute medical 
issues that typically trigger hospital admissions in old age, owing to the fact that the latter 
result in higher reimbursement and are thus economically more rewarding for healthcare 
providers.897 Yet, contrary to the United Kingdom where hospital data can be linked in 
routine to high-quality primary care medical records,898,899 such data are not available for 
the full Swedish population. This prevented us from computing a more sensitive and 
reliable frailty instrument, such as the newly developed electronic Frailty Index (eFI),612 
which has shown great potential for palliative and end-of-life care research.363 
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5.5 CONCLUSIONS 
By examining drug utilisation patterns during the last year of life of older adults, we found 
that the number of drugs increased significantly, fuelled not only by the initiation of 
symptomatic drugs to ensure comfort but also by the frequent continuation of preventive 
and disease-oriented treatments. The use of high-quality mortality and drug dispensing 
data with full population coverage, the categorisation of decedents into four illness 
trajectories, and the development of robust and scalable methods for estimating drug 
exposure periods in large cohorts represent important methodological contributions to 
the published literature on this topic. 
We demonstrated that older adults with unpredictable end-of-life trajectories were not 
driving the observed increase in polypharmacy and in the continuation of preventive 
drugs. Among individuals who died with solid cancer—a set of diseases most often 
characterised by a poor prognosis and a clinically discernible terminal phase—drugs 
prescribed for the long-term management of chronic comorbidities were frequently 
continued until the last month of life. Moreover, we estimated that preventive drugs 
account for ~20% of the total drug expenditures. In our opinion, even though preventive 
drugs are not necessarily clinically inappropriate at the end of life, the large proportion 
of older cancer patients who continue to receive statins, antihypertensives, low-dose 
aspirin, and vitamins until the very end of life does indicate that routine-based prescribing 
practices contribute to low-value albeit costly treatments. 
We also provided a clinically-driven, consensus-based list of drugs considered ‘often 
adequate’, ‘questionable’, and ‘often inadequate’ for use in older persons aged ≥75 years 
with a life expectancy of three months or less. In the absence of robust evidence from 
randomised controlled trials and well-designed observational studies, these criteria 
represent an important step in the on-going international effort to rationalise drug 
therapy among older people near the end of life. They also offer a standardised 
methodology to examine the prevalence and adverse outcomes associated with the use 
of drugs of limited clinical benefit at the end of life. 
Finally, by applying these criteria on a population of older adults who died from 
conditions potentially amenable to palliative care, we found that one out of three patients 
continued and one out of seven patients initiated at least one drug considered ‘often 
inadequate’ during their last three months of life. 
In sum, the findings from this thesis indicate that many older people are probably 
overtreated at the end of life, which exposes them to unnecessary risks. Deprescribing in 
the context of end-of-life care is not about denying older people access to treatments 
that would be beneficial. It is about avoiding harm, maintaining the best possible quality 
of life, and minimising the disruptive impact of medicine on the patients’ everyday life.  
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5.6 FUTURE PERSPECTIVES 
The epidemiological studies that compose the present thesis provide a bird’s eye view of 
drug treatments among older adults at the end of life. Furthermore, the proposed set of 
consensus-based criteria can provide guidance to clinicians and facilitate comparisons 
across patient populations, care settings, and countries. However, future research efforts 
are required to improve prescribing practices and reduce the burden of unnecessary and 
potentially harmful drugs near the end of life. In our opinion, future studies would be 
particularly helpful in four research areas. 
First, the available data were insufficient to shed light on the prevalence of undertreatment 
among seriously ill older adults at the end of life, both in terms of disease management 
and in terms of symptom relief. Investigating the underuse of necessary drug treatments 
is made difficult by the fact that it requires an impeccable assessment of the care needs 
at the patient level and precise information about the indication of the prescribed drugs. 
In specific cases, underuse is easily detected in electronic medical records (e.g. absence 
of antithrombotic therapy among patients at high risk of stroke). However, in the context 
of end-of-life care—at a time when the non-initiation of otherwise recommended drugs 
can be justified by patient preferences and poor prognosis—measuring underuse with 
routinely collected administrative and healthcare data proves to be prohibitively difficult. 
Cross-sectional (e.g. single-day prevalence surveys) and prospective cohort studies with 
specific data collection procedures, fine-grained clinical appraisal of care needs, and 
patient-reported outcome measures would be better suited for this purpose. 
Second, we believe that qualitative evidence is warranted to gain a better understanding 
of the underlying mechanisms that drive the provision of preventive drugs at the end of 
life, especially to disentangle prescribing practices guided by clinically justified reasons 
from low-value care driven by cognitive biases and irrational decision-making. In addition, 
carefully designed longitudinal studies with repeated in-depth qualitative interviews 
could shed light on the experience of seriously ill older adults regarding the impact of 
disease-oriented drug treatments on their quality of life and wellbeing. Ideally, such 
studies would enrol patient-caregiver dyads rather than patients or caregivers alone, in 
order to allow for triangulating similarities and divergences between them. Conducting 
this type of research comes with important challenges, including the recruitment of 
participants and the substantial attrition rate during follow-up. However, researchers in 
The Netherlands have recently demonstrated that longitudinal qualitative studies among 
advanced cancer patients are practically feasible and provide invaluable.822,900 
Third, there is a need for leveraging the potential of pharmacoepidemiological methods 
to evaluate the harms of inadequate drug prescribing among older adults with life-
limiting disease and poor prognosis. The validity of comparative effectiveness and safety 
studies using observational data is typically compromised by the lack of conditional 
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exchangeability between the treated and the untreated patients due to the residual, 
unmeasured confounding that stems from the prognostic imbalance between these two 
groups (confounding-by-indication bias).901,902 In other words, even if all measured 
covariates are perfectly balanced at baseline, the main reason why some patients 
received the treatments while others did not is most likely related to the prognosis 
established by the prescribers. If cancer patients who continue statins seem to live longer 
than those who discontinue their treatment, it is less because statins prolong their lives 
than because the high risk of death was precisely the reason that prompted the decision 
to forgo treatment in the first place.903 Without random treatment assignment, removing 
confounding-by-indication bias is a daunting task in observational parallel-group study 
designs. However, two methodological approaches could potentially help overcome this 
conundrum: (1) prior event rate ratio analysis,904–907 which relies on the assumption that 
the difference in the likelihood of having experienced the outcome of interest before 
treatment initiation reflects the influence of confounders independently from the effect 
of the treatment; and (2) case-time-control design,908–910 a variation of the case-crossover 
design in which the change in treatment exposure between T0 and T1 among cases (i.e. 
individuals who develop the adverse outcome of interest during the T1 time window) is 
compared to the change in treatment exposure among controls (i.e. individuals who do 
not develop the outcome during T1). The main limitation of both methods is their intrinsic 
inability to examine non-repeatable events and, thus, to study mortality as the outcome 
of interest. Moreover, implementing these designs will require high-quality data to assess 
the exposure of study subjects during different observation windows and to ascertain the 
occurrence of the clinical outcomes under observation with sufficient accuracy. 
Finally, pragmatic randomised clinical trials should be designed and implemented to 
assess the efficacy, safety, and cost-effectiveness of different deprescribing approaches 
among older adults with life-limiting disease and poor prognosis. To date, only one such 
RCT has been conducted, which showed that statins could be safely withdrawn among 
patients with a predicted life expectancy inferior or equal to 12 months and that 
discontinuation was associated with modest improvements in quality of life.718 Other 
clinical trials have also proven the feasibility and safety of deprescribing cardiovascular 
drugs in the more general context of ageing and frailty, such as the DANTE trial 
(antihypertensives in older adults with mild cognitive impairment911) and the ECSTATIC 
study (lipid-lowering medications and antihyper-tensives among adult patients at low risk 
of cardiovascular event912). However, these trials failed to unequivocally demonstrate the 
benefit of discontinuing unnecessary drugs in terms of symptom management, quality of 
life, adverse events, and survival. The purpose of deprescribing is not merely to 
discontinue unnecessary drugs; it is to discontinue unnecessary drugs to avoid harms 
and improve health outcomes. In future trials, a potentially fruitful approach could be to 
focus on high-risk medications (e.g. anticoagulants, low-dose aspirin, antipsychotics) 
among patients at high risk of drug-related harm (e.g. frailty, multimorbidity) in high-risk 
situations (e.g. cardiovascular polypharmacy, surgery, transition between care settings). 
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they never miss an occasion to explain that “doctors aren’t that bad, they are just caught 
up in tricky situations.” Over the years, I have had the privilege of working with a 
remarkable group of oncologists, geriatricians, palliative care physicians, general 
practitioners and pharmacists who share a deep commitment to improving patient care 
at the end of life. I have learnt a great deal of what I know with Professor Christophe 
Tournigand and Dr Emmanuelle Kempf (Henri Mondor, Paris), Professor François 
Goldwasser (Hôpital Cochin, Paris), Dr Philippe Rochigneux (Institut Paoli Calmettes, 
Marseille), Dr Yvan Beaussant (Dana Farber Cancer Institute, Boston), Barbara Roux 
(CHU Limoges), Dr Thomas Tannou (CHU Besançon), Dr Laurent Calvel (CHU 
Strasbourg), Dr Rémy Thirion (CH Dinan), Dr Stephen Barclay (Cambridge University). I 
am deeply indebted to Adam Todd (University of Newcastle) for his encouragements, his 
expert advices and his friendship, and to Professor Jean Kutner (University of Colorado) 
for her thoughtful support, her unparalleled kindness, and for the stimulating discussions 
that we’ve have. My gratitude also goes to Marie Tournigand (Empreintes) and Nancy 
Kentish-Barnes (Hôpital Saint-Louis, Paris), with whom collaborating is always a treat. 
Since its first meeting in Brussels in June 2017, the “Big data for end-of-life care research” 
task force of the European Association for Palliative Care has been a great success. A 
special mention to Professor Joachim Cohen (VU Brussels) and Professor Bregje 
Onwuteaka-Philipsen (Amsterdam UMC), with whom I share the coordination of this 
initiative. It is not only a pleasure but also a privilege to collaborate with them, in this 
atmosphere of trust, mutual respect, scientific rigor, and fun. Within the group, I would 
like to acknowledge and thank Kim Beernaert, Tinne Smets, Robrecht De Schreye, 
Veerle Piette, Arno Maetens, Annicka Van der Plas, and Peter May. I also want to 
express my gratitude to Professor Lieve Van den Block for her friendly support over the 
years and her refreshingly no-nonsense approach to research. 
Spending a little over one month with the “Pharmaco- and Device epidemiology” research 
group at the University of Oxford has been a wonderful experience. Thank you to 
Professor Daniel Prieto-Alhambra, who is not only an exceptionally kind and generous 
person but also a razor-sharp researcher when it comes to discussing methods for causal 
inference in pharmacoepidemiology. “A good head and good heart are always a 
formidable combination”, Nelson Mandela wrote. Dani also has impeccable taste in wine, 
which—as everyone knows—is paramount to entertain French collaborators. The whole 
team has been endearingly welcoming while I was in Oxford, especially Samuel Hawley, 
Vicky Strauss, Paloma O'Dogherty Cordero and Mahkameh (Maki) Mafi. 
Finally, this journey would not have been possible without Irène. I honestly don’t think I 
would have dared to get involved in academic research without your support and 
confidence in me. You are the most brilliant person I know. I will follow you anywhere, no 
matter how far, as long as we keep learning new things together. And the answer is yes.
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te
nt
ia
lly
 in
ap
pr
op
ria
te
” 
ac
co
rd
in
g 
to
 
Be
er
s’ 
cr
ite
ria
. T
he
 p
re
va
le
nc
e 
of
 p
ol
yp
ha
rm
ac
y 
(≥
7)
 in
cr
ea
se
d 
fr
om
 
17
%
 a
t t
im
e 
of
 in
cl
us
io
n 
to
 2
7%
 a
t t
im
e 
of
 fi
na
l a
ss
es
sm
en
t b
ef
or
e 
de
at
h.
 In
cr
ea
se
 in
 t
he
 t
ot
al
 n
um
be
r 
of
 m
ed
ic
at
io
ns
 w
as
 fu
el
ed
 b
y 
sy
m
pt
om
-s
pe
ci
fic
 d
ru
gs
, w
hi
le
 t
he
re
 w
as
 a
 d
ec
re
as
e 
in
 d
ru
gs
 f
or
 
co
m
or
bi
d 
co
nd
iti
on
s.
 
9.
*D
e
Sc
hr
ey
e,
 
20
17
28
4
Be
lg
iu
m
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
re
gi
st
er
-b
as
ed
 
Ad
ul
t 
w
ho
 d
ie
d 
fr
om
 
ca
nc
er
  
26
 4
64
 
78
 
(S
D
 
Ø
) 
24
%
 <
65
 y
 
D
ur
in
g 
th
e 
fin
al
 m
on
th
 b
ef
or
e 
de
at
h,
 1
7%
 o
f 
de
ce
de
nt
s 
re
ce
iv
ed
 
ch
em
ot
he
ra
py
, 
6.
6%
 
st
ar
te
d 
us
in
g 
an
tid
ep
re
ss
an
ts
, 
an
d 
7%
 
re
ce
iv
ed
 b
lo
od
 tr
an
sf
us
io
n.
 In
 a
dd
iti
on
, 6
7%
 o
f i
nd
iv
id
ua
ls
 re
ce
iv
ed
 
op
io
id
s.
 
10
.
D
ew
hu
rs
t,
20
16
57
4
U
ni
te
d 
Ki
ng
do
m
 
Cr
os
s-
se
ct
io
na
l, 
si
ng
le
-c
en
te
r 
Pa
tie
nt
s 
re
ce
iv
in
g 
ca
re
 
in
 
a 
pa
lli
at
iv
e 
se
rv
ic
e 
54
 
N
R 
Av
er
ag
e 
lif
e 
ex
pe
ct
an
cy
, 1
8 
m
on
th
s.
 7
4%
 o
f 
pa
tie
nt
s 
w
ith
 c
an
ce
r.
 
26
 p
at
ie
nt
s 
ha
d 
do
cu
m
en
te
d 
hy
pe
rt
en
si
on
 (
m
ea
n 
BP
 1
22
/6
5 
m
m
H
g)
. O
f t
he
se
, a
ll 
w
er
e 
tr
ea
te
d 
w
ith
 a
nt
ih
yp
er
te
ns
iv
es
, b
ut
 2
5 
/ 
26
 w
er
e 
us
in
g 
th
e 
m
ed
ic
at
io
n 
in
ap
pr
op
ria
te
ly
.  
  
# 
Au
th
or
, y
ea
r 
(r
ef
) 
Co
un
tr
y 
St
ud
y 
de
si
gn
 
St
ud
y 
po
pu
la
tio
n 
N
o.
 
Ag
e,
 y
ea
rs
 
M
ai
n 
fin
di
ng
s 
11
. 
 
D
om
in
gu
es
, 
20
15
53
9  
Po
rt
ug
al
 
Pr
os
pe
ct
iv
e 
co
ho
rt
, 
si
ng
le
-
ce
nt
er
 
Pa
tie
nt
s 
w
ith
 
ad
va
nc
ed
 
ca
nc
er
 
re
fe
rr
ed
 
to
 
a 
pa
lli
at
iv
e 
ca
re
 u
ni
t 
71
 
68
.2
 (1
2)
 
42
 p
at
ie
nt
s 
(6
0%
) h
ad
 a
n 
EC
O
G
 ≥
3.
 A
t t
im
e 
of
 p
al
lia
tiv
e 
ca
re
 re
fe
rr
al
, 
th
e 
m
ea
n 
nu
m
be
r 
of
 m
ed
ic
at
io
ns
 w
as
 8
.9
, w
ith
 8
6%
 o
f 
pa
tie
nt
s 
re
ce
iv
in
g 
5 
or
 m
or
e 
dr
ug
s 
an
d 
27
%
 r
ec
ei
vi
ng
 1
0 
or
 m
or
e 
dr
ug
s.
 
M
os
t 
co
m
m
on
 
dr
ug
s 
w
er
e 
an
al
ge
si
cs
, 
ps
yc
ho
tr
op
ic
s,
 
an
tih
yp
er
te
ns
iv
es
, 
an
d 
an
tia
ci
ds
. 
U
si
ng
 
th
e 
M
ed
ic
at
io
n 
Ap
pr
op
ria
te
ne
ss
 I
nd
ex
 (
M
AI
), 
ph
ys
ic
ia
ns
 e
st
im
at
ed
 t
ha
t 
23
%
 o
f 
pr
es
cr
ib
ed
 d
ru
gs
 d
id
 n
ot
 h
av
e 
a 
cl
in
ic
al
 in
di
ca
tio
n 
in
 p
al
lia
tiv
e 
ca
re
, 
7.
2%
 w
er
e 
no
t 
ef
fe
ct
iv
e,
 1
0%
 h
ad
 i
na
pp
ro
pr
ia
te
 p
os
ol
og
y 
or
 
do
sa
ge
, 
3%
 p
re
se
nt
ed
 s
ig
ni
fic
an
t 
ris
k 
of
 d
ru
g-
dr
ug
 i
nt
er
ac
tio
ns
, 
11
%
 h
ad
 s
ig
ni
fic
an
t 
ris
k 
of
 d
ru
g-
di
se
as
e 
in
te
ra
ct
io
ns
, 
6%
 w
er
e 
du
pl
ic
at
es
, 
an
d 
25
%
 h
ad
 a
n 
in
ap
pr
op
ria
te
 d
ur
at
io
n 
(fo
r 
ch
ro
ni
c 
m
ed
ic
at
io
ns
 o
nl
y)
. 
12
. 
 
D
w
ye
r, 
20
15
56
3  
U
ni
te
d 
St
at
es
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, s
ur
ve
y 
O
ld
er
 
ad
ul
ts
 
(≥
65
 
ye
ar
s)
 
re
ce
iv
in
g 
ho
sp
ic
e 
ca
re
 
w
ho
 
di
ed
 
w
ith
 
ca
nc
er
, 
de
m
en
tia
, 
de
bi
lit
y,
 
he
ar
t d
is
ea
se
 o
r 
lu
ng
 
di
se
as
e.
 
26
23
 
80
%
 
ag
ed
 
≥7
5 
ye
ar
s 
D
ur
in
g 
th
e 
fin
al
 w
ee
k 
of
 l
ife
, 
m
ea
n 
nu
m
be
r 
of
 m
ed
ic
at
io
ns
 w
as
 
10
.2
, 
va
ry
in
g 
fr
om
 9
.5
 a
m
on
g 
de
ce
de
nt
s 
w
ith
 d
em
en
tia
 t
o 
11
.4
 
am
on
g 
th
os
e 
w
ith
 l
un
g 
di
se
as
e.
 N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 a
cr
os
s 
ag
e 
gr
ou
ps
. M
os
t 
co
m
m
on
 m
ed
ic
at
io
ns
 in
cl
ud
ed
 a
na
lg
es
ic
s 
(9
8%
, 
in
cl
 9
1%
 o
pi
oi
ds
), 
an
tie
m
et
ic
s 
(7
8%
), 
an
xi
ol
yt
ic
 a
nd
 s
ed
at
iv
es
 (7
5%
), 
an
tie
pi
le
pt
ic
s 
(7
0%
), 
la
xa
tiv
es
 
(5
3%
), 
an
tih
yp
er
te
ns
iv
es
 
(4
9%
), 
an
tip
sy
ch
ot
ic
s 
(3
8%
), 
br
on
ch
od
ila
to
r 
(2
7%
), 
PP
Is
 
(2
6%
), 
an
tic
oa
gu
la
nt
s 
(2
5%
), 
an
tid
ep
re
ss
an
ts
 (2
4%
), 
an
tia
ci
ds
 (1
9%
), 
an
d 
an
tib
io
tic
s 
(1
8%
). 
13
. 
 
Fa
hl
m
an
, 
20
07
57
5,
57
6  
U
ni
te
d 
St
at
es
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
re
gi
st
er
-b
as
ed
 
O
ld
er
 
ad
ul
ts
 
(≥
65
 
ye
ar
s)
 c
ov
er
ed
 b
y 
th
e 
M
ed
ic
ar
e+
Ch
oi
ce
 
in
su
ra
nc
e 
w
ho
 d
ie
d 
46
02
 
55
%
 
ag
ed
 
≥7
5 
ye
ar
s 
25
%
 o
f 
de
ce
de
nt
s 
ha
d 
≥5
 c
hr
on
ic
 c
om
or
bi
di
tie
s.
 D
ur
in
g 
th
e 
fin
al
 
ye
ar
 o
f l
ife
, 4
4%
 o
f d
ec
ed
en
ts
 re
ce
iv
ed
 a
t l
ea
st
 o
ne
 d
ru
g 
co
ns
id
er
ed
 
“p
ot
en
tia
lly
 i
na
pp
ro
pr
ia
te
” 
ac
co
rd
in
g 
to
 B
ee
r’s
 c
rit
er
ia
, 
in
cl
ud
in
g 
pr
op
ox
yp
he
ne
 (1
5.
0%
), 
zo
lp
id
em
 (3
.8
%
), 
an
d 
am
itr
ip
ty
lin
e 
(2
.8
%
) 
# 
Au
th
or
, y
ea
r 
(r
ef
) 
Co
un
tr
y 
St
ud
y 
de
si
gn
 
St
ud
y 
po
pu
la
tio
n 
N
o.
 
Ag
e,
 y
ea
rs
 
M
ai
n 
fin
di
ng
s 
14
.
Fe
de
, 2
01
15
34
Br
az
il 
Cr
os
s-
se
ct
io
na
l, 
si
ng
le
-c
en
te
r 
H
os
pi
ta
liz
ed
 p
at
ie
nt
s 
w
ith
 te
rm
in
al
 c
an
ce
r 
 
87
 
M
ed
ia
n 
61
 
At
 t
im
e 
of
 in
cl
us
io
n 
(li
fe
 e
xp
ec
ta
nc
y 
< 
6 
m
on
th
s)
, m
ed
ia
n 
nu
m
be
r 
of
 m
ed
ic
at
io
ns
 w
as
 4
. A
 to
ta
l o
f 2
6%
 o
f p
at
ie
nt
s 
se
lf-
re
po
rt
ed
 d
ru
g-
re
la
te
d 
ad
ve
rs
e 
ev
en
ts
. 2
1 
pa
tie
nt
s 
(2
4%
) w
er
e 
ta
ki
ng
 a
t l
ea
st
 o
ne
 
un
ne
ce
ss
ar
y 
m
ed
ic
at
io
n,
 i
nc
lu
di
ng
 P
PI
s 
w
ith
ou
t 
hi
st
or
y 
of
 G
I 
bl
ee
di
ng
 
or
 
N
SA
ID
 
pr
es
cr
ip
tio
n.
 
O
th
er
 
dr
ug
s 
co
ns
id
er
ed
 
un
ne
ce
ss
ar
y 
w
er
e 
st
at
in
s 
w
ith
ou
t 
ca
rd
io
va
sc
ul
ar
 e
ve
nt
 in
 t
he
 la
st
 
12
 
m
on
th
s,
 
an
tih
yp
er
te
ns
iv
es
 
w
ith
 
lo
w
 
bl
oo
d 
pr
es
su
re
, 
an
d 
an
tid
ia
be
tic
s 
w
ith
 h
yp
og
ly
ce
m
ia
. 
15
.
*G
ra
nd
e,
 2
01
75
66
 
Sw
ed
en
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
re
gi
st
er
-b
as
ed
 
O
ld
er
 
ad
ul
ts
 
(≥
65
 
ye
ar
s)
 w
ho
 d
ie
d 
fr
om
 
Am
yo
tr
op
hi
c 
La
te
ra
l 
Sc
le
ro
si
s 
(A
LS
) 
16
03
 
76
 (7
) 
43
%
 o
f d
ec
ed
en
ts
 h
ad
 ≥
4 
ch
ro
ni
c 
co
m
or
bi
di
tie
s.
 M
ea
n 
nu
m
be
r 
of
 
dr
ug
s 
in
cr
ea
se
d 
fr
om
 5
.7
 o
ne
 y
ea
r 
be
fo
re
 d
ea
th
 t
o 
8.
3 
du
rin
g 
th
e 
fin
al
 m
on
th
 o
f l
ife
 a
m
on
g 
co
m
m
un
ity
-d
w
el
le
rs
, a
nd
 fr
om
 7
.5
 to
 9
.7
 
am
on
g 
nu
rs
in
g 
ho
m
e 
re
si
de
nt
s.
 T
he
 p
ro
po
rt
io
n 
of
 i
nd
iv
id
ua
ls
 
ex
po
se
d 
to
 1
0 
or
 m
or
e 
dr
ug
s 
in
cr
ea
se
d 
fr
om
 1
9%
 d
ur
in
g 
th
e 
12
th
 
m
on
th
 b
ef
or
e 
de
at
h 
to
 3
7%
 d
ur
in
g 
th
e 
la
st
 m
on
th
. P
sy
ch
ol
ep
tic
s 
(5
7%
), 
an
al
ge
si
cs
 (
47
%
), 
la
xa
tiv
es
 (
46
%
), 
ps
yc
ho
an
al
ep
tic
s 
(4
4%
, 
in
cl
. 
42
%
 a
nt
id
ep
re
ss
an
ts
), 
an
d 
ril
uz
ol
 (
45
%
) 
w
er
e 
th
e 
fiv
e 
m
os
t 
co
m
m
on
ly
 u
se
d 
dr
ug
 c
la
ss
es
 d
ur
in
g 
th
e 
fin
al
 m
on
th
s 
be
fo
re
 d
ea
th
. 
D
ru
gs
 o
f 
qu
es
tio
na
bl
e 
be
ne
fit
 i
nc
lu
de
d 
st
at
in
s 
(1
1%
), 
m
in
er
al
 
su
pp
le
m
en
ts
 (
11
%
), 
ca
lc
iu
m
 c
ha
nn
el
 b
lo
ck
er
s 
(1
3%
) 
an
d 
be
ta
-
bl
oc
ke
rs
 (2
7%
). 
16
.
*H
am
ad
a,
20
17
70
0
U
ni
te
d 
Ki
ng
do
m
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
re
gi
st
er
-b
as
ed
 
O
ld
er
 
ad
ul
ts
 
(≥
80
 
ye
ar
s)
 w
ho
 d
ie
d 
w
ith
 
di
ab
et
es
 m
el
lit
us
 
53
24
 
M
ed
ia
n 
86
 
H
ig
h 
bu
rd
en
 o
f 
co
m
or
bi
di
tie
s,
 i
nc
lu
di
ng
 c
an
ce
r 
(3
5%
), 
co
ro
na
ry
 
he
ar
t 
di
se
as
e 
(4
2%
), 
st
ro
ke
 (
15
%
), 
an
d 
de
m
en
tia
 (
13
%
). 
15
%
 o
f 
de
ce
de
nt
s 
ha
d 
an
 e
st
im
at
ed
 g
lo
m
er
ul
ar
 f
ilt
ra
tio
n 
ra
te
 <
30
, 
an
d 
24
%
 h
ad
 a
n 
eG
FR
 3
0–
44
. D
ur
in
g 
th
e 
fin
al
 y
ea
r 
of
 li
fe
, t
he
 n
um
be
r 
of
 p
re
sc
rib
ed
 d
ru
gs
 r
em
ai
ne
d 
st
ab
le
, w
ith
 a
n 
av
er
ag
e 
of
 6
.2
 (
SD
 
3.
1)
. O
ve
ra
ll,
 7
3%
 o
f d
ec
ed
en
ts
 re
ce
iv
ed
 ≥
5 
dr
ug
s 
an
d 
18
%
 re
ce
iv
ed
 
≥1
0 
dr
ug
s;
 
  
# 
Au
th
or
, y
ea
r 
(r
ef
) 
Co
un
tr
y 
St
ud
y 
de
si
gn
 
St
ud
y 
po
pu
la
tio
n 
N
o.
 
Ag
e,
 y
ea
rs
 
M
ai
n 
fin
di
ng
s 
17
. 
 
H
ep
pe
ns
ta
ll,
 
20
16
88
9  
N
ew
 
Ze
al
an
d 
Pr
os
pe
ct
iv
e 
co
ho
rt
, 
m
ul
tic
en
te
r 
N
ur
si
ng
 
ho
m
e 
re
si
de
nt
s 
w
ho
 
di
ed
 
w
ith
in
 1
2 
m
on
th
s 
15
82
 
85
 (S
D
 Ø
) 
At
 t
im
e 
of
 in
cl
us
io
n,
 n
ur
si
ng
 h
om
e 
re
si
de
nt
s 
w
er
e 
pr
es
cr
ib
ed
 o
n 
av
er
ag
e 
7.
4 
dr
ug
s.
 
Co
m
m
on
 
m
ed
ic
at
io
n 
cl
as
se
s 
in
cl
ud
ed
 
ps
yc
ho
tr
op
ic
s 
(6
9%
), 
an
al
ge
si
cs
 (
62
%
), 
an
tih
yp
er
te
ns
iv
es
 (
58
%
), 
an
tip
la
te
le
t 
ag
en
ts
 
(5
2%
), 
di
ur
et
ic
s 
(4
0%
), 
st
at
in
s 
(2
2%
), 
bi
sp
ho
sp
ho
na
te
s 
(1
6%
), 
an
d 
an
tid
ia
be
tic
s 
(9
%
). 
Su
b-
an
al
ys
is
 o
n 
56
 
pa
tie
nt
s 
re
ve
al
ed
 
th
at
 
13
/3
3 
w
er
e 
pr
es
cr
ib
ed
 
fo
r 
pr
im
ar
y 
pr
ev
en
tio
n.
 
18
. 
 
H
ui
, 2
01
55
64
 
U
ni
te
d 
St
at
es
 
Pr
os
pe
ct
iv
e 
co
ho
rt
, 
si
ng
le
-
ce
nt
er
 
H
os
pi
ta
liz
ed
 p
at
ie
nt
s 
w
ith
 
ad
va
nc
ed
 
ca
nc
er
 r
ef
er
re
d 
to
 a
 
pa
lli
at
iv
e 
ca
re
 s
er
vi
ce
 
10
0 
57
 (1
3)
 
Av
er
ag
e 
nu
m
be
r 
of
 d
ru
gs
 c
ha
ng
ed
 f
ro
m
 9
.2
 (
SD
 4
.5
) 
be
fo
re
 
pa
lli
at
iv
e 
ca
re
 re
fe
rr
al
, t
o 
10
.1
 a
t t
im
e 
of
 d
ea
th
 (S
D
 3
.8
). 
In
cr
ea
se
 in
 
th
e 
nu
m
be
r 
of
 s
ym
pt
om
-s
pe
ci
fic
 m
ed
ic
at
io
ns
 a
nd
 d
ec
re
as
e 
in
 th
e 
nu
m
be
r 
of
 m
ed
ic
at
io
ns
 f
or
 c
om
or
bi
di
tie
s.
 C
om
m
on
 d
ru
g 
cl
as
se
s 
in
cl
ud
ed
 P
PI
s 
(8
2%
), 
m
or
ph
in
e 
(6
4%
) 
an
d 
hy
dr
om
or
ph
on
e 
(5
7%
), 
an
tid
ia
be
tic
s 
(3
0%
), 
m
et
oc
lo
pr
am
id
e 
(5
5%
), 
fu
ro
se
m
id
e 
(2
4%
), 
de
xa
m
et
ha
so
ne
 (
68
%
), 
la
xa
tiv
es
 (
81
%
), 
ha
lo
pe
rid
ol
 (
68
%
), 
an
d 
br
on
ch
od
ila
to
rs
 (7
5%
) 
19
. 
 
Ja
ns
en
, 2
01
45
65
 
N
or
w
ay
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
m
ul
tic
en
te
r 
(n
=3
) 
N
ur
si
ng
 
ho
m
e 
re
si
de
nt
s 
w
ho
 d
ie
d 
52
4 
M
ed
ia
n 
86
 
M
os
t 
co
m
m
on
 c
hr
on
ic
 c
on
di
tio
ns
 i
nc
lu
de
d 
de
m
en
tia
 (
37
%
), 
CH
F 
(3
0%
), 
ca
nc
er
 (2
4%
), 
an
d 
CO
PD
 (1
8%
). 
M
ed
ia
n 
le
ng
th
 o
f 
st
ay
, 1
03
 
da
ys
. A
t t
im
e 
of
 d
ea
th
, >
99
%
 o
f n
ur
si
ng
 h
om
e 
re
si
de
nt
s 
ha
d 
ac
tiv
e 
pr
es
cr
ip
tio
ns
. M
ea
n 
nu
m
be
r 
of
 m
ed
ic
at
io
ns
 w
as
 9
 (
to
ta
l o
f 
47
36
 
dr
ug
s)
. 2
8%
 o
f p
re
sc
rib
ed
 d
ru
gs
 w
er
e 
pa
lli
at
iv
e,
 5
1%
 w
er
e 
cu
ra
tiv
e 
of
 p
re
ve
nt
iv
e.
 C
om
m
on
 d
ru
gs
 w
ith
 c
le
ar
 p
al
lia
tiv
e 
in
di
ca
tio
n 
w
er
e 
m
or
ph
in
e 
(7
1%
), 
m
id
az
ol
am
 (
55
%
), 
gl
yc
op
yr
ro
ni
um
 (
47
%
), 
an
d 
ha
lo
pe
rid
ol
 
(4
7%
). 
Cu
ra
tiv
e 
or
 
pr
ev
en
tiv
e 
de
at
hs
 
in
cl
ud
ed
 
an
tit
hr
om
bo
tic
s 
(2
4%
), 
be
ta
-b
lo
ck
er
s 
(1
8%
), 
an
d 
AC
E 
in
hi
bi
to
rs
 
(9
%
). 
20
. 
 
Ki
er
ne
r, 
20
16
91
5  
Au
st
ria
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
si
ng
le
-
ce
nt
er
 
H
os
pi
ta
liz
ed
 p
at
ie
nt
s 
w
ho
 
di
ed
 
fr
om
 
ad
va
nc
ed
 c
an
ce
r 
10
0 
M
ed
ia
n 
63
 
M
ed
ia
n 
nu
m
be
r 
of
 d
ru
gs
 d
ec
re
as
ed
 fr
om
 1
1 
to
 6
 b
et
w
ee
n 
th
e 
9t
h  
an
d 
th
e 
fin
al
 d
ay
 b
ef
or
e 
de
at
h.
 D
ur
in
g 
th
e 
fin
al
 d
ay
 o
f l
ife
, 6
0%
 o
f 
pa
tie
nt
s 
re
ce
iv
ed
 5
 o
r 
m
or
e 
dr
ug
s.
 M
os
t 
dr
ug
s 
w
er
e 
fo
r 
ch
ro
ni
c 
us
e.
 
  
# 
Au
th
or
, y
ea
r 
(r
ef
) 
Co
un
tr
y 
St
ud
y 
de
si
gn
 
St
ud
y 
po
pu
la
tio
n 
N
o.
 
Ag
e,
 y
ea
rs
 
M
ai
n 
fin
di
ng
s 
21
. 
 
Ko
tli
ns
ka
-
Le
m
ie
sz
ek
, 
20
14
55
9  
M
ul
tip
le
 
Eu
ro
pe
an
 
co
un
tr
ie
s 
Cr
os
s-
se
ct
io
na
l, 
m
ul
tic
en
te
r 
(n
=1
7)
 
Pa
tie
nt
s 
w
ith
 
ad
va
nc
ed
 
ca
nc
er
 
us
in
g 
St
ep
-3
 
an
al
ge
si
cs
 
22
82
 
62
 (1
2)
 
Pa
tie
nt
s 
w
er
e 
re
cr
ui
te
d 
in
 N
or
w
ay
 (n
=5
65
), 
Ita
ly
 (n
=4
62
), 
G
er
m
an
y 
(n
=4
52
), 
U
ni
te
d 
Ki
ng
do
m
 (n
=2
95
), 
Ic
el
an
d 
(n
=1
50
), 
Sw
ed
en
 (n
=1
35
), 
Sw
itz
er
la
nd
 (
n=
11
5)
, 
Li
th
ua
ni
a 
(n
=5
4)
, 
D
en
m
ar
k 
(n
=3
1)
, 
Fi
nl
an
d 
(n
=3
0)
 a
nd
 G
re
ec
e 
(n
=5
). 
O
ve
ra
ll,
 9
1%
 o
f 
pa
tie
nt
s 
ha
d 
m
et
as
ta
tic
 
ca
nc
er
. 
D
ur
in
g 
th
e 
pa
st
 2
4 
ho
ur
s,
 p
at
ie
nt
s 
us
ed
 o
n 
av
er
ag
e 
7.
8 
m
ed
ic
at
io
ns
, w
ith
 8
4%
 r
ec
ei
vi
ng
 ≥
5 
dr
ug
s 
an
d 
28
%
 r
ec
ei
vi
ng
 ≥
10
 
dr
ug
s.
 1
8%
 o
f 
pa
tie
nt
s 
re
ce
iv
ed
 u
nn
ec
es
sa
ry
 d
ru
gs
, 
in
cl
ud
in
g 
st
at
in
s 
(6
%
), 
ho
rm
on
e 
re
pl
ac
em
en
t 
th
er
ap
y 
(1
%
), 
an
d 
vi
ta
m
in
s 
(1
2%
). 
33
%
 o
f 
pa
tie
nt
s 
re
ce
iv
ed
 p
ot
en
tia
lly
 u
nn
ec
es
sa
ry
 d
ru
gs
, 
in
cl
ud
in
g 
an
tic
an
ce
r 
ag
en
ts
 
(5
%
), 
ca
rd
io
va
sc
ul
ar
 
dr
ug
s 
(1
4%
), 
G
O
RD
s,
 (2
9%
), 
an
d 
al
lo
pu
rin
ol
 (2
%
). 
22
. 
 
Kw
ok
, 2
01
69
16
 
H
on
g 
Ko
ng
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
si
ng
le
-
ce
nt
er
 
Pa
tie
nt
s 
w
ith
 
en
d-
st
ag
e 
re
na
l 
di
se
as
e 
re
ce
iv
in
g 
pa
lli
at
iv
e 
ca
re
 
22
6 
76
 (9
.7
) 
M
ea
n 
nu
m
be
r 
of
 
co
m
or
bi
di
tie
s 
w
as
 
9.
0 
(S
D
 
2.
3)
, 
in
cl
ud
in
g 
hy
pe
rt
en
si
on
 (9
0%
), 
di
ab
et
es
 (6
7%
), 
is
ch
em
ic
 h
ea
rt
 d
is
ea
se
 (3
4%
), 
co
ng
es
tiv
e 
he
ar
t f
ai
lu
re
 (3
4%
), 
an
d 
st
ro
ke
 (3
0%
). 
At
 ti
m
e 
of
 a
dv
an
ce
 
ca
re
 p
la
nn
in
g,
 a
ve
ra
ge
 e
G
FR
 w
as
 1
2.
0 
(S
D
 4
.6
). 
D
ur
in
g 
th
e 
fin
al
 2
 
w
ee
ks
 
of
 
lif
e,
 
m
ed
ic
at
io
ns
 
in
cl
ud
ed
 
an
tib
io
tic
s 
(5
3%
), 
bl
oo
d 
tr
an
sf
us
io
n 
(3
0%
), 
no
n-
op
io
id
 a
na
lg
es
ic
s 
(1
4%
), 
st
ro
ng
 o
pi
oi
ds
 
(2
1%
), 
m
id
az
ol
am
 (
5%
), 
ha
lo
pe
rid
ol
 (
21
%
), 
an
d 
bu
ty
ls
co
po
la
m
in
e 
(4
.4
%
). 
In
 a
dd
iti
on
, 1
0%
 o
f p
at
ie
nt
s 
st
ar
te
d 
ar
tif
ic
ia
l n
ut
rit
io
n 
(N
G
 o
r 
pe
rc
ut
an
eo
us
) 
23
. 
 
Le
e,
 2
01
35
77
 
Ko
re
a 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
m
ul
tic
en
te
r 
(n
=2
) 
Te
rm
in
al
ly
 i
ll 
ca
nc
er
 
pa
tie
nt
s 
w
ho
 d
ie
d 
in
 
ho
sp
ita
ls
 
19
6 
M
ed
ia
n 
67
 
M
os
t c
om
m
on
ly
 p
re
sc
rib
ed
 d
ru
gs
 in
cl
ud
ed
 o
pi
oi
ds
 (f
en
ta
ny
l, 
62
.2
%
 
an
d 
m
or
ph
in
e,
 
44
.3
%
), 
m
eg
es
tr
ol
 
fo
r 
an
or
ex
ia
 
(4
6%
), 
m
et
oc
lo
pr
am
id
e 
fo
r 
na
us
ea
 (3
7%
), 
tr
am
ad
ol
 (3
1%
) a
nd
 d
ic
lo
fe
na
c 
(1
9%
) f
or
 m
ild
-t
o-
m
od
er
at
e 
pa
in
, m
or
ph
in
e 
fo
r d
ys
pn
ea
 (2
3%
), 
an
d 
ga
ba
pe
nt
in
 f
or
 n
eu
ro
pa
th
ic
 p
ai
n 
(2
2%
). 
Bu
ty
ls
co
po
la
m
in
e 
w
as
 
us
ed
 i
n 
on
ly
 6
%
 o
f 
pa
tie
nt
s.
 P
ot
en
tia
lly
 f
ut
ile
 m
ed
ic
at
io
ns
 w
er
e 
de
fin
ed
 
ba
se
d 
on
 
Ri
ec
he
lm
an
n’
s 
an
d 
Fe
de
’s5
34
 
ap
pr
oa
ch
. 
It 
in
cl
ud
ed
 
ga
st
ro
pr
ot
ec
to
rs
 
(4
9%
, 
in
cl
ud
in
g 
25
%
 
fu
til
e)
, 
an
tih
yp
er
te
ns
iv
es
 (
28
%
, 
in
cl
ud
in
g 
13
%
 f
ut
ile
), 
an
tid
ia
be
tic
s 
(1
4%
, 
in
cl
ud
in
g 
1%
 fu
til
e)
, a
nd
 s
ta
tin
s 
(6
%
, i
nc
lu
di
ng
 4
%
 fu
til
e)
. 
  
# 
Au
th
or
, y
ea
r 
(r
ef
) 
Co
un
tr
y 
St
ud
y 
de
si
gn
 
St
ud
y 
po
pu
la
tio
n 
N
o.
 
Ag
e,
 y
ea
rs
 
M
ai
n 
fin
di
ng
s 
24
. 
 
M
a,
 2
01
45
78
 
Ca
na
da
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
m
ul
tic
en
te
r 
(n
=2
) 
Pa
tie
nt
s 
w
ith
 
po
or
 
pr
og
no
si
s 
re
fe
rr
ed
 to
 
pa
lli
at
iv
e 
ca
re
 
70
 
76
 (1
2.
1)
 
D
ur
in
g 
th
e 
la
st
 w
ee
k 
be
fo
re
 d
ea
th
 (
or
 t
he
 la
st
 w
ee
k 
be
fo
re
 P
CU
 
tr
an
si
tio
n)
, p
at
ie
nt
s 
w
er
e 
pr
es
cr
ib
ed
 o
n 
av
er
ag
e 
6 
m
ed
ic
at
io
ns
 fo
r 
co
m
fo
rt
, 4
 m
ed
ic
at
io
ns
 “
po
ss
ib
ly
 f
or
 c
om
fo
rt
” 
an
d 
3 
m
ed
ic
at
io
ns
 
“d
ef
in
ite
ly
 
no
t 
fo
r 
co
m
fo
rt
.” 
Th
e 
la
tt
er
 
ca
te
go
ry
 
in
cl
ud
es
 
an
tih
yp
er
te
ns
iv
es
, 
an
tip
la
te
le
t 
ag
en
ts
, 
bi
sp
ho
sp
ho
na
te
s,
 A
Ch
EI
, 
ho
rm
on
e 
re
pl
ac
em
en
t, 
iro
n 
an
d 
vi
ta
m
in
s,
 s
ta
tin
s,
 a
nd
 a
llo
pu
rin
ol
. 
N
ot
 d
et
ai
ls
 a
bo
ut
 th
e 
pr
ev
al
en
ce
 o
f e
ac
h 
dr
ug
 c
la
ss
. 
25
. 
 
*M
at
lo
w
, 2
01
75
67
 
Ca
na
da
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
re
gi
st
er
-b
as
ed
 
D
ec
ea
se
d 
nu
rs
in
g 
ho
m
e 
re
si
de
nt
s 
w
ith
 
ad
va
nc
ed
 
de
m
en
tia
 
w
ho
 r
ec
ei
ve
d 
at
 le
as
t 
on
e 
m
ed
ic
at
io
n 
of
 
qu
es
tio
na
bl
e 
be
ne
fit
 
92
98
 
86
.4
 (6
.7
) 
D
ur
in
g 
th
e 
la
st
 4
 m
on
th
s 
of
 l
ife
, 
m
os
t 
co
m
m
on
 m
ed
ic
at
io
ns
 o
f 
qu
es
tio
na
bl
e 
be
ne
fit
 w
er
e 
an
tid
em
en
tia
 d
ru
gs
 (6
4%
), 
st
at
in
s 
(4
8%
), 
an
tip
la
te
le
t 
ag
en
ts
 e
xc
l. 
as
pi
rin
 (
18
%
) 
an
d 
se
x 
ho
rm
on
es
 (
2.
1%
). 
O
ve
ra
ll,
 4
5%
 o
f 
nu
rs
in
g 
ho
m
e 
re
si
de
nt
s 
w
er
e 
st
ill
 r
ec
ei
vi
ng
 ≥
1 
m
ed
ic
at
io
n 
of
 q
ue
st
io
na
bl
e 
be
ne
fit
 d
ur
in
g 
th
e 
fin
al
 w
ee
k 
of
 li
fe
. 
Le
ss
 s
ev
er
e 
co
gn
iti
ve
 im
pa
irm
en
t 
as
 m
ea
su
re
d 
w
ith
 t
he
 C
og
ni
tiv
e 
Pe
rf
or
m
an
ce
 S
co
re
 w
as
 a
ss
oc
ia
te
d 
w
ith
 a
n 
in
cr
ea
se
d 
lik
el
ih
oo
d 
of
 
re
ce
iv
in
g 
m
ed
ic
at
io
ns
 o
f q
ue
st
io
na
bl
e 
be
ne
fit
. 
26
. 
 
M
cL
ea
n,
 2
01
35
51
 
Ir
el
an
d 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
si
ng
le
-
ce
nt
er
  
Pa
tie
nt
s 
re
fe
rr
ed
 t
o 
pa
lli
at
iv
e 
ca
re
 
w
ho
 
di
ed
 
52
 
M
ed
ia
n 
74
.5
 
M
ea
n 
tim
e 
be
tw
ee
n 
pa
lli
at
iv
e 
ca
re
 r
ef
er
ra
l 
an
d 
de
at
h 
w
as
 1
0.
8 
w
ee
ks
. M
ed
ia
n 
nu
m
be
r 
of
 c
om
or
bi
di
tie
s 
w
as
 3
, r
an
gi
ng
 fr
om
 0
 t
o 
7.
 D
ur
in
g 
th
e 
fin
al
 w
ee
k 
of
 li
fe
, p
at
ie
nt
s 
w
er
e 
pr
es
cr
ib
ed
 a
 to
ta
l o
f 
10
 m
ed
ic
at
io
ns
. T
he
 n
um
be
r o
f m
ed
ic
at
io
n 
fo
r t
he
 m
an
ag
em
en
t o
f 
co
m
or
bi
di
tie
s 
re
m
ai
ne
d 
st
ab
le
 b
et
w
ee
n 
th
e 
3r
d  
m
on
th
 b
ef
or
e 
de
at
h 
an
d 
th
e 
fin
al
 w
ee
k 
of
 l
ife
 (
4–
3)
, 
w
hi
le
 t
he
 n
um
be
r 
of
 
m
ed
ic
at
io
ns
 
fo
r 
sy
m
pt
om
 
co
nt
ro
l 
in
cr
ea
se
d 
fr
om
 
4 
to
 
7.
2.
 
M
ed
ic
at
io
ns
 fo
r 
co
m
or
bi
d 
co
nd
iti
on
s 
in
cl
ud
ed
 a
sp
iri
n 
(3
6%
), 
be
ta
-
bl
oc
ke
rs
 (2
7%
), 
st
at
in
s 
(2
3%
), 
AC
E/
AR
B 
(1
5%
), 
an
d 
ca
lc
iu
m
 c
ha
nn
el
 
in
hi
bi
to
rs
 (1
5%
). 
  
# 
Au
th
or
, y
ea
r 
(r
ef
) 
Co
un
tr
y 
St
ud
y 
de
si
gn
 
St
ud
y 
po
pu
la
tio
n 
N
o.
 
Ag
e,
 y
ea
rs
 
M
ai
n 
fin
di
ng
s 
27
. 
 
M
cN
ei
l, 
20
15
91
7  
U
ni
te
d 
St
at
es
 
Cl
us
te
r 
ra
nd
om
iz
ed
 
co
nt
ro
lle
d 
tr
ia
l 
(s
ec
on
da
ry
 
an
al
ys
is
) 
Ad
ul
t 
pa
tie
nt
s 
w
ith
 
<1
2 
m
on
th
s 
es
tim
at
ed
 p
ro
gn
os
is
 
ta
ki
ng
 
a 
st
at
in
 
m
ed
ic
at
io
n 
fo
r 
pr
im
ar
y 
pr
ev
en
tio
n 
of
 
ca
rd
io
-v
as
cu
la
r 
di
se
as
e.
 
24
4 
74
.3
 (1
1.
5)
 
M
ea
n 
tim
e 
fr
om
 in
cl
us
io
n 
to
 d
ea
th
 w
as
 2
64
 d
ay
s.
 4
7%
 o
f p
at
ie
nt
s 
ha
d 
a 
di
ag
no
si
s 
of
 c
an
ce
r.
 M
ea
n 
Ch
ar
ls
on
 C
om
or
bi
di
ty
 In
de
x 
sc
or
e 
4.
8 
(S
D
 2
.8
). 
At
 t
im
e 
of
 e
nr
ol
lm
en
t, 
pa
tie
nt
s 
w
er
e 
pr
es
cr
ib
ed
 o
n 
av
er
ag
e 
11
.5
 (S
D
 5
) d
iff
er
en
t m
ed
ic
at
io
ns
, d
ec
re
as
in
g 
to
 1
0.
7 
(S
D
 5
) 
at
 ti
m
e 
of
 d
ea
th
 o
r e
nd
 o
f f
ol
lo
w
-u
p.
 M
os
t c
om
m
on
 d
ru
gs
 in
cl
ud
ed
 
an
tih
yp
er
te
ns
iv
es
 (
70
%
), 
br
on
ch
od
ila
to
rs
 (
40
%
), 
la
xa
tiv
es
 (
57
%
), 
an
tid
ep
re
ss
an
ts
 (5
4%
), 
an
d 
ga
st
ro
pr
ot
ec
to
rs
 (6
0%
). 
28
. 
 
M
or
ga
n,
 2
01
55
52
 
Au
st
ra
lia
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
m
ul
tic
en
te
r 
(n
=4
) 
Pa
tie
nt
s 
re
fe
rr
ed
 t
o 
pa
lli
at
iv
e 
ca
re
 
w
ho
 
di
ed
 
26
6 
68
.9
 (1
3.
2)
 
Pr
im
ar
y 
di
ag
no
si
s:
 s
ol
id
 t
um
or
 (
89
%
), 
he
m
at
ol
og
ic
al
 m
al
ig
na
nc
y 
(1
.5
%
), 
ne
ur
od
eg
en
er
at
iv
e 
di
se
as
e 
(1
.5
%
), 
or
 o
rg
an
 f
ai
lu
re
 (
8%
). 
D
ur
in
g 
th
e 
la
st
 t
w
o 
w
ee
ks
 o
f 
lif
e,
 p
at
ie
nt
s 
w
er
e 
pr
es
cr
ib
ed
 o
n 
av
er
ag
e 
10
.8
 (7
.1
) d
ru
gs
 (m
ed
ia
n 
9,
 IQ
R 
6–
14
). 
72
%
 o
f p
at
ie
nt
s 
ha
d 
at
 
le
as
t 
on
e 
po
te
nt
ia
l 
dr
ug
-d
ru
g 
in
te
ra
ct
io
n.
 
M
os
t 
fr
eq
ue
nt
 
cl
in
ic
al
ly
 s
ig
ni
fic
an
t p
ot
en
tia
l D
D
Is
 in
vo
lv
ed
 h
al
op
er
id
ol
 (n
=1
85
) o
r 
m
et
ha
do
ne
 (n
=1
13
). 
29
. 
 
*M
or
in
, 2
01
75
68
 
Sw
ed
en
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
re
gi
st
er
-b
as
ed
 
O
ld
er
 
ad
ul
ts
 
(≥
75
 
ye
ar
s)
 w
ho
 d
ie
d 
w
ith
 
de
m
en
tia
  
12
0 
06
7 
87
.3
 (5
.6
) 
Th
e 
pr
ev
al
en
ce
 
of
 
m
ed
ic
at
io
ns
 
de
em
ed
 
“n
ev
er
 
ap
pr
op
ria
te
” 
(H
ol
m
es
’ c
rit
er
ia
) d
ec
re
as
ed
 fr
om
 3
8.
6%
 1
2 
m
on
th
s 
be
fo
re
 d
ea
th
 to
 
34
.7
%
 
du
rin
g 
th
e 
fin
al
 
m
on
th
 
be
fo
re
 
de
at
h.
 
Af
te
r 
ex
cl
ud
in
g 
an
tid
em
en
tia
 
dr
ug
s 
fr
om
 
th
e 
an
al
ys
is
, 
th
e 
pr
ev
al
en
ce
 
of
 
m
ed
ic
at
io
ns
 o
f q
ue
st
io
na
bl
e 
be
ne
fit
 d
ur
in
g 
th
e 
fin
al
 m
on
th
 o
f l
ife
 
w
as
 1
9.
1%
. 
M
os
t 
co
m
m
on
 m
ed
ic
at
io
ns
 o
f 
qu
es
tio
na
bl
e 
be
ne
fit
 
w
er
e 
an
tid
em
en
tia
 d
ru
gs
 (2
0%
), 
st
at
in
s 
(8
.3
%
), 
an
d 
se
x 
ho
rm
on
es
 
(1
0%
 o
f w
om
en
). 
In
st
itu
tio
na
liz
at
io
n 
w
as
 in
de
pe
nd
en
tly
 a
ss
oc
ia
te
d 
w
ith
 a
 1
5%
 r
ed
uc
tio
n 
of
 t
he
 li
ke
lih
oo
d 
to
 r
ec
ei
ve
 m
ed
ic
at
io
ns
 o
f 
qu
es
tio
na
bl
e 
be
ne
fit
. 
  
# 
Au
th
or
, y
ea
r 
(r
ef
) 
Co
un
tr
y 
St
ud
y 
de
si
gn
 
St
ud
y 
po
pu
la
tio
n 
N
o.
 
Ag
e,
 y
ea
rs
 
M
ai
n 
fin
di
ng
s 
30
. 
 
M
ul
lv
ai
n,
 2
01
59
18
 
U
ni
te
d 
St
at
es
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
m
ul
tic
en
te
r 
(n
=2
) 
Ad
ul
t 
pa
tie
nt
s 
w
ith
 
br
ai
n 
m
et
as
ta
se
s 
20
6 
22
%
 
ag
ed
 
≥7
0 
ye
ar
s 
O
ve
ra
ll,
 5
3/
20
6 
pa
tie
nt
s 
(2
6%
) w
er
e 
pr
es
cr
ib
ed
 w
ith
 s
ta
tin
s 
at
 t
he
 
tim
e 
of
 in
iti
al
 r
ef
er
ra
l t
o 
w
ho
le
-b
ra
in
 r
ad
ia
tio
n 
th
er
ap
y.
 1
9 
of
 th
em
 
ha
d 
a 
hi
st
or
y 
of
 
m
yo
ca
rd
ia
l 
in
fa
rc
tio
n 
or
 
an
gi
na
 
(s
ec
on
da
ry
 
pr
ev
en
tio
n)
. 
13
/5
3 
pa
tie
nt
s 
di
sc
on
tin
ue
d 
st
at
in
 t
he
ra
py
 d
ur
in
g 
fo
llo
w
-u
p.
 T
he
 a
ut
ho
rs
 p
ro
po
se
 a
 c
om
m
un
ic
at
io
n 
to
ol
 (
sc
rip
te
d 
di
al
og
ue
) t
o 
he
lp
 p
hy
si
ci
an
s 
de
pr
es
cr
ib
e 
pr
ev
en
tiv
e 
tr
ea
tm
en
ts
. 
31
. 
 
N
au
ck
, 2
00
49
19
 
G
er
m
an
y 
Pr
os
pe
ct
iv
e 
co
ho
rt
, 
m
ul
tic
en
te
r 
(n
=5
5)
 
Pa
tie
nt
s 
ho
sp
ita
liz
ed
 
in
 p
al
lia
tiv
e 
ca
re
 u
ni
ts
 
13
04
 
65
.1
 (1
2.
8)
 
M
os
t 
co
m
m
on
 d
ru
g 
cl
as
se
s 
w
er
e 
st
ep
-3
 o
pi
oi
ds
 (
68
%
, 
in
cl
ud
in
g 
m
or
ph
in
e 
42
%
 a
nd
 f
en
ta
ny
l 2
8%
), 
no
n-
op
io
id
s-
 a
na
lg
es
ic
s 
(5
9%
), 
sy
st
em
ic
 c
or
tic
os
te
ro
id
s 
(3
2%
, 
in
cl
ud
in
g 
de
xa
m
et
ha
so
ne
 2
7%
), 
la
xa
tiv
es
 (3
1%
), 
an
tie
m
et
ic
s 
(2
7%
, i
nc
lu
di
ng
 m
et
oc
lo
pr
am
id
e 
21
%
), 
ga
st
ro
pr
ot
ec
tiv
e 
ag
en
ts
 (
24
%
), 
ne
ur
ol
ep
tic
s 
(1
9%
), 
se
da
tiv
es
 a
nd
 
an
xi
ol
yt
ic
s 
(1
8%
), 
an
tid
ep
re
ss
an
ts
 (1
6%
) a
nd
 d
iu
re
tic
s 
(1
5%
). 
32
. 
 
O
liv
ei
ra
, 2
01
65
69
 
Po
rt
ug
al
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
si
ng
le
-
ce
nt
er
  
Pa
tie
nt
s 
re
fe
rr
ed
 t
o 
pa
lli
at
iv
e 
ca
re
 
44
8 
M
ed
ia
n 
68
 
M
ed
ia
n 
tim
e 
fr
om
 a
dm
is
si
on
 to
 d
ea
th
 w
as
 1
5 
da
ys
. C
om
or
bi
di
tie
s 
in
cl
ud
ed
 
hy
pe
rt
en
si
on
 
(4
8%
), 
hi
gh
 
ch
ol
es
te
ro
l 
(2
1%
), 
ve
no
us
 
th
ro
m
bo
em
bo
lis
m
 (1
5%
), 
an
d 
di
ab
et
es
 m
el
lit
us
 (2
0%
). 
Po
te
nt
ia
lly
 
fu
til
e 
m
ed
ic
at
io
ns
 w
er
e 
de
fin
ed
 b
as
ed
 o
n 
Fe
de
’s 
ap
pr
oa
ch
.53
4  
69
 
(1
5%
) 
pa
tie
nt
s 
w
er
e 
pr
es
cr
ib
ed
 
w
ith
 
st
at
in
s 
w
ith
ou
t 
an
y 
ca
rd
io
va
sc
ul
ar
 e
ve
nt
 in
 th
e 
pr
ev
io
us
 1
2 
m
on
th
s,
 1
25
 (2
8%
) p
at
ie
nt
s 
w
er
e 
gi
ve
n 
ga
st
ro
pr
ot
ec
tiv
e 
ag
en
ts
 d
ee
m
ed
 fu
til
e,
 4
2 
(9
%
) p
at
ie
nt
s 
re
ce
iv
ed
 
an
tih
yp
er
te
ns
iv
e 
tr
ea
tm
en
ts
 
w
ith
 
ei
th
er
 
lo
w
 
BP
 
or
 
hy
po
te
ns
io
n 
sy
m
pt
om
s,
 a
nd
 9
 p
at
ie
nt
s 
re
ce
iv
ed
 a
nt
id
em
en
tia
 
dr
ug
s.
 
# 
Au
th
or
, y
ea
r 
(r
ef
) 
Co
un
tr
y 
St
ud
y 
de
si
gn
 
St
ud
y 
po
pu
la
tio
n 
N
o.
 
Ag
e,
 y
ea
rs
 
M
ai
n 
fin
di
ng
s 
33
.
O
nd
er
, 2
01
35
50
M
ul
tip
le
 
Eu
ro
pe
an
 
co
un
tr
ie
s 
Cr
os
s-
se
ct
io
na
l, 
su
rv
ey
 
(S
H
EL
TE
R)
 
N
ur
si
ng
 
ho
m
e 
re
si
de
nt
s 
w
ith
 
ad
va
nc
ed
 
de
m
en
tia
 
(C
PS
 ≥
5)
 
82
2 
84
.6
 (8
.0
) 
N
ur
si
ng
 h
om
e 
re
si
de
nt
s 
fr
om
 8
 d
iff
er
en
t c
ou
nt
rie
s 
w
er
e 
in
cl
ud
ed
. 
12
3 
(1
5%
) o
f r
es
id
en
ts
 h
ad
 a
n 
Ad
va
nc
ed
 D
em
en
tia
 P
ro
gn
os
tic
 T
oo
l 
(A
D
EP
T)
 s
co
re
 ≥
13
.5
, i
nd
ic
at
in
g 
lim
ite
d 
lif
e 
ex
pe
ct
an
cy
.75
1  
14
%
 o
f 
th
e 
ov
er
al
l s
tu
dy
 p
op
ul
at
io
n 
ha
d 
po
ly
ph
ar
m
ac
y.
 M
os
t 
co
m
m
on
ly
 
pr
es
cr
ib
ed
 m
ed
ic
at
io
ns
 in
cl
ud
ed
 la
xa
tiv
es
 (4
7%
), 
ga
st
ro
pr
ot
ec
tiv
e 
ag
en
ts
 
(3
4%
), 
an
tip
sy
ch
ot
ic
s 
(3
6%
), 
be
nz
od
ia
ze
pi
ne
s 
(3
3%
), 
an
tid
ep
re
ss
an
ts
 
(2
9%
), 
an
tid
em
en
tia
 
dr
ug
s 
(1
3%
), 
an
tip
la
te
le
t 
ag
en
ts
 (
34
%
), 
AC
Ei
 (
16
%
), 
be
ta
-b
lo
ck
er
s 
(1
6%
), 
st
at
in
s 
(8
%
), 
an
d 
ca
lc
iu
m
 c
ha
nn
el
 in
hi
bi
to
rs
 (1
4%
). 
34
.
Ra
ijm
ak
er
s,
20
13
53
5
Ita
ly
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
si
ng
le
-
ce
nt
er
  
Pa
tie
nt
s 
w
ho
 
di
ed
 
fr
om
 c
an
ce
r 
19
5 
73
 (S
D
 Ø
) 
D
ur
in
g 
th
e 
la
st
 3
 d
ay
s 
of
 li
fe
, m
ea
n 
nu
m
be
r 
of
 m
ed
ic
at
io
n 
w
as
 4
.8
 
(S
D
 2
.1
), 
va
ry
in
g 
fr
om
 5
.1
 a
m
on
g 
ho
sp
ita
liz
ed
 p
at
ie
nt
s 
an
d 
4.
7 
am
on
g 
ho
sp
ic
e 
pa
tie
nt
s.
 M
ed
ic
at
io
ns
 c
on
si
de
re
d 
as
 “
lik
el
y 
to
 b
e 
in
ap
pr
op
ria
te
” 
in
cl
ud
ed
 
iro
n 
an
d 
vi
ta
m
in
 
su
pp
le
m
en
ts
 
(1
1%
), 
re
pl
ac
em
en
t 
ho
rm
on
es
 
(1
4%
), 
bi
sp
ho
sp
ho
na
te
s 
(1
%
), 
an
tic
oa
gu
la
nt
s 
(2
6%
), 
an
tih
yp
er
te
ns
iv
es
 
(1
3%
), 
an
tia
rr
yt
hm
ic
s 
(1
5%
), 
ga
st
ro
pr
ot
ec
tiv
e 
ag
en
ts
 
(5
6%
), 
an
tib
io
tic
s 
(3
1%
), 
co
rt
ic
os
te
ro
id
s 
(6
5%
), 
va
so
di
la
to
rs
 (
11
%
), 
an
d 
do
pa
m
in
e 
(7
%
). 
“A
pp
ro
pr
ia
te
 
m
ed
ic
at
io
ns
” 
in
cl
ud
ed
 
op
io
id
s 
(8
7%
), 
m
id
az
ol
am
 
(2
8%
), 
ha
lo
pe
rid
ol
 (
46
%
), 
m
ed
ic
at
io
ns
 f
or
 p
ul
m
on
ar
y 
se
cr
et
io
ns
 
(3
6%
), 
an
d 
m
et
oc
lo
pr
am
id
e/
le
vo
m
ep
ro
m
az
in
e 
fo
r n
au
se
a 
(1
1%
). 
35
.
Ri
ec
he
lm
an
n,
20
09
53
6
Br
az
il 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
si
ng
le
-
ce
nt
er
  
Am
bu
la
to
ry
 
pa
tie
nt
s 
w
ith
 
ad
va
nc
ed
 
ca
nc
er
 
re
ce
iv
in
g 
pa
lli
at
iv
e 
ca
re
 
37
2 
M
ed
ia
n 
66
 
M
or
e 
th
an
 5
0%
 o
f p
at
ie
nt
s 
re
ce
iv
ed
 ≥
6 
dr
ug
s.
 P
re
va
le
nc
e 
of
 fu
til
e 
m
ed
ic
at
io
n 
w
as
 2
2%
 b
ef
or
e 
pa
lli
at
iv
e 
ca
re
 c
on
su
lta
tio
n.
 M
os
t 
fr
eq
ue
nt
 u
nn
ec
es
sa
ry
 m
ed
ic
at
io
ns
 u
se
d 
by
 p
at
ie
nt
s 
w
er
e 
st
at
in
s 
(n
=4
8)
, m
ul
tiv
ita
m
in
s 
(n
=2
5)
, a
nd
 a
llo
pu
rin
ol
 (n
=4
). 
M
os
t 
co
m
m
on
 
du
pl
ic
at
e 
m
ed
ic
at
io
ns
 in
vo
lv
ed
 b
en
zo
di
az
ep
in
es
 (n
=7
). 
  
# 
Au
th
or
, y
ea
r 
(r
ef
) 
Co
un
tr
y 
St
ud
y 
de
si
gn
 
St
ud
y 
po
pu
la
tio
n 
N
o.
 
Ag
e,
 y
ea
rs
 
M
ai
n 
fin
di
ng
s 
36
. 
 
Ru
ss
el
l, 
20
14
55
3  
Au
st
ra
lia
 
Pr
os
pe
ct
iv
e 
co
ho
rt
, 
si
ng
le
-
ce
nt
er
 
Ad
ul
t 
pa
tie
nt
s 
w
ith
 
lif
e-
lim
iti
ng
 
ill
ne
ss
 
re
fe
rr
ed
 t
o 
pa
lli
at
iv
e 
ca
re
 
20
3 
72
.9
 (1
2.
6)
 
Pr
im
ar
y 
di
ag
no
si
s 
w
as
 c
an
ce
r f
or
 6
8%
 o
f p
at
ie
nt
s.
 M
ed
ia
n 
Ch
ar
ls
on
 
Co
m
or
bi
di
ty
 
In
de
x 
sc
or
e 
8 
(r
an
ge
 
2–
20
). 
M
ea
n 
nu
m
be
r 
of
 
m
ed
ic
at
io
ns
 a
t 
tim
e 
of
 p
al
lia
tiv
e 
ca
re
 r
ef
er
ra
l w
as
 7
.2
 (S
D
 3
.3
), 
of
 
w
hi
ch
 5
.3
 (3
.5
) w
er
e 
fo
r 
th
e 
m
an
ag
em
en
t 
of
 c
hr
on
ic
 d
is
ea
se
s 
an
d 
1.
9 
(2
.0
) 
w
er
e 
fo
r 
sy
m
pt
om
 
co
nt
ro
l. 
Av
er
ag
e 
nu
m
be
r 
of
 
m
ed
ic
at
io
ns
 
w
as
 
hi
gh
er
 
am
on
g 
pa
tie
nt
s 
w
ith
 
no
n-
m
al
ig
na
nt
 
di
se
as
e 
(8
.5
 v
s 
6.
6)
. 2
2%
 o
f 
pa
tie
nt
s 
w
er
e 
pr
es
cr
ib
ed
 w
ith
 s
ta
tin
s,
 
w
ith
 
no
 
si
gn
ifi
ca
nt
 
di
ff
er
en
ce
s 
ac
ro
ss
 
di
se
as
e 
gr
ou
ps
 
or
 
pe
rf
or
m
an
ce
 s
ta
tu
s 
sc
or
es
.  
37
. 
 
Se
ra
, 2
01
45
54
 
U
ni
te
d 
St
at
es
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
m
ul
tic
en
te
r 
H
os
pi
ce
 p
at
ie
nt
s 
w
ho
 
di
ed
 
42
52
 
77
.5
 (1
4.
3)
 
Pa
tie
nt
s 
w
er
e 
ad
m
itt
ed
 t
o 
ho
sp
ic
e 
in
 1
1 
di
ff
er
en
t 
st
at
es
. 
M
os
t 
co
m
m
on
 p
rim
ar
y 
di
ag
no
se
s 
w
er
e 
ca
nc
er
 (
35
%
), 
de
m
en
tia
 (
18
%
), 
lu
ng
 d
is
ea
se
 (1
0%
), 
an
d 
he
ar
t d
is
ea
se
 (1
0%
). 
Av
er
ag
e 
le
ng
th
 o
f s
ta
y 
w
as
 2
2 
da
ys
. 
M
ea
n 
nu
m
be
r 
of
 m
ed
ic
at
io
ns
 a
t 
an
y 
tim
e 
du
rin
g 
ho
sp
ic
e 
st
ay
 w
as
 1
5.
7,
 w
ith
 ≥
30
 d
ru
gs
. M
os
t 
co
m
m
on
 p
re
sc
rib
ed
 
dr
ug
s 
w
er
e 
pa
ra
ce
ta
m
ol
 (8
6%
), 
lo
ra
ze
pa
m
 (8
4%
), 
m
or
ph
in
e 
(8
4%
), 
ha
lo
pe
rid
ol
 (
49
%
), 
an
d 
at
ro
pi
ne
 (
62
%
). 
O
th
er
 c
om
m
on
ly
 u
se
d 
m
ed
ic
at
io
ns
 in
cl
ud
ed
 p
ro
ch
lo
rp
er
az
in
e 
(a
nt
ie
m
et
ic
, 4
7%
), 
la
xa
tiv
es
 
(e
.g
. 
do
cu
sa
te
 a
nd
 b
is
ac
od
yl
, 
29
%
 a
nd
 2
6%
), 
sa
lb
ut
am
ol
 (
29
%
), 
sc
op
ol
am
in
e 
(2
5%
), 
an
d 
fu
ro
se
m
id
e 
(1
8%
). 
An
tih
yp
er
te
ns
iv
es
 
(3
3%
), 
an
tia
ci
d 
ag
en
ts
 (
35
%
), 
an
d 
an
tip
la
te
le
t 
ag
en
ts
 (
11
%
) 
w
er
e 
co
m
m
on
 a
m
on
g 
ca
nc
er
 p
at
ie
nt
s.
 
38
. 
 
*S
ev
ill
a-
Sa
nc
he
z,
 
20
17
92
0  
Sp
ai
n 
Cr
os
s-
se
ct
io
na
l, 
si
ng
le
-c
en
te
r 
H
os
pi
ta
liz
ed
 
ol
de
r 
ad
ul
ts
 
id
en
tif
ie
d 
as
 
“p
al
lia
tiv
e”
 
23
5 
86
.8
 (5
.4
) 
M
od
er
at
e 
to
 s
ev
er
e 
co
gn
iti
ve
 i
m
pa
irm
en
t 
in
 5
6.
6%
 o
f 
pa
tie
nt
s.
 
M
ea
n 
nu
m
be
r 
of
 d
ru
gs
 9
.5
 (S
D
 3
.8
), 
w
ith
 4
7%
 o
f p
at
ie
nt
s 
us
in
g 
10
 
or
 m
or
e 
dr
ug
s.
 1
9%
 o
f 
pa
tie
nt
s 
us
ed
 c
ar
di
ov
as
cu
la
r 
m
ed
ic
at
io
ns
, 
an
d 
31
%
 
us
ed
 
m
ed
ic
at
io
ns
 
fo
r 
th
e 
ce
nt
ra
l 
ne
rv
ou
s 
sy
st
em
. 
Pr
ev
al
en
ce
 
of
 
in
ap
pr
op
ria
te
 
m
ed
ic
at
io
ns
 
ac
co
rd
in
g 
to
 
ST
O
PP
 
cr
ite
ria
 w
as
 8
8%
. O
ve
ra
ll,
 2
5%
 o
f p
at
ie
nt
s 
ex
pe
rie
nc
ed
 a
t l
ea
st
 o
ne
 
ad
ve
rs
e 
dr
ug
 e
ve
nt
. 
# 
Au
th
or
, y
ea
r 
(r
ef
) 
Co
un
tr
y 
St
ud
y 
de
si
gn
 
St
ud
y 
po
pu
la
tio
n 
N
o.
 
Ag
e,
 y
ea
rs
 
M
ai
n 
fin
di
ng
s 
39
.
Si
lv
ei
ra
, 2
00
89
21
U
ni
te
d 
St
at
es
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
m
ul
tic
en
te
r 
VA
 
pa
tie
nt
s 
tr
ea
te
d 
w
ith
 s
ta
tin
s 
6 
m
on
th
s 
be
fo
re
 d
ea
th
 
15
84
 
72
-7
5 
(9
) 
A 
to
ta
l o
f 3
37
 p
at
ie
nt
s 
w
ho
 d
ie
d 
fr
om
 li
fe
-li
m
iti
ng
 c
on
di
tio
ns
 (b
as
ed
 
on
 th
e 
Pa
lli
at
iv
e 
Ca
re
 In
de
x)
, m
at
ch
ed
 w
ith
 1
24
7 
pa
tie
nt
s 
w
ho
 d
ie
d 
w
ith
ou
t l
ife
-li
m
iti
ng
 c
on
di
tio
n.
 9
9%
 m
al
e.
 A
t t
im
e 
of
 d
ea
th
, 5
1%
 o
f 
ca
se
s 
an
d 
64
%
 o
f 
co
nt
ro
ls
 w
er
e 
st
ill
 r
ec
ei
vi
ng
 s
ta
tin
s.
 A
m
on
g 
pa
tie
nt
s 
w
ho
 d
is
co
nt
in
ue
d 
st
at
in
s,
 d
is
co
nt
in
ua
tio
n 
oc
cu
rr
ed
 o
n 
av
er
ag
e 
65
 d
ay
s 
(S
D
 5
0)
 b
ef
or
e 
de
at
h.
 
40
.
Su
hr
ie
, 2
00
95
38
U
ni
te
d 
St
at
es
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
si
ng
le
-
ce
nt
er
 
VA
 p
at
ie
nt
s 
w
ho
 d
ie
d 
in
 
a 
ge
ria
tr
ic
 
pa
lli
at
iv
e 
ca
re
 u
ni
t 
89
 
79
.7
 (7
.8
) 
98
%
 o
f p
at
ie
nt
s 
w
er
e 
m
al
e.
 P
rim
ar
y 
di
ag
no
si
s 
w
as
 m
ai
nl
y 
de
m
en
tia
 
(3
9%
), 
fo
llo
w
ed
 b
y 
ca
nc
er
 (1
7%
), 
an
d 
ca
rd
io
va
sc
ul
ar
 d
is
ea
se
 (1
1%
). 
M
ea
n 
nu
m
be
r 
of
 c
hr
on
ic
 d
is
ea
se
s 
w
as
 8
.4
 (
SD
 4
.3
). 
At
 t
im
e 
of
 
ad
m
is
si
on
, m
ea
n 
nu
m
be
r 
of
 p
re
sc
rib
ed
 m
ed
ic
at
io
ns
 w
as
 9
.7
 (
SD
 
4.
3)
. B
as
ed
 o
n 
3 
ite
m
s 
fr
om
 th
e 
M
ed
ic
at
io
n 
Ap
pr
op
ria
te
ne
ss
 In
de
x 
(M
AI
), 
th
e 
pr
op
or
tio
n 
of
 p
at
ie
nt
s 
w
ith
 u
nn
ec
es
sa
ry
 m
ed
ic
at
io
ns
 
w
as
 7
4%
 a
t a
dm
is
si
on
, a
nd
 d
ec
re
as
ed
 to
 3
9%
 a
t t
im
e 
of
 d
ea
th
 (i
nc
l. 
24
%
 la
ck
 o
f e
ff
ec
tiv
en
es
s 
an
d 
20
%
 la
ck
 o
f i
nd
ic
at
io
n)
. 
41
.
Tj
ia
, 2
01
45
55
U
ni
te
d 
St
at
es
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
, 
re
gi
st
er
-b
as
ed
 
N
ur
si
ng
 
ho
m
e 
re
si
de
nt
s 
w
ith
 
ad
va
nc
ed
 
de
m
en
tia
 
(C
PS
 ≥
6)
 
10
 2
12
 
85
.0
 (7
.3
) 
In
ce
pt
io
n 
co
ho
rt
: n
ur
si
ng
 h
om
e 
re
si
de
nt
s 
ar
e 
in
cl
ud
ed
 a
t t
he
 ti
m
e 
of
 t
ra
ns
iti
on
 t
o 
se
ve
re
 c
og
ni
tiv
e 
im
pa
irm
en
t. 
Co
m
m
on
 c
om
or
bi
d 
di
se
as
es
 in
cl
ud
ed
 d
ia
be
te
s 
m
el
lit
us
 (2
9.
6%
), 
he
ar
t 
fa
ilu
re
 (2
0.
8%
), 
st
ro
ke
 (2
4.
4%
), 
hy
pe
rt
en
si
on
 (6
8%
), 
re
na
l f
ai
lu
re
 (1
1%
), 
an
d 
ca
nc
er
 
(7
.5
). 
O
ve
ra
ll,
 m
ea
n 
nu
m
be
r 
of
 d
ru
gs
 a
t 
ba
se
lin
e 
w
as
 7
.1
 (S
D
 4
.8
). 
16
99
 (1
7%
) o
f 
re
si
de
nt
s 
w
er
e 
us
in
g 
st
at
in
s,
 o
f 
w
ho
m
 6
32
 (3
7.
2%
) 
di
sc
on
tin
ue
d 
th
ei
r 
tr
ea
tm
en
t 
du
rin
g 
fo
llo
w
-u
p 
tim
e.
 A
m
on
g 
st
at
in
 
us
er
s 
w
ho
 d
ie
d 
du
rin
g 
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